CN1195340A - Inhibitors of farnesyl-protein transferase - Google Patents
Inhibitors of farnesyl-protein transferase Download PDFInfo
- Publication number
- CN1195340A CN1195340A CN96194206A CN96194206A CN1195340A CN 1195340 A CN1195340 A CN 1195340A CN 96194206 A CN96194206 A CN 96194206A CN 96194206 A CN96194206 A CN 96194206A CN 1195340 A CN1195340 A CN 1195340A
- Authority
- CN
- China
- Prior art keywords
- aryl
- replace
- alkyl
- heterocycle
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000992 Transferases Proteins 0.000 title claims abstract description 36
- 102000004357 Transferases Human genes 0.000 title claims abstract description 36
- 239000003112 inhibitor Substances 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 172
- 238000000034 method Methods 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 125000003118 aryl group Chemical group 0.000 claims description 216
- 125000000623 heterocyclic group Chemical group 0.000 claims description 171
- 229910052739 hydrogen Inorganic materials 0.000 claims description 138
- 239000001257 hydrogen Substances 0.000 claims description 127
- -1 4-hetaroylpyrazol Chemical group 0.000 claims description 75
- 229910052799 carbon Inorganic materials 0.000 claims description 64
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 62
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 56
- 150000002431 hydrogen Chemical class 0.000 claims description 56
- 229910052736 halogen Inorganic materials 0.000 claims description 55
- 150000002367 halogens Chemical class 0.000 claims description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims description 54
- 229910052801 chlorine Inorganic materials 0.000 claims description 54
- 229910052731 fluorine Inorganic materials 0.000 claims description 54
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 52
- 229910052794 bromium Inorganic materials 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 40
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 125000002883 imidazolyl group Chemical group 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 238000006073 displacement reaction Methods 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 12
- 125000003435 aroyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 10
- 125000005493 quinolyl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- 125000005002 aryl methyl group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000005331 Hepatitis D Diseases 0.000 claims description 5
- 208000037262 Hepatitis delta Diseases 0.000 claims description 5
- 229940073608 benzyl chloride Drugs 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 201000004569 Blindness Diseases 0.000 claims description 4
- 101710145505 Fiber protein Proteins 0.000 claims description 4
- 210000004126 nerve fiber Anatomy 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- OITGWZQOTKBNHC-MHAHJAEUSA-N [(3s)-4-[(2r)-2-amino-3-hydroxyheptadecyl]-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C1[C@H](CCCC)N(C[C@@H](N)C(O)CCCCCCCCCCCCCC)CCN1C(=O)C1=CC=CC2=CC=CC=C12 OITGWZQOTKBNHC-MHAHJAEUSA-N 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- BKOOMYPCSUNDGP-UHFFFAOYSA-N trimethyl-ethylene Natural products CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- RTVOEPCPPNTPRP-NRFANRHFSA-N [(3s)-3-butyl-4-(2-imidazol-1-ylethylsulfonyl)piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C([C@@H]1CCCC)N(C(=O)C=2C3=CC=CC=C3C=CC=2)CCN1S(=O)(=O)CCN1C=CN=C1 RTVOEPCPPNTPRP-NRFANRHFSA-N 0.000 claims description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000006126 farnesylation Effects 0.000 abstract description 13
- 108700020796 Oncogene Proteins 0.000 abstract description 6
- 102000043276 Oncogene Human genes 0.000 abstract description 6
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 115
- 239000002585 base Substances 0.000 description 53
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 239000000460 chlorine Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 28
- 238000004128 high performance liquid chromatography Methods 0.000 description 28
- 108010014186 ras Proteins Proteins 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- 102000016914 ras Proteins Human genes 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 238000012360 testing method Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000010828 elution Methods 0.000 description 17
- 238000001819 mass spectrum Methods 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- 239000012071 phase Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 11
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- NARSWBLQNUFOIM-UHFFFAOYSA-N naphthalen-1-yl(piperazin-1-yl)methanone Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)N1CCNCC1 NARSWBLQNUFOIM-UHFFFAOYSA-N 0.000 description 9
- 238000005932 reductive alkylation reaction Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 0 CC(C1)*CC(*)N1C(c1cccc2c1cccc2)=O Chemical compound CC(C1)*CC(*)N1C(c1cccc2c1cccc2)=O 0.000 description 5
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000007738 vacuum evaporation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102100029974 GTPase HRas Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150040459 RAS gene Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 108700042226 ras Genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- RCCIRNZUDAQTPB-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-naphthalen-1-ylmethanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC2=CC=CC=C12 RCCIRNZUDAQTPB-UHFFFAOYSA-N 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 2
- KHEVPDFAQFJIGK-UHFFFAOYSA-N 2-sulfooxyethanesulfonic acid Chemical compound OS(=O)(=O)CCOS(O)(=O)=O KHEVPDFAQFJIGK-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 102000003916 Arrestin Human genes 0.000 description 2
- 108090000328 Arrestin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000006612 Transducin Human genes 0.000 description 2
- 108010087042 Transducin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- KPFZRSHCCBNZOG-FQEVSTJZSA-N [(3s)-3-butyl-4-(1h-imidazol-5-ylmethyl)piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C([C@@H]1CCCC)N(C(=O)C=2C3=CC=CC=C3C=CC=2)CCN1CC1=CNC=N1 KPFZRSHCCBNZOG-FQEVSTJZSA-N 0.000 description 2
- CVHOIJQASBTTTE-QFIPXVFZSA-N [(3s)-3-butyl-4-(pyridin-3-ylmethyl)piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C([C@@H]1CCCC)N(C(=O)C=2C3=CC=CC=C3C=CC=2)CCN1CC1=CC=CN=C1 CVHOIJQASBTTTE-QFIPXVFZSA-N 0.000 description 2
- KTLHLXSJEQRAKO-NRFANRHFSA-N [(3s)-3-butyl-4-[2-(1h-imidazol-5-yl)ethyl]piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C([C@@H]1CCCC)N(C(=O)C=2C3=CC=CC=C3C=CC=2)CCN1CCC1=CN=CN1 KTLHLXSJEQRAKO-NRFANRHFSA-N 0.000 description 2
- IVFJZZVFLCGKMR-MOPGFXCFSA-N [(3s)-4-[(2r)-2-amino-3-hydroxypropyl]-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C1CN(C[C@@H](N)CO)[C@@H](CCCC)CN1C(=O)C1=CC=CC2=CC=CC=C12 IVFJZZVFLCGKMR-MOPGFXCFSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000012966 malignant exocrine pancreas neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 239000012434 nucleophilic reagent Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ONCNIMLKGZSAJT-UHFFFAOYSA-N thieno[3,2-b]furan Chemical compound S1C=CC2=C1C=CO2 ONCNIMLKGZSAJT-UHFFFAOYSA-N 0.000 description 2
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FWLWTILKTABGKQ-UHFFFAOYSA-N 1-(bromomethyl)-3-methylbenzene Chemical compound CC1=CC=CC(CBr)=C1 FWLWTILKTABGKQ-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 description 1
- YQYLLBSWWRWWAY-UHFFFAOYSA-N 1-tritylimidazole-4-carbaldehyde Chemical compound C1=NC(C=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YQYLLBSWWRWWAY-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- WLYVAVCZXRPTIH-UHFFFAOYSA-N 2-(1-tritylimidazol-4-yl)acetaldehyde Chemical compound C1=NC(CC=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WLYVAVCZXRPTIH-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical compound N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- XEKCTIFQAYFUSM-UHFFFAOYSA-N OC(C1c2ccccc2C=CC1)=O Chemical compound OC(C1c2ccccc2C=CC1)=O XEKCTIFQAYFUSM-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- CISMUEMTXYYHAX-SZJWURTPSA-N [(3S)-4-butan-2-yl-3-[(2R)-3-hydroxy-2-[(4-nitrophenyl)methylamino]propyl]piperazin-1-yl]-naphthalen-1-ylmethanone dihydrochloride Chemical compound Cl.Cl.N([C@@H](CO)C[C@H]1CN(CCN1C(C)CC)C(=O)C=1C2=CC=CC=C2C=CC=1)CC1=CC=C([N+]([O-])=O)C=C1 CISMUEMTXYYHAX-SZJWURTPSA-N 0.000 description 1
- DSPPCOUSGYJEON-UXHICEINSA-N [(3s)-4-[(2r)-2-amino-4-hydroxybutyl]-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C1CN(C[C@H](N)CCO)[C@@H](CCCC)CN1C(=O)C1=CC=CC2=CC=CC=C12 DSPPCOUSGYJEON-UXHICEINSA-N 0.000 description 1
- IDEMMFMVOWYBHK-AAYDIPMQSA-N [(3s)-4-[(2r)-2-amino-4-hydroxybutyl]-3-butylpiperazin-1-yl]-naphthalen-1-ylmethanone;dihydrochloride Chemical compound Cl.Cl.C1CN(C[C@H](N)CCO)[C@@H](CCCC)CN1C(=O)C1=CC=CC2=CC=CC=C12 IDEMMFMVOWYBHK-AAYDIPMQSA-N 0.000 description 1
- XSAJRSTXUWYGPC-KGLYDCNGSA-N [(3s)-4-butan-2-yl-3-[(2r)-3-hydroxy-2-[(4-nitrophenyl)methylamino]propyl]piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound N([C@@H](CO)C[C@H]1CN(CCN1C(C)CC)C(=O)C=1C2=CC=CC=C2C=CC=1)CC1=CC=C([N+]([O-])=O)C=C1 XSAJRSTXUWYGPC-KGLYDCNGSA-N 0.000 description 1
- PURWQTAHOUPNBE-UHFFFAOYSA-N [N+](=O)([O-])BrCC1=CC=CC=C1 Chemical compound [N+](=O)([O-])BrCC1=CC=CC=C1 PURWQTAHOUPNBE-UHFFFAOYSA-N 0.000 description 1
- IVAOQJNBYYIDSI-UHFFFAOYSA-N [O].[Na] Chemical compound [O].[Na] IVAOQJNBYYIDSI-UHFFFAOYSA-N 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical class O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- IBDXKWOEXZZKNA-QCBYUQAPSA-N butyl 2-[[(2s)-2-butyl-4-(naphthalene-1-carbonyl)piperazin-1-yl]methyl]aziridine-1-carboxylate Chemical compound CCCCOC(=O)N1CC1CN1[C@@H](CCCC)CN(C(=O)C=2C3=CC=CC=C3C=CC=2)CC1 IBDXKWOEXZZKNA-QCBYUQAPSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- RBZVCMKUEIDTSC-UHFFFAOYSA-N formaldehyde;1h-imidazole Chemical compound O=C.C1=CNC=N1 RBZVCMKUEIDTSC-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- KFOPKOFKGJJEBW-ZSSYTAEJSA-N methyl 2-[(1s,7r,8s,9s,10r,13r,14s,17r)-1,7-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]acetate Chemical compound C([C@H]1O)C2=CC(=O)C[C@H](O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC(=O)OC)[C@@]1(C)CC2 KFOPKOFKGJJEBW-ZSSYTAEJSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 108700024543 mos Genes Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HWJHZLJIIWOTGZ-UHFFFAOYSA-N n-(hydroxymethyl)acetamide Chemical compound CC(=O)NCO HWJHZLJIIWOTGZ-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- 229940098221 silver cyanide Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
Description
Related application
Present patent application is the part continuation application of the unexamined application serial 08/470,690 of submission on June 6 nineteen ninety-five, and the latter is again the part continuation application of the unexamined application serial 08/412,829 of submission on March 29 nineteen ninety-five.
Background of invention
Ras albumen (Ha-Ras, Ki4a-Ras, Ki4b-Ras and N-Ras) is the integral part of the signal pipeline of contact cell surface growth factor receptors and the nuclear signal that starts cell proliferation.The biological study and the biochemical research of Ras effect show that the Ras role is regulated albumen as G.Under its inactivated state, Ras combines with GDP.When growth factor receptors activates, lure that Ras is exchanged into GTP with GDP into, and conformational change takes place.The GTP combining form of Ras can be propagated the growth-stimulating signal, stopped by the intrinsic GTP enzymic activity of Ras until this signal, the latter makes this albumen get back to the GDP combining form of its inactivation (D.R.Lowy and D.M, Willumsen, Ann.Rev.Biochem.62:851-891 (1993)).In a lot of human body cancers, comprise in colorectal carcinoma, exocrine pancreas cancer and the myeloid leukemia, all found the Ras gene (Ha-ras, Ki4a-ras, Ki4b-ras and N-ras) of sudden change.The protein product of these genes has lost its GTP enzymic activity, and propagates a kind of growth-stimulating signal in itself.
Ras must navigate to just has normal function and oncogenic function on the plasma membrane.Translate modification after Ras film location relates at least 3 kinds, and 3 kinds of modifications all occur in the C-terminal of Ras.This RasC end comprises a kind of precedence diagram, is referred to as " CAAX " or " Cys-Aaa
1-Aaa
2-Xaa " case (Cys is a halfcystine, and Aaa is a kind of aliphatic amino acid, and Xaa is any amino acid) (Willumsen et al., Nature 310:583-586 (1984)).Different because of concrete order, this figure can be used as the signal sequence of farnesyl-protein transferase or geranyl-enzymes such as geranyl protein transferase, the cysteine residues of these enzyme catalysiss CAAX figure respectively with C
15Or C
20Isoprenoid generation alkylation.(S.Clarke.,Ann.Rev.Biochem.61:355-386(1992);W.R.Schafer?and?J.Rine,Ann.Rev.Genetics?30:209-237(1992))。Ras albumen is one of known some kinds of albumen that translation farnesylation in back can take place.Other farnesylation albumen comprises the gtp binding protein relevant with Ras, for example γ-the subunit of Rho, fungi conjugative element, stratum nucleare (nuclear lamins) and transducin (transducin).People such as James (J.Biol.Chem.269,14182 (1994)) have confirmed that a kind of Pxf of the peroxysome that associated also is a farnesylation.People such as James have also proposed, except that above listed those, also have the farnesylation albumen with unknown structure and function.
The inhibition of farnesylation protein transferase, demonstrated can block the Ras transformant in soft agar growth and change the others that it transforms phenotype.Also confirm, some inhibitor of farnesyl-protein transferase can optionally be blocked the interior processing of cell (N.E.Kohlet al., Science, the 260:1934-1937 (1993) and the G.L.James et al. of Ras oncoprotein, Science, 260:1937-1942 (1993)).Recently, show, a kind of inhibitor of farnesyl-protein transferase has been blocked ras dependent form growth of tumor (N.E.Kohl et al. in the nude mice, Proc.Natl.Acad.Sci U.S.A., 91:9141-9145 (1994)) and brought out (the N.E.Kohl et al. that disappears of mammary cancer and salivary-gland carcinoma in the ras sudden change mouse, Nature Medicine, 1:792-797 (1995)).
Lovastatin (Merck ﹠amp has been used in the indirect inhibition of farnesyl-protein transferase in the live body; Co., Rahway, NJ) and compactin (Hancock et al., ibid; Casey et al., ibid; Schafer et al., Science 245:379 (1989)) confirmed.These medicines suppress the HMG-CoA reductase enzyme, comprise that promptly the cluster isoprene of farnesyl pyrophosphate produces the speed limit enzyme.Farnesyl-protein transferase utilizes farnesyl pyrophosphate to make the Cys sulfydryl of Ras CAAX case and farnesyl group that covalent modified (Reiss et al., Cell, 62:81-88 (1990) take place; Schaber et al., J.Biol.Chem., 265:14701-14704 (1990); Schafer et al., Science, 249:1133-1139 (1990); Manne et al., Proc.Natl.Acad, Sci USA, 87:7541-7545 (1990)).To the biosynthetic inhibition of farnesyl pyrophosphate, blocked the Ras film location in the culturing cell by suppressing the HMG-CoA reductase enzyme.Yet the direct inhibition of farnesyl-protein transferase can be more single-minded, and its side effect few side effects that can take place than the biosynthetic general inhibitor required dosage of isoprene.
The inhibitor of farnesyl-protein transferase (FPT enzyme) has been described to two big classes.The first kind is the analogue of farnesyl diphosphate (FPP), and the second class inhibitor is relevant with the protein Substrate (as Ras) of this enzyme.The peptide that existing people the describes inhibitor of deriving generally is to contain halfcystine, scheme relevant molecule with CAAX as protein prenyl signal.(Schaber?et?al.,ibid;Reiss?et.al.,ibid;Reiss?et?al.,PNAS,88:732-736(1991))。Such inhibitor can arrestin matter prenylization, serves as the substitution effect thing of farnesyl-protein transferase this kind of enzyme simultaneously, also can be that (U.S.Patent 5,141,851, University of Texas for the inhibitor of pure competition; N.E.Kohl et al., Science, 260:1934-1937 (1993); Graham, et al., J.Med.Chem., 37,725 (1994)).In general, the deletion of sulfydryl has been proved the inhibition drug effect that can reduce this compound significantly on the CAAX derivative.Yet sulfydryl has limited the treatment of FPT enzyme inhibitors potentially and has used, and this is relevant with pharmacokinetics, pharmacodynamics and toxicity.Therefore, the functional displacement of sulfydryl is desirable.
Recently existing people reports that farnesyl protein transferase inhibitor is the inhibitor of vascular smooth muscle cell proliferation, therefore, can be used for prevention and treatment arteriosclerosis and diabetic vascular disorder (JPH7-112930).
Recently existing people is open, and some randomly contains the inhibitor that the pulsating tricyclic compound of piperidines is the FPT enzyme (WO 95/10514, WO 95/10515 and WO 95/10516).What also existing people disclosed the farnesyl protein enzyme contains imidazoles inhibitor (WO 95/09001 and EP0 675 112A1).
Therefore, thus an object of the present invention is to develop the imitative peptide compounds that does not have the sulfydryl segment and can suppress the back translation farnesylation of farnesyl-protein transferase arrestin matter.A further purpose of the present invention is that exploitation contains the chemotherapy group compound of The compounds of this invention and the production method of The compounds of this invention.
Brief summary of the invention
The present invention comprises the imitative peptide that can suppress farnesyl-protein transferase and contains diethylenediamine compound.The compounds of this invention does not have the sulfydryl segment, thereby provide following unique advantage: improved pharmacokinetics behavior in animal body, prevent for example fast automatic oxidation of sulfydryl dependent form chemical reaction and generate disulphide and reduction general toxicity with interior living mercaptan.What further comprise among the present invention is chemotherapy group compound and the production method thereof that contains these farnesyl tranfering enzyme inhibitors.
Detailed description of the invention
Compound of the present invention can be used for suppressing farnesyl-protein transferase and makes oncogene protein Ras farnesylation.In first specific embodiments of the present invention, the inhibitor of farnesyl-protein transferase can illustrate with following formula A or its pharmaceutically acceptable salt:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4And R
5Be independently selected from H and CH
3And R
2, R
3, R
4And R
5In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Y is an aryl unsubstituted or that replace, or heterocycle unsubstituted or that replace, and wherein the heterocycle of aryl of Qu Daiing or replacement is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5.
In second specific embodiments of the present invention, the inhibitor of farnesyl-protein transferase can illustrate with following formula B or its pharmaceutically acceptable salt:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2Or O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5.
In the 3rd specific embodiments of the present invention, the inhibitor of farnesyl-protein transferase can illustrate with following formula C or its pharmaceutically acceptable salt:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 1;
T is 0 or 1; With
U is 4 or 5.
A preferred version of The compounds of this invention can illustrate with following formula: compound or its pharmaceutically acceptable salt:
In the formula:
R
1aBe independently selected from: hydrogen or C
1-C
6Alkyl;
R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, cycloalkyl, R
10O-,-N (R
10)
2Or C
2-C
6Alkenyl,
C) the unsubstituted or C that replaces
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocycle, cycloalkyl, alkenyl, R unsubstituted or that replace
10O-and-N (R
10)
2
R
3, R
4And R
5Be independently selected from H and CH
3
R
2Be H;
Or C
1-C
5Alkyl can be unbranched or side chain is arranged, and can be unsubstituted or replaced by following one or more groups:
1) aryl,
2) heterocycle,
3)OR
6,
4) SR
6a, SO
2R
6a, or
And R
2, R
3, R
4And R
5In any 2 can randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H; C
1-C
4Alkyl, C
3-C
6Cycloalkyl, aryl, heterocycle can be unsubstituted, or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
6aBe selected from: C
1-C
4Alkyl or C
3-C
6Cycloalkyl, can be unsubstituted or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
8Be independently selected from:
A) hydrogen,
B) C
1-C
6Alkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) by C
1-C
6Perfluoroalkyl, R
10O-, R
10C (O) NR
10-, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) unsubstituted or by C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl or aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: a key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-, O ,-N (R
10)-, or S (O) m;
V is selected from:
A) hydrogen,
B) be selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo pyridine base, indyl, quinolyl, isoquinolyl and thienyl,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl,
But its condition is if A
1Be S (O) m, then V is not a hydrogen, and if A
1Be a key, n is 0, A
2Be S (O) m, then V neither hydrogen;
W is selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo-piperidine base, indyl, quinolyl, or isoquinolyl;
X is-CH
2Or-C (=O)-;
Y is monocycle or bicyclic aryl, and perhaps monocycle or bicyclic heterocycle can be unsubstituted or replaced by following one or more groups:
A) C
1-C
4Alkyl,
B) C
1-C
4Alkoxyl group,
C) halogen, or
d)NR
6R
7;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
R is 0-5, but r is 0 when V is hydrogen;
S is 0 or 1; And
T is 0 or 1.
In second preferred version of the present invention, the inhibitor of farnesyl-protein transferase can illustrate with following formula B compound or its pharmaceutically acceptable salt:
In the formula:
R
1aBe independently selected from: hydrogen or C
1-C
6Alkyl;
R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, cycloalkyl, R
10O-,-N (R
10)
2Or C
2-C
6Alkenyl,
C) the unsubstituted or C that replaces
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocycle, cycloalkyl, alkenyl, R unsubstituted or that replace
10O-and-N (R
10)
2
R
3And R
4Be independently selected from H and CH
3
R
2Be H;
Or C
1-C
5Alkyl can be unbranched or side chain is arranged, and can be unsubstituted or replaced by following one or more groups:
1) aryl,
2) heterocycle,
3)OR
6,
And R
2, R
3, R
4And R
5In any 2 can randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H; C
1-C
4Alkyl, C
3-C
6Cycloalkyl, aryl, heterocycle can be unsubstituted, or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
6aBe selected from: C
1-C
4Alkyl or C
3-C
6Cycloalkyl, can be unsubstituted or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
8Be independently selected from:
A) hydrogen,
B) C
1-C
6Alkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) by C
1-C
6Perfluoroalkyl, R
10O-, R
10C (O) NR
10-, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) unsubstituted or by C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl or aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: a key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-, O ,-N (R
10)-, or S (O) m;
V is selected from:
A) hydrogen,
B) be selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo pyridine base, indyl, quinolyl, isoquinolyl and thienyl,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl,
But its condition is if A
1Be S (O) m, then V is not a hydrogen, and if A
1Be a key, n is 0, A
2Be S (O) m, then V neither hydrogen;
G is H
2Or O;
W is selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo-piperidine base, indyl, quinolyl, or isoquinolyl;
X is-CH
2Or-C (=O)-;
Z is monocycle or bicyclic aryl, monocycle or bicyclic heteroaryl, monocycle or bicyclic aryl methyl, monocycle or bicyclic heteroaryl methyl, monocycle or bicyclic aryl sulphonyl, monocycle or bicyclic heteroaryl sulphonyl can be unsubstituted or replaced by following one or more groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5,
But its condition be when G be H
2, and W is when being imidazolyl, substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not H, and
Its condition be when X be-C (=O)-, or-S (=O) during m-, t is 1, and substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not hydrogen.
Preferred compounds of the invention are following compound and pharmaceutically acceptable salt thereof:
2 (S)-butyl-1-(2,3-diamino third-1-yl)-4-(1-naphthoyl)-piperazine
1-(3-amino-2-(2-naphthyl methyl amino) third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-{5-[1-(2-naphthyl methyl)]-4, the 5-glyoxalidine } methyl-4-(1-naphthoyl)-piperazine
1-[5-(1-benzyl imidazole) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-{5-[1-(4-nitrobenzyl) imidazolyl] methyl }-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(3-kharophen methylthio group-2 (R)-amino third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[2-(1-imidazolyl) ethyl] sulphonyl-4-(1-naphthoyl)-piperazine
2 (R)-butyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-4-(1-naphthoyl)-1-(3-pyridylmethyl) piperazine
1-2 (S)-butyl-(2 (R)-(4-nitrobenzyl) amino-3-hydroxypropyl)-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-hydroxyl heptadecyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-benzyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-(3-benzylthio-) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-[3-(4-nitrobenzyl sulfenyl) propyl group]))-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(4-imidazolyl) ethyl]-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(4-imidazolyl) methyl]-4-(1-naphthoyl)-piperazine
2 (S) butyl-1-[(1-naphthalene-2-ylmethyl)-and 1H-imidazoles-5-yl) ethanoyl]-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-and 1H-imidazoles-5-yl) ethyl]-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-4-hydroxy butyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2-amino-3-(2-benzyloxy phenyl) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2-amino-3-(2-hydroxy phenyl) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-[3-(4-imidazolyl) propyl group]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(1-naphthyl methyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-naphthyl methyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-methoxy-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(3-methyl-2-butene base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-luorobenzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-benzyl chloride base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
1-[1-(4-bromobenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
1-[1-(4-bromobenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethyl benzyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-1-[1-(4-methyl-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(3-methyl-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
1-[1-(4-phenylbenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-phenylethyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethoxy) imidazoles-5-ylmethyl]-piperazine
1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
5 (S)-normal-butyl-1-(2, the 3-3,5-dimethylphenyl)-4-(4-imidazolyl methyl)-piperazine-2-ketone
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2, the 3-3,5-dimethylphenyl) piperazine-2-ketone
4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2,3-3,5-dimethylphenyl-5 (S)-(2-methoxy ethyl) piperazine-2-ketone
(S)-the 1-[3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(methylsulfonyl) ethyl]-2-piperazine ketone
(S)-the 1-[3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) ethyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) methyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[N-ethyl-2-kharophen]-2-piperazine ketone
(±)-5-(2-butyne base)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-2-piperazine ketone
1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-2-piperazine ketone
5 (S)-butyl-4-[1-(4-cyano group benzyl-2-methyl)-5-imidazolyl methyl]-1-(2, the 3-3,5-dimethylphenyl)-piperazine-2-ketone
4-[1-(2-(4-cyano-phenyl)-2-propyl group)-5-imidazolyl methyl]-1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-ketone
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-1-(2-aminomethyl phenyl) piperazine-2-ketone
4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5 (S)-(2-fluoro ethyl)-1-(3-chloro-phenyl-) piperazine-2-ketone
4-[3-(4-cyano group benzyl) pyridin-4-yl]-1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-ketone
4-[5-(4-cyano group benzyl)-1-imidazolyl ethyl]-1-(3-chloro-phenyl-) piperazine-2-ketone.
The specific examples of The compounds of this invention is following compound and pharmaceutically acceptable salt thereof:
1-{5-[1-(4-nitrobenzyl) imidazolyl] methyl }-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-[5-(1-benzyl imidazole) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(2, the 3-3,5-dimethylphenyl) piperazine-5-ketone
2 (S)-normal-butyl-1-[1-(4-benzyl chloride base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(2, the 3-3,5-dimethylphenyl)-2 (S)-(2-methoxy ethyl) piperazine-5-ketone
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-1-(2-aminomethyl phenyl) piperazine-2-ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(methylsulfonyl) ethyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) ethyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) methyl]-2-piperazine ketone
Compound of the present invention can have asymmetric center, thereby can exist with racemic modification, racemic mixture and various diastereomeric form, and therefore all possible isomer comprises that executing photoisomer all should comprise within the scope of the invention.As arbitrary variable (for example aryl, heterocycle, R
1, R
2Deng) when occurring (not comprising 1 time) more than 1 time in arbitrary constituent, being defined in each appearance of its each time appearance is independently.In addition, substituting group/or the combination of variable has only to be only permission when this bound energy produces stable compound.
" alkyl " used herein is meant the side chain that contains the defined amount carbon atom and the radical of saturated aliphatic alkyl of straight chain; " alkoxyl group " representative is by the alkyl that indicates carbonatoms that contains of an oxo bridge connection." halogen " used herein or " halogen " are meant fluorine, chlorine, bromine and iodine.
" aryl " used herein is meant in each ring and is at most 7 yuan any stable monocycle or bicyclic carbocyclic, and it is aromatic wherein having 1 ring at least.The example of this class aryl comprises phenyl, naphthyl, tetralyl, 2,3-indanyl, xenyl, phenanthryl, anthryl or acenaphthenyl.
5-7 unit's monocyclic heterocycles that term used herein " heterocycle " or " heterocyclic " representative are stable or stable 8-11 unit bicyclic heterocycle, can be saturated or unsaturated, and constitute by several carbon atoms and 1-4 heteroatoms that is selected from N, O and S, comprise any bicyclic radicals, wherein any one above-mentioned definition is heterocyclic fused to phenyl ring.This heterocyclic ring can be connected to any can causing and form on a kind of heteroatoms or carbon atom of rock steady structure.This comprises for the heterocyclic example, but be not limited to, azepines, benzimidazolyl-, the benzoisoxazole base, benzo furazan base, benzopyranyl, the benzo thiapyran base, benzofuryl, benzothiazolyl, benzothienyl benzoxazolyl, chromanyl, cinnolinyl, dihydro benzo furyl, the dihydrobenzo thienyl, the thiochroman base, thiochroman base sulfone, furyl, imidazolidyl, imidazolinyl, imidazolyl, indolinyl, indyl, the isochroman base, iso-dihydro-indole-group, isoquinolyl, the isothiazole alkyl, isothiazolyl, the isothiazole alkyl, morpholinyl, naphthyridine base oxadiazole base, 2-oxo azepines base oxazolyl, 2-oxo piperazinyl, 2-oxo-piperidine base, 2-oxo-pyrrolidine base, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidyl, pyrazolyl, pyridazinyl, pyrimidyl, pyrrolidyl, pyrryl, quinazolyl, quinolyl, quinoxalinyl, tetrahydrofuran base, tetrahydro isoquinolyl, tetrahydric quinoline group, thio-morpholinyl, the thio-morpholinyl sulfoxide, thiazolyl, thiazolinyl, the thienofuran base, the thienothiophene base, and thienyl.
" heteroaryl " used herein be meant in each ring and be at most 7 yuan any stable monocycle or bicyclic carbocyclic, wherein have at least 1 ring be aromatic series and, and wherein have 1-4 carbon atom to be selected from the heteroatoms replacement of N, O and S.The example of this class heterocyclic aryl comprises, but be not limited to benzimidazolyl-, the benzoisoxazole base, benzo furazan base, benzopyranyl, the benzo thiapyran base, benzofuryl, benzothiazolyl, benzothienyl benzoxazolyl, chromanyl, cinnolinyl, dihydro benzo furyl, the dihydrobenzo thienyl, the thiochroman base, thiochroman base sulfone, furyl, imidazolyl, indolinyl, indyl, the isochroman base, iso-dihydro-indole-group, isoquinolyl, isothiazolyl, naphthyridine base oxadiazole base, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidyl, pyrryl, quinazolyl, quinolyl, quinoxalinyl, tetrahydro isoquinolyl, tetrahydric quinoline group, thiazolyl, the thienofuran base, the thienothiophene base, and thienyl.
R in this article
2And R
3Definition in used term " group of replacement " be meant the C of replacement
1-8The C of alkyl, replacement
2-8The C of alkenyl, replacement
2-8The aryl of alkynyl, replacement or the heterocycle of replacement, substituent R
2And R
3Just be selected from these groups.
R in this article
6, R
7And R
7aDefinition in the C that replaces
1-8The C of alkyl, replacement
3-8The heteroaryl sulphonyl of the 4-hetaroylpyrazol of the aroyl of alkenyl, replacement, the aryl of replacement, replacement, the arylsulfonyl of replacement, replacement and the heterocycle of replacement comprise the link position that contains 1-3 substituent part and be connected to this compound rest part.
Term used herein " aryl of replacement " means and comprises 1 or 2 aryl that group replaces that are selected from following one group of group, and this group group includes, but are not limited to F, Cl, Br, CF
3, NH
2, N (C
1-C
6Alkyl)
2, NO
2, CN, (C
1-C
6Alkyl) O-,-OH, (C
1-C
6Alkyl) S (O) m-, (C
1-C
6Alkyl) C (O) NH-, H
2N-C (NH)-, (C
1-C
6Alkyl) C (O)-, (C
1-C
6Alkyl) OC (O)-, N
3, (C
1-C
6Alkyl) OC (O) NH-and C
1-C
20Alkyl.
Work as R
2And R
3Combining becomes-(CH
2) during u-, just form circular part.Such circular part includes, but are not limited to:
In addition, such circular part can randomly comprise 1 or several heteroatoms.Thisly contain heteroatomic circular part and example includes, but are not limited to:
From substituting group (for example from R
2, R
3, R
4Deng) the pointed key of line explanation signed on the ring system can be connected on any commutable ring carbon atom.
Be preferably R
1aAnd R
1bBe independently selected from: hydrogen ,-N (R
10)
2, R
10C (O) NR
10-, the perhaps unsubstituted or C that replaces
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from unsubstituted or the phenyl that replaces ,-N (R
10)
2, R
10O-and R
10C (O) NR
10-.
Better be R
2Be selected from: H
With group unsubstituted or that replace, this group is selected from C
1-8Alkyl, C
2-8Alkenyl and C
2-8Alkynyl;
The group of wherein said replacement is replaced by following one or more groups: 1) aryl or heterocycle unsubstituted or that replaced by following groups;
A) C
1-C
4Alkyl,
b)(CH
2)pOR
6,
c)(CH
2)pNR
6R
7,
15) N
3, or
16)F,
Better be R
3Be selected from: hydrogen and C
1-C
6Alkyl.
Better be R
4And R
5Be hydrogen.
Better be R
6, R
7And R
7aBe selected from: hydrogen, the unsubstituted or C that replaces
1-C
6Alkyl, unsubstituted or the aryl and the cycloalkyl unsubstituted or that replace that replace.
Better be R
6aBe C unsubstituted or that replace
1-C
6Alkyl, unsubstituted or the aryl and the cycloalkyl unsubstituted or that replace that replace.
Better be R
9Be hydrogen or methyl.Best R
9Be hydrogen.
Better be R
10Be selected from H, C
1-C
6Alkyl and benzyl.
Better be A
1And A
2Be independently selected from: 1 key ,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-and-N (R
10) S (O)
2-.
Better be that V is selected from hydrogen, heterocycle and aryl.Best, V is a phenyl.
Better be that Y is selected from the unsubstituted or phenyl that replaces, the unsubstituted or naphthyl that replaces, the unsubstituted or pyridyl that replaces, unsubstituted or the furyl and the thienyl unsubstituted or that replace that replace.Best, Y is a phenyl unsubstituted or that replace.
Better be that Z is selected from the unsubstituted or phenyl that replaces, the unsubstituted or naphthyl that replaces, the unsubstituted or pyridyl that replaces, unsubstituted or the furyl and the thienyl unsubstituted or that replace that replace.Best, Z is a phenyl unsubstituted or that replace.
Better be that W is selected from imidazolinyl, imidazolyl, oxazolyl, pyrazolyl, pyrrolidyl, thiazolyl and pyridyl.Best, W is selected from imidazolyl and pyridyl.
Better be that n and r are 0,1 or 2 independently.
Better be that p is 1,2 or 3.
Better be that s is 0.
Better be that t is 1.
Better be, in the compound of formula B, when G is H2 and W when being imidazolyl, substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not H.
Better be, in the compound of formula B, when X be-C (=O)-or-S (=O) during m-, t is 1, and substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not H.
Intention is that any substituting group or variable are (as R on specific position of an intramolecularly
1a, R
9, n etc.) definition and it is irrelevant in other the locational definition of this intramolecularly.Therefore ,-N (R
10)
2Representative-NHH ,-NHCH
3,-NHC
2H
5Deng.Should be understood that, substituting group on the The compounds of this invention and replacement mode can be by the personnel selections with the general technical ability of this gate technique, to provide chemically stable and can be easily with technical known technology and the calm facile starting raw material synthetic compound of those methods proposed below.
The pharmaceutically acceptable salt of The compounds of this invention comprises the non-toxic salt commonly used of The compounds of this invention, can be from generating such as nontoxic mineral acid or organic acid.For example, such non-toxic salt commonly used comprises from mineral acid deutero-salt such as hydrochloric acid, Hydrogen bromide, sulfuric acid, thionamic acid, phosphoric acid, nitric acid; With salt from the preparation of organic acids such as acetate, propionic acid, succsinic acid, oxyacetic acid, stearyl, lactic acid, oxysuccinic acid, tartrate, citric acid, xitix, palmitinic acid, toxilic acid, hydroxymaleic acid, toluylic acid, L-glutamic acid, phenylformic acid, Whitfield's ointment, 2-acetoxy-benzoic acid, fumaric acid, toluenesulphonic acids, methylsulfonic acid, ethionic acid, oxalic acid, different ethionic acid, trifluoroacetic acid.
The pharmaceutically acceptable salt of The compounds of this invention can be synthetic from the The compounds of this invention that contains base with chemical process commonly used.In general, these salt or be to use ion exchange chromatography, or prepare by making this free alkali and stoichiometric quantity or reacting in a kind of suitable solvents or all kinds of SOLVENTS combination with excessive desired salify mineral acid or organic acid.
Be used for producing the reaction of The compounds of this invention, may be known on document or other standard operations such as the ester hydrolysis of experimental arrangement illustrated, blocking group fracture, can also adopt the reaction shown in the scheme 1~22 to prepare.Substituent R shown in these schemes, R
aAnd R
bRepresent substituent R
2, R
3, R
4And R
5Yet they are exemplary with the tie point of ring, and do not mean that and limit.
These reactions can be used to provide The compounds of this invention by linear precedence, also can be used for synthesizing some segments, are linked in sequence by means of the alkylated reaction described in these schemes then.
Scheme 1~22 general introduction
Needed intermediate, major part is commercial getting in some cases, also can prepare according to literature method.For example, in scheme 1, having summarized has the synthetic of piperazine that the 2-alkyl replaces, and this to be J.S.Kiely and S.R.Priebe basically exist
Organic Preparations and Proceedings Int., 1990,22, the method described in the 761-768.Commercial get or can be according to the amino acid I preparation of the known method of the personnel that are familiar with this gate technique, that the Boc protection is arranged; can be in a kind of solvent such as methylene dichloride, chloroform, ethylene dichloride or dimethyl formamide; with various dewatering agents such as DCC (dicyclohexyl carbodiimide) or EDCHCl (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride), be coupled on the N-benzylamino acid esters.Then, product II for example uses hydrogenchloride, or make it deprotection with trifluoroacetic acid in methylene dichloride with acid in chloroform or ethyl acetate, and cyclisation under weak basic condition, provides diketopiperazine III.III provides piperazine IV with lithium aluminum hydride reduction under ether refluxes, and the latter is protected and become Boc derivative V.This N-benzyl group can rupture under the standard processing conditions, for example carries the palladium hydrogenation 24~48 hours with the Pa Er device with 60psi hydrogen and 10% charcoal.Product VI can be handled with a kind of carboxylic acid with a kind of acyl chlorides or under the standard dehydration conditions, provides carboxylic acid amides VII; Final sour deprotection as described above provides intermediate VIII (scheme 2).Intermediate VIII can with various aldehyde for example IX carry out standard reductive alkylation.These aldehyde can be used such as O.P.Goel, U.Krolls, and M.Stier and S.Kesten exist
Organic Syntheses, 1988.67, standard program such described in the 69-75 is from suitable amino acid preparation (scheme 3).This standard reductive alkylation can with various reductive agents such as triacetyl oxygen sodium borohydride or sodium cyanoborohydride, carry out at pH 5~7 in a kind of solvent such as ethylene dichloride, methyl alcohol or dimethyl formamide.Product X can use the trifluoroacetic acid deprotection and provide final compounds X I in methylene dichloride.Final compounds X I is isolating with salt form, for example, becomes a kind of trifluoroacetate, hydrochloride or acetate, and other salt.Further selective protection is to obtain XII for product diamines XI, and the latter can carry out standard reductive alkylation and obtain XIII subsequently with second kind of aldehyde.The removing and, can carry out of protecting group according to literature method to the conversion of cyclisation product such as glyoxalidine XV.
In addition, have protection piperazine intermediate VII can also with other aldehyde for example 1-trityl-4-imidazolyl formaldehyde or 1-trityl-4-imidazolyl acetaldehyde carry out standard reductive alkylation, provide such as the such product of XVI (scheme 4).Trityl-protecting group is removed to provide XVII from XVI, and perhaps substituting is, XVI can handle with a kind of alkylogen earlier, makes it deprotection subsequently again to provide alkylation imidazoles XVIII.Another kind of way is to make intermediate VIII alkylation or sulfonation with standard technique.Imidazoleacetic acid XIX can change into acetate XXI by standard step, and XXI can react with a kind of alkylogen earlier, handles with backflow methyl alcohol then, so that the alkylating imidazoleacetic acid ester of regiospecific XXII to be provided.Hydrolysis and condensation reagent for example 1-(3-dimethylamino-propyl)-3-ethyl carbodiimide (EDC) in the presence of with piperazine VIII reaction, cause for example XXIV of alkylating product.
If piperazine VIII be with a kind of aldehyde that a protected hydroxyl also arranged for example the XXV in the scheme 6 carry out standard reductive alkylation, these blocking groups are removed, thereby make this hydroxyl lose shielding (scheme 6,7).This alcohol can be oxidized to for example a kind of aldehyde under standard conditions, can make it then and for example Grignard reagent reaction of various organometallic reagents, to obtain secondary alcohol such as XXIX.In addition, the amino alcohol XXX of deprotection can (under the described in front condition) carry out standard reductive alkylation with various aldehyde fully, to obtain secondary amine such as XXXI (scheme 7) or tertiary amine.
The amino alcohol XXVII of Boc protection also can be used for for example XXXII (scheme 8) of Synthetic 2-aziridine methylpiperazine.A kind of solvent for example in the dimethyl formamide with 1,1 '-sulphonyl diimidazole and sodium hydride handle XXVII, cause generating aziridine XXXII.This aziridine a kind of nucleophilic reagent for example mercaptan in the presence of and in the presence of alkali, react, produce open-loop products XXXIII.
In addition, piperazine VIII can also with from amino acid derived aldehyde for example O-alkylation tyrosine react according to standard program, obtain such compound such as XXXIX.When R ' is an aryl, XXXIX can first hydrogenation so that phenol exposes true colours, make amino deprotection to produce XL with acid again.In addition, can also remove the amine protecting group among the XXXIX, produce such as the such O-alkylated phenol type amine of XLI.
Different because of the title of amino acid I, can be connected to various side chains on this piperazine.For example, when I is the aspartic acid β-benzyl ester of Boc protection, obtain the intermediate diketopiperazine XLII of n=1 and R=benzyl, as shown in scheme 10.Lithium aluminium hydride reduction subsequently makes this ester be reduced into pure XLIII, then can be in dimethyl formamide or tetrahydrofuran (THF) at alkaline condition for example under the sodium hydride, with for example alkyl iodide reaction of various alkylating agents.Then, can described in scheme 3~9, make resultant ether XLIV continue to be advanced to final product.
The N-aryl piperazines prepares can be described in scheme 11.A kind of arylamines XLV is reacted with two (chloroethyl) amine hydrochlorate (XLVI) in the backflow propyl carbinol, provide compounds X LVII.Then, can described in scheme 3~9, resulting piperazine XLVII be continued to be advanced to final product.
Piperazine-5-ketone can prepare as shown in the scheme 12.(preparing from I like that as previously described) has the reductive amination of the amino-aldehyde XLIX of Boc protection, produces compound L. and then, this compound reacts with bromoacetyl bromide under the Schotten-Baumann condition; In a kind of polar aprotic solvent such as dimethyl formamide, carry out closed loop, provide LI with a kind of alkali such as sodium hydride.This carboxylamine ester protecting group for example removes with hydrogen chloride gas with trifluoroacetic acid or in methyl alcohol or ethyl acetate in methylene dichloride under acidic conditions, can described in scheme 3~9 resulting piperazine be advanced to final product then.
Isomer piperazine-3-ketone prepares can be described in scheme 13.The imines that generates from the amino sweet ammonium aldehyde diethyl acetal of aryl carboxylic acid amides LII and 2-(LIII) can be included in the ethylene dichloride under various conditions with the sodium triacetoxy borohydride reduction, provides amine LIV.Amino acid I is coupled on the amine LIV, and resulting acid amides LV can be cyclized into undersaturated LVI when handling with aqueous acids in tetrahydrofuran (THF).Shortening provides needed intermediate LVII under standard conditions, and the latter is advanced to final product according to method described in the scheme 3~9.
Have described in the square case 14 of acquisition of the piperazine that alternate manner replaces.With after the trifluoroacetic acid deprotection, N-benzyl diethylenediamine V can be with a kind of aryl carboxylic acid acidylate.Resulting N-benzyl aryl carboxylic acid amides LIX can provide piperazine carboxylic acid amides LX at hydrogenation in the presence of a kind of catalyzer, can it be advanced to final product according to method described in the scheme 3~9 then.
Reaction scheme 15 provides an illustrative example, with the explanation substituent R
2With R
3Be combined to form-(CH
2) The compounds of this invention synthetic of u-.For example, 1-aminocyclohexane-1-carboxylic acid LXI can change into spiral shell piperazine LXVI according to the step described in scheme 1 and 2 basically.Piperazine intermediate LXIX is deprotection as before, and is advanced to final product according to the method described in the scheme 3~9.It being understood that to be used to provide the reagent that substituting group Y is 2-naphthyl and imidazolyl alkyl substituent, can easily be replaced with technical well-known and other reagent of being easy to obtain, on this piperazine so that other N-substituting group to be provided.
From the aldehyde XLIX of scheme 12, also can as shown in the scheme 16, carry out standard reductive alkylation with a kind of aniline.Product LXXI can change into a kind of piperazine ketone by carry out acidylate with chloroacetyl chloride, provides LXXII, carries out alkali subsequently and induces cyclisation and become LXXIII.Deprotection has the imidazole formaldehyde of protection to carry out standard reductive alkylation with a kind of subsequently, causes LXXV, and the latter can carry out alkylation with a kind of arylmethyl halides, to provide imidazole salts LXXVI.Carry out solvolysis with a kind of low-grade alkane alcohol such as methyl alcohol, or in the presence of trifluoroacetic acid, in methylene dichloride, handle and blocking group is finally removed, provide final product LXXVII with triethyl-silicane.
Scheme 17 explanation is a kind of also can to have the homoserine lactone LXXIX of replacement to be used for preparing the situation of a kind of piperazine ketone LXXXII of Boc protection.Intermediate LXXXII can carry out deprotection and standard reductive alkylation or acidylate as illustrated in the scheme in front.In addition, the hydroxylic moiety of intermediate LXXXII also can carry out methylsulfonylization and replace with a kind of nucleophilic reagent such as sulfur alcohol sodium salt, so that intermediate LXXXIII to be provided.Intermediate LXXXII also can oxidation, and to provide carboxylic acid on intermediate LXXXIV, the latter can be with the form utilization of ester or amide group.
That find, that a side chain is not arranged general formula LXXXVI amino acid in natural amino acid can be from the imines LXXXV of easy preparation, according to the prepared in reaction of explanation in the scheme 18.
The aldehyde that scheme 19~22 explanation can be used for The compounds of this invention synthetic that its variable W exists with the pyridyl form, have suitable replacement synthetic.Preparation is the similar synthetic strategy of the alkanol of variable W with other heterocyclic group, also is technical well-known.
Scheme 1 Scheme 2 Scheme 3 Scheme 3 (continuing) Scheme 4 Scheme 5 Scheme 5 (continuing) Scheme 6 Scheme 6 (continuing) Scheme 7 Scheme 8 Scheme 9 Scheme 9 (continuing) Scheme 10 Scheme 11 Scheme 12 Scheme 12 (continuing) Scheme 13 Scheme 14 Scheme 15 Scheme 15 (continuing) Scheme 16 Scheme 16 (continuing) Scheme 17 Scheme 17 (continuing) Scheme 18 Reaction scheme 19 Reaction scheme 20 Reaction scheme 21 Reaction scheme 22
The compounds of this invention can be used as medical agent and is used for Mammals, especially human.These compounds can be used for the treatment of cancer to patient's administration.Can include but not limited to colorectal carcinoma, exocrine pancreas cancer, myeloid leukemia and neurological tumour with the cancer types example of The compounds of this invention treatment.Such tumour can result from ras gene itself sudden change, can regulate the sudden change of the active protein of Ras (being nerve fiber protein (NF-1), neu, scr, abl, lck, fyn), or other mechanism.
The compounds of this invention can suppress the methodization of farnesyl-protein transferase and oncogenes albumen Ras.The compounds of this invention also can suppress tumor vessel to be taken place, thereby influences tumor growth (JRak et al.Cancer Research, 55:4575-4580 (1995)).More such angiogenesis inhibitor performances of The compounds of this invention also can be used for treating some blindness form relevant with retinal vesselization.
The compounds of this invention also can be used for suppressing other optimum and malignant proliferation disease, wherein Ras albumen owing to oncogenes results of mutation in other gene by the activation of distortion property (promptly, Ras gene itself does not activate into the oncogenes form because of sudden change), described inhibition is to realize by the The compounds of this invention to the administration significant quantity of this type of treatment of needs.For example, the NF-1 composition is a kind of optimum proliferative imbalance.
The compounds of this invention also may can be used for treating some viral infection, is particularly useful for treating hepatitis-δ and relevant virus (J.S.Glenn et al.Science, 256:1331-1333 (1992)).
The compounds of this invention also can be used for forming the restenosis (C.Indolfi et al.Nature medicine, 1:541-545 (1995)) that prevents behind the percutaneous puncture coronary angioplasty by suppressing neointima.
The compounds of this invention also can be used for the treatment of and prevent multicystic kidney disease (D.L.Schaffner etal.American Journal of Pathology, 142:1051-1060 (1993) and B.Cowley, Jr.et al.FASEB Journal, 2:A3160 (1988)).
The compounds of this invention also can be used for the treatment of fungi infestation.
The compounds of this invention can be learned practice or separately according to standard drug, perhaps better is combined into medical composition with pharmaceutically acceptable carrier or thinner and randomly known auxiliary agent such as alum, to Mammals, better human body administration.These compounds can per os ground or parenterally, comprises through intravenously, through intramuscular, through intraperitoneal, through subcutaneous, per rectum and local route of administration administration.
For the per os purposes according to chemotherapy compound of the present invention, the compound of selecting for use can be such as with tablet or Capsule form or with formulation administrations such as aqueous pharmaceutical or suspension liquors.Under the situation of the tablet of per os purposes, common carrier comprises lactose and W-Gum, and adds lubricant such as Magnesium Stearate usually.For the oral administration with capsule formulation, the available thinner comprises lactose and dried corn starch.When the per os purposes needs the aqueous suspension liquor, with effective constituent and emulsifying agent and suspension agent combination.If wish, can also add some sweetener and/or drug flavoring.For through intramuscular, through intraperitoneal, through subcutaneous and, prepare the sterile solution of effective constituent usually, and the pH of these solution should regulate suitably and cushion through intravenous purposes.For through intravenous purposes, the total concn of solute should be controlled, in the hope of giving said preparation with isotonicity.
Compound of the present invention also can with other well-known therapeutical agent administration in the lump, these therapeutical agents are to select according to its specific availability to the illness for the treatment of.For example, The compounds of this invention can be used for and known anticancer agents and cytotoxic agent combination.Similarly, The compounds of this invention can be used for and the medicament combination that can effectively treat and prevent following disease: NF-1, restenosis, multicystic kidney disease, hepatitis-δ and relevant virus infection, and fungi infestation.
If be mixed with fixed dosage, then such combination product adopts beneficial agents on interior The compounds of this invention of the following stated dosage range and the other medicines in the permissible dose scope thereof.When combination formula is inapplicable, compound of the present invention can also be in certain sequence on known drug acceptable medicament use.
A kind of medical composition is also contained in the present invention, and it can be used for cancer therapy, comprise the The compounds of this invention of a certain treatment significant quantity administration, have or do not have pharmaceutically acceptable carrier or thinner.Suitable compositions of the present invention comprises containing can accept carrier such as salt solution, pH level for such as 7.4 aqueous pharmaceutical on The compounds of this invention and the medicine.These solution can be introduced in patient's the blood flow with topica group injection (local bolus injection) method.
When according to compound of the present invention during to the human object administration, per daily dose will be determined by the prescription doctor usually, and this dosage is generally different because of the seriousness of age, body weight and the reaction of individual patients and patient's symptom.
In a kind of exemplary application, to the compound of a certain proper amt of Mammals administration of accepting cancer therapy.Dosage is about 0.1mg/kg body weight~about 60mg/kg body weight every day, is preferably about 0.5mg/kg body weight every day~about 40mg/kg body weight.
The compounds of this invention also can be used as a kind of composition, is used for determining rapidly the existence of a certain composition farnesyl-protein transferase (FPT enzyme) and the test of quantity.For example, composition to be tested can be divided into two parts, make these two parts to contact with the mixture of farnesyl pyrophosphate, and contain a kind of compound of the present invention in one of these mixtures with a kind of known action thing that contains the FPT enzyme (for example, the tetrapeptide of a halfcystine being arranged at its amine end).After this test, with one technical well-known enough period of each mixture incubation, make this FPT enzyme can allow this Substrate farnesylation, the chemical content of test mixture can be determined with well-known immunological technique, radiological chemistry technology or chromatographic technique.Because The compounds of this invention is the selective depressant of FPT enzyme, thereby for the existence of no change Substrate in the test that contains The compounds of this invention, not the existing or quantitatively reduce of Substrate quantity in the test mixture of no The compounds of this invention is exactly the indication of the existence of FPT enzyme in the composition to be tested.
It is evident that for the personnel that the general technical ability of this gate technique is arranged above-described a kind of like this test will can be used for differentiating the tissue sample that contains farnesyl-protein transferase and this enzyme is carried out quantitatively.Therefore, potent inhibitor compound of the present invention can be used for being intended to determine the reactive site burette test of the quantity of enzyme in the sample.The known action thing that contains the tissue extract of unknown quantity farnesyl-protein transferase, excessive FPT enzyme by some parts (for example, the tetrapeptide that a halfcystine is arranged at its amine end) and a series of samples of forming of farnesyl pyrophosphate, one section reasonable time of incubation in the presence of the The compounds of this invention of different concns.Make the enzymic activity of this sample suppress the concentration of 50% needed a kind of enough potent inhibitors (being the concentration much smaller inhibitor of its Ki), approximate half of concentration of this enzyme in this specific sample greatly than enzyme in test container.
Example
The example that is provided is intended to help further understand the present invention.The certain material, species and the condition that adopt, its intention is to further specify the present invention, and is not restrictive in its zone of reasonableness.It is with 40 * 100mm Waters PrepPa that the HPLC method is purified
Anti-phase HPLC post (Delta-Pak
TMC18 15 μ m, 100 ) finish.Gradient elution adopts 0.1% trifluoroacetic acid aqueous solution (solvent orange 2 A) and 0.1% trifluoroacetic acid acetonitrile solution (solvent B).The muriate salt is by means of making the trifluoroacetic acid salt brine solution by a Biorad AG
3 * 4 ion exchange resin columns (100~200 orders, Cl-type) obtain.Each example all utilizes the HPLC method to purify in the example of below mentioning 1~23,27,48 and 49.
Example 1
2 (S-)-butyl-1-(2,3-diamino third-1-yl)-4-(1-naphthoyl
Base)-piperazine trihydrochloride salt
Steps A: 1-benzyl-3 (S)-normal-butyl piperazine-2,5-diketone
Title compound is to exist according to John S.Kiely and Stephen R.Priebe
Organic Preparations and Procedures Int., 22 (6), the program preparation described in the 761-768 (1990).In view of the above, (9.33g, dichloromethane solution 45.2mmol) (0.5M) adds in the methylene dichloride (250ml) dicyclohexyl carbodiimide.This solution is cooled to 0 ℃ under nitrogen, and interpolation Boc-L-nor-leucine (10.5g, 45.2mmol).Resulting soup compound stirred 5 minutes, add then the N-n-benzylglycine ethyl ester (8.72g, 45.2mmol).This is reflected at 0 ℃ and stirred 2 hours, spends the night 20 ℃ of stirrings then.Throw out is removed by filter, allow hydrogen chloride gas pass through the dichloromethane solution bubbling 2~4 hours, show that until TLC this reaction finishes.Vacuum removal solvent, residue distribute between ethyl acetate (150ml) and saturated sodium bicarbonate solution (42ml).Dried over mgso, filtration and evaporation are washed, used to organic phase with saturated sodium-chloride.Thick diketopiperazine is developed with hexane, provides the white powder title compound.
1H?NMR(300MHz,CDCl
3)δ7.24-7.40(5H,m),6.22(1H,brs),4.07(1H,dt,J=3,6Hz),3.87(1H,d,J=17Hz),3.80(1H,d,J=17?Hz),1.88(2H,m),1.35(4H,m),0.91(3H,t,J=7Hz).
Step B:4-benzyl-1-tertbutyloxycarbonyl-2 (S)-normal-butyl piperazine
The product of steps A (4.95g 0.019mol) is dissolved among the THF (200ml), is cooled to 0 ℃ on the following mechanical stirring of nitrogen limit.Slowly add lithium aluminum hydride (2.60g, 0.0685mol).This reaction refluxed 18 hours, was cooled to 0 ℃, and slowly added 5ml H successively
2O, 5ml 10% sodium hydroxide solution and 5ml H
2O stops reaction.Reactant stirred 30 minutes, filtered.The vacuum removal solvent, crude product is collected with methylene dichloride, uses dried over mgso.With the siccative filtering and removing, (4.35g 0.020mol) handles filtrate with di-t-butyl dicarbonate.At 20 ℃ after 2 hours, add saturated sodium bicarbonate.With two separate, organic phase is washed with saturated sodium-chloride water solution, uses dried over mgso then.Filter and evaporation, provide crude product, recycle silicon glue column chromatography is purified with 5% ethyl acetate-hexane solution wash-out.Obtain the spumescence title compound.
1HNMR(300MHz,DMSO-d
6)δ7.25(5H,m),3.90(1H,br?s,),3.73(1H,d,J=13?Hz),3.51(1H,d,J=13Hz),3.34(1H,d,J=13Hz),2.93(1H,m),2.75(1H,d,J=11Hz),2.62(1H,d,J=11Hz),1.90(2H,m),1.60(2H,m),1.38(9H,s),1.26(2H,m),1.04(2H,m),0.84?(3H,t,J=7Hz).
Step C:1-tertbutyloxycarbonyl-2 (S)-normal-butyl piperazine
(3.75g 11.3mmol) is dissolved in the interior methyl alcohol (75ml) of Parr bottle this container argon purge to the product of step B.Carry palladium (0.80g) to wherein adding 10% charcoal, reactant hydrogenation 24 hours under the 60psi hydrogen pressure.(Celite) removes by filter catalyzer by diatomite, and filtrate vacuum-evaporation provides the oily title compound.
1H?NMR(300?MHz,CDCl
3)δ4.08(1H,br?s),3.90(1H,d,J=12Hz),2.5-3.8(6H,m),1.80(1H,m),1.60(1H,m),1.46(9H,s),1.30(4H,m),0.90(3H,t,J=7Hz).
Step D:1-tertbutyloxycarbonyl-2 (S)-normal-butyl-4-(1-naphthoyl)
-piperazine
In the dimethyl formamide (7ml) of drying, the degassing, add 1-tertbutyloxycarbonyl-2 (S)-normal-butyl piperazine (0.325g, 1.34mmol), I-hydroxybenzotriazole (HOBT) (0.203g, 1.34mmol) and 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride (EDCHCl) (0.254g, 1.34mmol).The pH of reactant is adjusted to 7 with triethylamine, and reaction was stirred 2 hours.Decompression steams dimethyl formamide (DMF), and residue distributes between ethyl acetate and water.Organic phase is used dried over mgso with 2% aqueous potassium hydrogen sulfate, saturated sodium bicarbonate solution, saturated nacl aqueous solution washing.Obtain viscous crude shape title compound.
Step e: 2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine hydrochloride
The product of step D is dissolved in the ethyl acetate, is cooled to-40 ℃ under nitrogen, and solution is saturated with HCl (g).Make solution in 30 minutes, go back up to 0 ℃, use nitrogen purging then.Decompression removes solvent.Product evaporates 3 times with ethyl acetate.Obtain the white solid title compound.
Step F: 2,3-two (t-butoxycarbonyl amino) propionic acid
(2.86g 0.0204mol) is suspended in and contains triethylamine (5.97ml is in 1: 1 water ,-dioxs (100ml) 0.0204mol) diaminopropionic acid one hydrochloride.(11.0g 0.0448mol), adds triethylamine so that pH regulator to 9.5 simultaneously in addition to add BOC-ON.Reactant spends the night in 20 ℃ of stirrings under nitrogen.Limpid solution with water dilution is with diethyl ether (5 * 100ml) extractions.The aqueous solution is adjusted to pH1 with 5% cold aqueous hydrochloric acid, uses ethyl acetate extraction.Dried over mgso is used in organic layer water, saturated nacl aqueous solution washing then.Resulting foams (5.46g) are used the ethyl acetate crystallization, provide the white solid title compound.
Step G:N-methoxyl group-N-methyl-2,3-two (t-butoxycarbonyl amino) third
Acid amides
In the dimethyl formamide (25ml) 2,3-two (t-butoxycarbonyl amino) propionic acid (1.80g, 5.92mmol), with N-methoxyl group-N-methylamine hydrochloride (0.635g, 6.51mmol), EDCHCl (1.24g, 6.51mmol), N-hydroxybenzotriazole (0.80g, 5.92mmol) and triethylamine (0.825ml 5.92mmol) stirs together and spends the night.Decompression removes dimethyl formamide, and residue distributes between ethyl acetate and water.Organic phase is used dried over mgso with 10% hydrochloric acid, saturated sodium bicarbonate solution, saturated common salt water washing.Crude product is purified with 30% eluent ethyl acetate in the hexane with silica gel column chromatography.Obtain the spumescence title compound.
1HNMR(CDCl
3,300MHz)d?5.51(1H,br?d),4.87(1H,brs),4.72(1H,br?s),3.77(3H,s),3.50(1H,m),3.40(1H,dt,J=12,6Hz),3.20(3H,s),1.44(9H,s),1.42(9H,s).
Step H:2,3-two (t-butoxycarbonyl amino) propionic aldehyde
(0.384g 10.14mmol) is suspended in the diethyl ether (20ml) lithium aluminum hydride, is cooled to-45 ℃ under nitrogen.So that temperature of reaction the speed below-35 ℃ of remaining on is added the N-methoxyl group-N-methyl-2 in 1: 1 ether-tetrahydrofuran (THF) (60ml), and 3-two (t-butoxycarbonyl amino) propionic acid amide (2.07g, 5.96mmol).Make reaction go back up to 5 ℃, be cooled to-45 ℃ then again, (3.08g, 22.6mmol) water (20ml) solution makes reaction terminating with sal enixum.Reactant stirred 1 hour at 20 ℃, passed through diatomite filtration then.Organic phase is used dried over mgso then with 10% citric acid and saturated common salt water washing.Obtain the spumescence title compound.NMR(CDCl
3,300Mhz)d9.61(1H,s),5.60(1H,br?s),4.88(1H,br?s),4.24(1H,br?d,J=6Hz),3.68(1H,m),3.50(1H,m),1.40(9H,s),1.39(9H,s).
Step I:1-[2.3-two (t-butoxycarbonyl amino) third-1-yl]-2 (S)-
Butyl-4-(1-naphthoyl)-piperazine
(1.83g, 6.20mmol) (0.17ml, ethylene dichloride 2.9mmol) (20ml) solution is adjusted to pH 5.5 with triethylamine to 3 (S)-butyl-1-(1-naphthoyl) piperazine for (free alkali of the product of step e), acetate.(1.87g, 8.79mmol) with pulverizing molecular sieve (1g), this is reflected at and is cooled to 0 ℃ under the nitrogen to add sodium triacetoxy borohydride.Drip 2, (reactant spends the night 20 ℃ of stirrings 3-two (t-butoxycarbonyl amino) propionic aldehyde for 1.69g, ethylene dichloride 5.86mmol) (10ml) solution.Reactant is cooled to 0 ℃, makes reaction terminating with saturated sodium bicarbonate, stirs 1 hour.With 2 layers of separation, dried over mgso is used in organic layer saturated common salt water washing then.Crude product is purified with silica gel column chromatography, with 40~50% eluent ethyl acetates in the hexane, isolates spumescence title compound (Rf 0.30,50% ethyl acetate in the hexane).
Step J:1-(2,3-diamino third-1-yl)-2 (S)-butyl-4-(1
-naphthoyl)-piperazine hydrochloride
To 1-[2,3-two (t-butoxycarbonyl amino) third-1-yl] (2.13g adds trifluoroacetic acid (25ml) in methylene dichloride 3.75mmol) (75ml) solution to-2 (S)-butyl-4-(1-naphthoyl)-piperazine.At 20 ℃ after 25 minutes, solvent is steamed, residue distributes between chloroform and 20% aqueous sodium hydroxide solution.Dried over mgso is used in organic layer saturated common salt water washing.Obtain the free alkali of title compound, be yellow gluey (1.72g).A this material (52mg) is by using a 100mm Waters PrepPak
Anti-phase post (DeltaPak
TMC-18,50mM, 100 ) preparation HPLC purify, pure products separates with the gradient elution method, use be the 100%[0.1% trifluoroacetic acid aqueous solution] (solvent orange 2 A) to 50% solvent orange 2 A and 50%[0.1% trifluoroacetic acid-acetonitrile solution] (solvent B).Merge pure fraction and steam solvent, crude product is dissolved in the water, by a radical ion exchange column (Biorad AG
3 * 4 ion exchange resin, chloride type).After the lyophilize, obtain the white solid title compound.Analytical calculation value C
22H
32N
404.45HCl:
C,49.78;H,6.92;N,10.56。Measured value: C, 49.75; H, 6.72; N, 10.36.
Example 2
1-(3-amino-2-(2-naphthyl methyl amino) third-1-yl)-2 (S)
-butyl-4-(1-naphthoyl)-piperazine trihydrochloride salt
Steps A: 1-[2-amino-3-(t-butoxycarbonyl amino) third-1-yl]-
2 (S)-butyl-4-(1-naphthoyl)-piperazine
To 4-(2,3-diamino third-1-yl)-2 (S)-butyl-1-(1-naphthoyl) piperazine (0.476g, add in methylene dichloride 1.29mmol) (10ml) solution tert-Butyl dicarbonate (0.282g, 1.29mmol).Reactant stirred 2 hours altogether at 20 ℃, termination reaction then, water extraction.Dried over mgso is used in organic phase saturated common salt water washing.Crude product is purified with silica gel column chromatography, earlier with 5% methyl alcohol chloroformic solution, use 5% (9: 1 methanol-hydrogen ammonium oxide) chloroformic solution wash-out then, isolates title compound as staple crop FAB ms (m+1) 469.
Step B:1-[3-t-butoxycarbonyl amino-2-(2-naphthyl methyl amino) third
-1-yl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
Title compound prepares according to program described in the example 1 step D; different is to use the amino third-1-yl of 1-[2-amino-3-(tertbutyloxycarbonyl)]-2 (S)-butyl-4-(1-naphthoyl)-piperazine (0.287g; 0.613mmol), naphthalene-2-formaldehyde (0.95g; 0.613mmol), sodium triacetoxy borohydride (0.194g; 0.919mmol), in methylene dichloride (15ml), carry out at pH6.Crude product is purified with silica gel column chromatography, with 5% methyl alcohol chloroformic solution (Rf 0.30) wash-out, isolates the foam title compound.FAB?ms(m+1)609。
Step C:1-(3-amino-2-(2-naphthyl methyl amino) third-1-yl)
-2 (S)-butyl-4-(1-naphthoyl)-piperazine trihydrochloride salt
1-[3-t-butoxycarbonyl amino-2-(2-naphthyl methyl amino) third-1-yl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine (0.313g; 0.514mmol) methylene dichloride (10ml) solution with trifluoroacetic acid (5ml) deprotection, and change into free alkali (255mg) according to the program described in example 1 step e.40mg is by the purification of preparation HPLC, adopts with solvent orange 2 A and B (from example 1; 95% → 5% solvent orange 2 A) gradient elution of carrying out.Ion-exchange as previously discussed and lyophilize provide the white solid title compound.FAB?ms(m+1)509。Analyze: calculated value C
33H
40N
4O0.05H
2O4.45HCl:
C,59.00;H,6.68;N,8.34。Measured value: C, 59.00; H, 6.51; N, 8.44.
Example 3
2 (S)-butyl-1-{5-[1-(2-naphthyl methyl)]-4, the 5-glyoxalidine } first
Base-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
1-(3-amino-2-(2-naphthyl methyl amino) third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine (0.105g; 0.207mmol), tertiary butyl isocyanic ester (1.5ml) and silver cyanide (0.023g, 0.207mmol) under nitrogen in tube sealing 90 ℃ of heated overnight.Decompression removes volatile matter, and residue is purified with silica gel column chromatography, with 5-10% methyl alcohol chloroformic solution wash-out, provides free alkali (73mg).This free alkali is purified with the preparation HPLC described in the example 1, uses solvent orange 2 A and B (from example 1; 95% → 5% solvent orange 2 A) carries out gradient elution.Lyophilize provides the white solid title compound.FAB?ms(m+1)519。Analyze: calculated value C
34H
38N
4O0.85H
2O3.75TFA:
C,51.84;H,4.55;N,5.83。Measured value: C, 51.83; H, 4.56; N, 6.32.
Example 4
1-[5-(1-benzyl imidazole) methyl]-2 (S)-butyl-4-(1-naphthoyl
Base)-piperazine dihydrochloride
Under nitrogen in 20 ℃, to 2 (S)-butyl-1-[5-(3-trityl imidazole)] methyl-4-(1-naphthoyl)-piperazine (and 63mg, add in acetonitrile 0.103mmol) (0.5ml) solution bromotoluene (0.012ml, 0.103mmol).Reactant stirs and spends the night, and vacuum concentration is collected with the methylene dichloride (2ml) that contains triethyl-silicane (0.100ml).Add trifluoroacetic acid, reactant stirred 1 hour at 20 ℃.Steam solvent, residue is purified with HPLC (95% → 5% solvent orange 2 A).Pure fraction merges, and changes into HCl salt described in example 1 step e.Behind the cooling drying, isolate the white solid title compound.FAB?ms(m+1)467。Analyze: calculated value C
30H
34N
4O0.05H
2O3.70HCl:
C,59.81;H,6.32;N,9.30。Measured value: C, 59.78; H, 6.33; N, 9.30.
Example 5
1-{5-[1-(4-nitrobenzyl)] imidazolyl methyl }-2 (S)-butyl-4-
(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Title compound is to prepare according to the program described in the example 4; different is to use nitrobenzyl bromine (0.043g; 0.199mmol) and 2 (S)-butyl-1-[5-(3-trityl imidazole)] methyl-4-(1-naphthoyl)-piperazine (123mg, acetonitrile 0.199mmol) (2ml) solution.Crude product in ethylene dichloride (4ml) with triethyl-silicane (0 127ml, 0.80mmol) and trifluoroacetic acid (2ml) processing.Preparation HPLC (95~5% solvent orange 2 A) provides the white solid title compound.FAB?ms(m+1)512。Analyze: calculated value C
30H
33N
5O
32CF
2CO
2H0.03H
2O:
C,41.42;H,3.98;N,10.18。Measured value: C, 41.43; H, 3.96; N, 10.51.
Example 6
1-(3-kharophen methylthio group-2 (R)-amino third-1-yl)-2 (S)-Ding
Base-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
1-(3-kharophen methylthio group-2 (R)-amino third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine dihydrochloride and N-hydroxymethyl acetamide (0.010g; 0.105mmol) (press M Bodansky; A.Bodansky; " The Practice ofPeptide Synthesis "; Sprmger-Verlag; 1984, p.82 described in method preparation) dissolving 0.5 hour in trifluoroacetic acid.The vacuum removal solvent, residue is purified with preparation HPLC (85~60% solvent orange 2 A).After the lyophilize, isolate the solid state title compound.FAB?ms(m+1)457。Analyze: calculated value C
25H
36N
4O
2S2CF
2CO
2H1.9H
2O:
C,44.38;H,5.12;N,6.64。Measured value: C, 44.35; H, 5.11; N, 6.97.
Example 7
2 (S)-butyl-1-[2-(1-imidazolyl) ethyl] alkylsulfonyl-4-(1-naphthalene
Formyl radical)-piperazine two (trifluoroacetic acid) salt
Steps A: 2 (S)-butyl-4-(1-naphthoyl)-1-vinylsulfonyl
Piperazine
To 3 (S)-butyl-1-(1-naphthoyl) piperazine (0.095g, 0.285mmol) and diisopropylethylamine (0.119ml, add in methylene dichloride 0.685mmol) (3ml) solution chloroethyl SULPHURYL CHLORIDE (0.038ml, 0.314mmol).Reactant stirs under nitrogen and spends the night, and uses the saturated sodium bicarbonate termination reaction, uses ethyl acetate extraction.After dried over mgso, isolate title compound.
Step B:2 (S)-butyl-1-[2-(1-imidazolyl) ethyl] alkylsulfonyl-4-
(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Sodium hydride in being suspended in dimethyl formamide (2ml) (60% oil based dispersions, 0.024g, 0.598mmol) add imidazoles (0.043g, 0.627mmol).Under nitrogen, reactant is cooled to 0 ℃, adds 2 (S)-butyl-4-(1-naphthoyl)-1-vinylsulfonyl piperazine (0.011g, dimethyl formamide 0.29mmol) (5ml) solution.Reactant spends the night 20 ℃ of stirrings.The vacuum removal dimethyl formamide, residue is dissolved in the ethyl acetate.This solution is used dried over mgso with saturated sodium bicarbonate solution, saturated aqueous common salt extraction.Crude product earlier with silica gel column chromatography with 8% methyl alcohol chloroformic solution wash-out, use preparation HPLC (80~40% solvent orange 2 A) purification then.Trifluoroacetate is dissolved in the water, and between saturated sodium bicarbonate and ethyl acetate, distributes.Organic phase with the saturated common salt water washing, use dried over mgso.Obtain the spumescence title compound.FAB?ms(m+1)455。Analyze: calculated value C
25H
36N
4O
2S0.8H
2O:
C,61.46;H,6.79;N,11.95。Measured value: C, 61.44; H, 6.97; N, 10.72.
Example 8
2 (R)-butyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
Piperazine
Steps A: 2 (R)-butyl-4-(1-naphthoyl)-(1-three for 1-[4-
The phenmethyl imidazolyl) methyl] piperazine
In the presence of the pulverizing molecular sieve; in ethylene dichloride (7ml); make 3 (R)-butyl-1-(1-naphthoyl) piperazine (0.202g; 0.607mmol) (according in the example 1 the described method of (S) enantiomorph being prepared) and 1-trityl imidazole-4-formaldehyde (0.226g; 0.667mmol), sodium triacetoxy borohydride (0.321g, 1.52mmol) reaction.PH is adjusted to 5~6 with triethylamine/acetate.Reactant stirs and spends the night, and uses the saturated sodium bicarbonate termination reaction then.Organic layer with the saturated common salt water washing, use dried over mgso.Crude product is purified with silica gel column chromatography, earlier with 30% acetate hexane solution, use 5% methyl alcohol chloroform wash-out then, obtains title compound.
Step B:2 (R)-butyl-1-imidazolyl-4-methyl-4-(1-naphthoyl
Base)-piperazine two (trifluoroacetic acid) salt
To 2 (R)-butyl-4-(1-naphthoyl)-1-[4-(1-trityl imidazole base) methyl] (0.381g, (1.0ml 11.80mmol), adds trifluoroacetic acid (8ml) to piperazine subsequently to add triethyl-silicane in dichloromethane solution 0.616mmol).After 1 hour, with solvent evaporation, residue distributes between water and hexane.Water is injected directly into (100~40% solvent orange 2 A) on the preparation HPLC post, isolates title compound after the lyophilize.FAB?ms(m+1)377。Analyze: calculated value C
25H
36N
4O
22.35CF
3CO
2H0.32H
2O:
C,48.93;H,4.52;N,7.98。Measured value: C, 48.93; H, 4.55; N, 8.26.
Example 9
2 (S)-butyl-4-(1-naphthoyl)-1-(3-pyridylmethyl) piperazine two
Hydrochloride
Described in example 8 steps A; in the presence of the pulverizing molecular sieve; in ethylene dichloride (7ml) in pH5~6; make 3 (S)-butyl-1-(1-naphthoyl) piperazine hydrochloride (0.200g; 0.601mmol) and pyridine-3-formaldehyde (0.062ml; 0.661mmol), sodium triacetoxy borohydride (0.321g, 1.52mmol) reaction.Crude product is purified with silica gel column chromatography, with 30% acetone hexane solution wash-out, uses preparation HPLC (80~75% solvent orange 2 A) to purify subsequently.After ion-exchange, isolate title compound.FAB?ms(m+1)388。Analyze: calculated value C
25H
29N
3O2.3HCl0.95H
2O:
C,61.49;H,6.85;N,8.60。Measured value: C, 61.49; H, 7.01; N, 8.76.
Example 10
1-2 (S)-butyl-(2 (R)-(4-nitrobenzyl) amino-3-hydroxypropyl)
-4-(1-naphthoyl)-piperazine dihydrochloride
According to program described in example 8 steps A; 4-nitrobenzaldehyde (0.493g is arranged; 0.327mmol), sodium triacetoxy borohydride (0.173g; 0.817mmol); in ethylene dichloride; (120mg 0.326mmol) changes into title compound to make 1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthoyl) piperazine.Crude product is purified with preparation HPLC (100~75% solvent orange 2 A), after ion-exchange becomes HCl salt and lyophilize, obtains title compound.FAB?ms(m+1)505。Analyze: calculated value C
25H
29N
3O3.6HCl0.10H
2O:
C,54.69;H,6.30;N,8.80。Measured value: C, 54.66; H, 5.85; N, 8.31.
Example 11
1-(2 (R)-amino-3-hydroxyl heptadecyl)-2 (S)-butyl-4-(1
-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Steps A: 1-(2 (R)-t-butoxycarbonyl amino-2-formyl ethyl)-2 (S)-
Butyl-4-(1-naphthoyl)-piperazine
Oxalyl chloride (1.36ml, methylene dichloride 14.9mmol) (35ml) solution is cooled to-65 ℃ under nitrogen, and (reactant stirred 2 minutes for 2.30ml, methylene dichloride 32.4mol) (7ml) solution to add dimethyl sulfoxide (DMSO).Add 1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine (3.19g6.79mmol) solution at-10 ℃ in this solution, reactant stirred 15 minutes in this temperature.Reactant is cooled to-55 ℃, and the interpolation triethylamine (4.76ml, 34mmol).Reactant stirred 5 minutes, went back up to room temperature then.Add extra methylene dichloride, the extraction of reactant water.Organic phase is with 2% sal enixum, water, dilute sodium bicarbonate solution, saturated common salt water washing.After dried over mgso, obtain title compound.
Step B:1-(2 (R)-amino-3-hydroxyl heptadecyl)-2 (S)-butyl-
4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
In a flame-dried three-necked flask, under nitrogen, (0.25g, anhydrous tetrahydro furan 0.53mmol) (5ml) solution is cooled to 0 ℃ to make 1-(2 (R)-t-butoxycarbonyl amino-2-formyl ethyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine.(1.01ml 1M diethyl ether solution 1.01mmol), allows reactant go back up to room temperature to add chlorination heptadecyl magnesium solution with syringe.Reactant saturated sodium bicarbonate solution termination reaction, ethyl acetate extraction then.After dried over mgso, crude product is purified with silica gel column chromatography, with 25% ethyl acetate isohexane solution, use 5% methyl alcohol chloroformic solution wash-out then.Product behind the purifying is dissolved in the methylene dichloride (7ml), handles with trifluoroacetic acid (3.5ml).After 45 minutes, the vacuum removal solvent, residue is purified with preparation HPLC (95~40% solvent orange 2 A).Separate two kinds of isomer.After the lyophilize, isolate title compound diastereomer A (retention time 8.405 minutes, the gradient in 15 minutes is 100~50% solvent orange 2 As), FAB ms (m+1) 566 analyzes: calculated value C
36H
59N
3O
22.35CF
3CO
2H0.35H
2O.C,58.19;H,7.44;N,5.00。Measured value: C, 58.21; H, 7.46; N, 5.36.After the lyophilize, also isolate title compound diastereomer B (retention time 9.269 minutes, the gradient in 15 minutes is 100~50% solvent orange 2 As), FABms (m+1) 566 analyzes: calculated value C
36H
59N
3O
22.35CF
3CO
2H0.05H
2O.C,58.56;H,7.42;N,5.03。Measured value: C, 58.53; H, 7.41; N, 5.17.
Example 12
2 (S)-benzyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
Steps A: 1,3 (S)-dibenzyl piperazine-2,5-diketone
Title compound prepares according to program described in example 1 steps A, different is to use Boc-L-phenylalanine (12.8g, 48.2mmol), N-n-benzylglycine ethyl ester (9.32g, 48.2mmol) and dicyclohexyl carbodiimide (96.5ml 0.5M dichloromethane solution, 48.2mmol).Thick diketopiperazine is developed with hexane, provides the white powder title compound.
1HNMR(300?MHz,CD
3OD)δ7.0-7.4(10H,m),4.61(1H,d,J=16Hz),4.37(1H,t,J=5Hz),4.24(1H,d,J=16Hz),3.42(1H,d,J=18Hz),3.28(1H,dd,J=4,16Hz),2.96(1H,dd,J=6,16Hz),2.55(1H,d,J=18Hz).
Step B:1-tertbutyloxycarbonyl-2 (S), 4 (S)-dibenzyl piperazines
This title compound is according to the preparation of program described in the example 1 step B, and different is to use 1,3 (S)-dibenzyl piperazine-2, the 5-diketone (5.01g, 17.1mmol) and lithium aluminum hydride (2.33g, 61.4mmol), add subsequently di-t-butyl dicarbonate (4.02g, 18.4mmol).Crude product is purified with silica gel column chromatography, with 7.5% ethyl acetate-hexane solution wash-out.Obtain the white solid title compound.
1H?NMR(300MHz,CD
3OD)δ7.2-7.4(5H,m),7.0-7.2(5H,m),4.15(1H,m),3.90(1H,d,J=15Hz),3.60(1H,d,J=15Hz),3.15(1H,m),2.95(3H,m),2.7(1H,d,J=13Hz),2.02(1H,dt,J=6,13Hz),1.95(1H,br?d),1.35(9H,s).
Step C:2 (S)-benzyl-1-tert-butoxycarbonyl-piperazine
This title compound is according to the preparation of program described in the example 1 step C, and different is to use 1-tertbutyloxycarbonyl-2 (S), and (4.78g 11.3mmol) carries palladium (1.04g) with 10% charcoal to 4-dibenzyl piperazine.Obtain the oily title compound.
1H?NMR(300MHz,CD
3OD)δ7.25(5H,m),4.35(1H,m),4.00(1H,d,J=12?Hz),2.7-3.3(7H,m),1.25(9H,s).
Step D:2 (S)-benzyl-1-tertbutyloxycarbonyl-4-(1-naphthoyl)-
Piperazine
This title compound is according to the described program preparation of example 1 steps A, different is to use 2 (S)-benzyl-1-tert-butoxycarbonyl-piperazine (0.292g, 1.06mmol), 2,3-mesitylenic acid (0.159g, 1.06mmol), HOBT (0.157g, 1.02mmol), EDCHCl (0.213g, 1.11mmol) and pH can be transferred to 7 triethylamine.Obtain viscous crude shape title compound.
1HNMR(DMSO-d
6,300MHz)δ7.15(2H,m),6.06(1H,m),4.42(1H,m),3.6-4.2(2H,m),2.7-3.24(4H,m),2.24(3H,s),2.03-2.20(3H,4s),1.10-1.6(15H,m),0.72-1.00(3H,m)。
Step e: 2 (S)-benzyl-4-(1-naphthoyl)-1-[4-(1-triphen
Methylimidazolyl) methyl] piperazine
Described in example 8 steps A; in the presence of the pulverizing molecular sieve; in ethylene dichloride (7ml); make 3 (S)-benzyl-1-(1-naphthoyl) piperazine (0.173g; 0.472mmol) and 1-trityl imidazole-4-formaldehyde (0.160g; 0.472mmol), sodium triacetoxy borohydride (0.300g, 1.42mmol) reaction.Obtain the oily title compound.
Step F: 2 (S)-benzyl-1-imidazolyl-4-methyl-4-(1-naphthoyl
Base)-piperazine two (trifluoroacetic acid) salt
With triethyl-silicane (0.300ml; 1.89mmo) add 2 (S)-benzyl-4-(1-naphthoyl)-1-[4-(1-trityl imidazole base) methyl to] piperazine (0.310g; 0.472mmol) methylene dichloride (5ml) solution in, add trifluoroacetic acid (5ml) subsequently.After 1 hour solvent is steamed, residue distributes between water and hexane.Water is injected directly into (85~45% solvent orange 2 A) on the preparation HPLC post, isolates title compound after the lyophilize.FAB?ms?(m+1)411。Analyze: calculated value C
26H
26N
4O
22.75CF
3CO
2H0.05H
2O:
C,52.11;H,4.14;N,7.72。Measured value: C, 52.10; H, 4.03; N, 8.16.
Example 13
1-(2 (R)-amino-3-(3-benzylthio-) propyl group)-2 (S)-butyl-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Steps A: the methyl 1-[(1-aziridinyl)]-2 (S)-butyl-4-(1-
Naphthoyl)-piperazine
(1.67g, dimethyl formamide 3.56mmol) (DMF) (10ml) is cooled to 0 ℃ in nitrogen with 1-(2 (R)-butoxy carbonyl amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine.Add sodium hydride (0.427g, 10.6mmol, 60% oily dispersion liquid), then add 1,1 again '-the sulphonyl diimidazole (0.704g, 3.56mol).Reactant is warmed to 20 ℃, kept 1 hour, be cooled to 0 ℃ again, then the water termination reaction.Vacuum distillation DMF, residue distributes between ethyl acetate and water.Organic phase is used dried over mgso after washing with saturated brine.Crude product carries out silica gel column chromatography purifies, and uses the hexane mixed solution of 70% ethyl acetate and the chloroform mixed solution wash-out of 5% methyl alcohol successively.Obtain the principal product title compound, FAB ms (m+1) 352.Also isolate more a spot of 1-[(1-butoxy carbonyl aziridinyl) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine.
Step B:1-(2 (R)-amino-3-(3-benzylthio-) propyl group)-2 (S)-
Butyl-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
The 1-[(1-aziridinyl) methyl] (0.05g, 0.142mmol) (0.100ml's-2 (S)-butyl-4-(1-naphthoyl)-piperazine 0.852mmol) and in methyl alcohol (4ml) solution of triethylamine (0.200ml) refluxed 18 hours at benzyl sulfhydrate.Crude product uses the silica gel column chromatography of the chloroform mixed solution wash-out of 3% methyl alcohol to purify earlier, purifies with preparation HPLC (85%-10% solvent orange 2 A) then.After lyophilize, obtain title compound.FAB?ms(m+1)476。Analyze: calculated value: C
29H
37N
3OS2.6CF
3CO
2H0.3H
2O:
C, 52.83; H, 521; N, 5.40 measured values: C, 52.78; H, 5.17; N, 5.66.
Example 14
1-(2 (R)-amino-3-[3-(4-nitrobenzyl sulfenyl) propyl group]))-2 (S)-
Butyl-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
1-[(1-butoxy carbonyl aziridinyl) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine (0.050g; 0.111mmol) methyl alcohol (4ml) solution (0.070g refluxed 2 hours 0.333mmol) and in the mixture of triethylamine (0.200ml) to the nitrobenzyl thioesters at acetate.Crude product carries out silica gel column chromatography purifies, with the chloroformic solution wash-out of 3% methyl alcohol.Product behind the purifying was handled 20 minutes with the dichloromethane solution of 33% trifluoroacetic acid.Product after the solvent evaporation is refining with preparation HPLC (85%-10% solvent orange 2 A).After lyophilize, obtain title compound.FAB?ms(m+1)529。Analyze: calculated value: C
29H
36N
4O
32CF
3CO
2H0.08H
2O:
C,51.94;H,5.23;N,7.34。Measured value: C, 51.87; H, 5.06; N, 7.47.
Example 15
2 (S)-butyl-1-[(4-imidazolyl) ethyl]-4-(1-naphthoyl)-piperazine
The piperazine dihydrochloride
Steps A: N-methyl-N-methoxyl group-2-(1-trityl-1H-miaow
Azoles-4-yl) ethanamide
(1.04g, (2.48g, (4.46ml 32mmol), at room temperature stirs this suspension 18 hours trityl bromide 6.40mmol) to add triethylamine in DMF 7.68mmol) (40ml) solution toward 4-imidazoleacetic acid.After this, this mixture 3-hydroxyl-1,2,3-phentriazine-4 (3H)-ketone (HOOBT) (1.31g, 8mmol), N, the O-dimethyl hydroxylamine hydrochloride (1.56g, 16mmol) and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) (1.53g, 8mmol) handle, at room temperature stirred 24 hours.Add saturated aqueous solution of sodium bicarbonate (50ml) and water (50ml) then, gained mixture ethyl acetate extraction (2 * 100ml).The extract that merges is used saturated NaHCO successively
3The aqueous solution (100ml) and salt solution (50ml) washing, solvent vacuum-evaporation.Residue is suspended in the ether (20ml), and white solid obtains the white solid title compound after filtering.
1NMR (CD
3OD, 300MHz) δ 7.37 (10H, m), 7.16 (6H, m), 6.84 (1H, s), 3.73 (2H, s), 3.68 (3H, s) and 3.18 (3H, s) ppm.
Step B:2-(1-trityl-1H-imidazol-4 yl) acetaldehyde
Toward the product of steps A (300mg, 0.73mmol) in new distillatory is cooled to solution among-40 ℃ the THF (15ml) with dry ice/acetone, add lithium aluminum hydride (33.2mg, 0.874mmol).Allow formed suspension be warmed to+5 ℃, kept 30 minutes at 0 ℃ then.After this, reaction mixture is cooled to-40 ℃ again, successively water (33 μ l), 1.0NNaOH (33 μ l) and water (100 μ l) termination reaction.With gained suspension stirring 30 minutes, filtration, vacuum removal solvent.Residue is dissolved in the methylene dichloride (5ml), uses the washing of 10% aqueous citric acid solution (5ml) and water (5ml) successively.With organic layer drying (MgSO
4), solvent obtains title compound after vacuum-evaporation.
1HNMR (CDCl
3, 300 MHz) δ 9.79 (1H, t, J=3Hz), 7.44 (1H, s), 7.4-7.1 (15H, m), 6.76 (1H, s) and 3.63 (2H, d, J=3Hz) ppm.
Step C:2 (S)-butyl-1-[(4-imidazolyl) ethyl]-4-(1-naphthoyl Base)-piperazine two (trifluoroacetic acid) salt
Product (89mg toward step B; 0.263mmol) and 3 (S)-butyl-1-benzoyl-piperazine hydrochloride (62.6mg; 0.188mmol) 1, add in 2-ethylene dichloride (4ml) solution 3A molecular sieve (400mg) and sodium triacetoxy borohydride (200mg, 0.94mmol).This mixture at room temperature stirred 4 days.Then this mixture is filtered by sintered glass.Filtrate is diluted with methylene dichloride (50ml), water (25ml) washing.Solvent vacuum-evaporation, residue is purified by dodging chromatogram, with 2-5% ethanol/methylene wash-out, obtains the oily title compound of trityl as protecting group.This oil is dissolved in methylene dichloride (2ml) and the trifluoroacetic acid (1ml), uses triethyl silicane (2) to handle then, obtain a kind of colourless solution.This solution at room temperature stirred 3 hours, then vacuum evaporating solvent.In the residue water-soluble (20ml) that generates, with hexane (20ml) washing.Water layer obtains this title compound after lyophilize.
1HNMR (CD
3OD, 300 MHz) δ 8.83 (1H, s), 8.08-7.75 (3H.m), 7.67-7.49 (4H, m), 7.45 (1H, s), 4.5-3.8 (2H, m), 3.65-2.95 (9H, m), 2.0-1.3 (4H, m) and 2.2-0.2 (5H, m) ppm. analyzes: calculated value C
24H
30N
4O 3.45TFA 0.75H
2O
C,46.54;H,4.42;N,7.03。Measured value: C, 46.54; H, 4.41; N, 7.35.FAB HRMS accurate mass calculated value: C
23H
31N
4O 391.249787 (MH
+), measured value 391.249028.
Example 16
2 (S)-butyl-1-[(4-imidazolyl) methyl]-4-(1-naphthoyl)-
Piperazine two (trifluoroacetic acid) salt
Product (102mg toward step C; 0.30mmol) and 3 (S)-butyl-1-naphthoyl piperazine hydrochloride (62.6mg; 0.188mmol) 1; add sodium triacetoxy borohydride (200mg in 2-ethylene dichloride (5ml) solution; 0.94mmol) and triethylamine to pH=5.5, at room temperature stirred then 18 hours.After this, mixture is filtered.Filtrate is dissolved in behind vacuum concentration in the ethyl acetate (25ml), uses saturated NaHCO successively
3The aqueous solution (10ml) and salt solution (10ml) washing.Solvent vacuum-evaporation, residue is purified by dodging chromatogram, with 3-8% ethanol/methylene wash-out, obtains the title compound of trityl as protecting group.This oil is dissolved in methylene dichloride (4ml) and the trifluoroacetic acid (2ml), handles till disappearing with triethyl silicane then, obtain a kind of colourless solution.At room temperature continue to stir 10 minutes, solvent is fallen in vacuum-evaporation.The white solid that generates is partially soluble in water (7ml), filtration, filtrate prepare HPLC device and Waters PrepPak chromatographic column (47 * 300mm with Nova Prep 5000 types, C18,15 μ m, 100 dusts) being prepared HPLC purifies, with the speed wash-out (chromatography A) of 5-95% acetonitrile/water (0.1%TFA), obtain title compound after the freeze-drying with 100ml/ minute.
1HNMR (DMSO-d
6, 400 MHz, 150 ℃) and δ 8.53 (1H, s), 7.94 (2H, m), 7.79 (1H, m), 7.53 (3H, m), 7.41 (1H, m), 7.40 (1H, s), 4.12 (1H, d, J=4.8Hz), 3.95 (1H, d, J=4.8Hz), 3.70 (1H, s), 3.63 (1H, s), 3.48 (1H, s), 3.40 (1H, s), 3.01 (1H, s), 2.82 (1H, s), 2.74 (1H, s), 1.70 (1H, m), 1.49 (1H, m) .1.18 (2H, s), 1.08 (2H, s) (J=5.5Hz) ppm. analyzes and 0.77: calculated value C for 3H, t
23H
29N
4O
22TFA 0.70H
2O
C,52.55;H,5.13;N,9.08。Measured value: C, 52.54; H, 5.11; N, 9.35.FAB MS Mass Calculation value C
23H
30N
4O 377 (MH
+), measured value 377.
Example 17
2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-1H-imidazoles-5-yl)
Ethanoyl]-4-(1-naphthoyl)-piperazine dihydrochloride
Steps A: the preparation of 1H-imidazoles-4-methyl acetate hydrochloride
(4.00g blasts hydrogen chloride gas till saturated in methyl alcohol 24.6mmol) (100ml) solution toward 1H-imidazoles-4-acetic acid hydrochloride.Allow this solution at room temperature leave standstill 18 hours, obtain the solid title compound that is white in color behind the vacuum evaporating solvent.
1H NMR (CDCl
3, 400MHz) δ 8.85 (1H, s), 7.45 (1H, s), 3.89 (2H, s) and 3.75 (3H, s) ppm.
The preparation of step B:1-trityl-1H-imidazol-4 yl methyl acetate
Toward the product of steps A (7.48g, add in methylene dichloride 42.4mmol) (200ml) suspension triethylamine (17.7ml, 127mmol) and trityl bromide (16.4g 50.8mmol), stirred 72 hours then.After this, reaction mixture is used saturated NaHCO successively
3The aqueous solution (100ml) and water (100ml) washing.With organic layer vacuum-evaporation, residue obtains the white solid title compound with dodging chromatographic purification (the hexane solution gradient elution of 30-100% ethyl acetate).
1H NMR (CDCl
3, 400MHz) δ 7.35 (1H, s), 7.31 (9H, m), 7.22 (6H, m), 6.76 (1H, s), 3.68 (3H, s) and 3.60 (2H, s) ppm.
Step C:2-[1-(naphthalene-2-ylmethyl)-1H-imidazoles-5-acetate first
The preparation of ester
(4.36g adds 2-brooethyl naphthalene to the product of past step B in acetonitrile 11.4mmol) (70ml) solution, be heated to 55 ℃ and kept 4 hours.After this, reaction mixture is cooled to room temperature, filters and collect the white precipitate that is generated.Filtrate is concentrated into 30ml, is heated to 55 ℃, keeps 18 hours.After this, reaction mixture is cooled to room temperature.Filter and collect the white precipitate that is generated.Filtrate is concentrated into the 10ml volume, is heated to 55 ℃, keeps 1 hour.After this, again reaction mixture is cooled to room temperature, with ethyl acetate (25ml) dilution.Filter and collect the throw out that generates, be incorporated in the methyl alcohol (100ml) reflux 30 minutes with preceding 2 times throw out.After this, remove solvent under vacuum, the gained residue distributes between methylene dichloride (200ml) and sodium bicarbonate (100ml).The organic layer vaporising under vacuum is to doing, and residue is purified (0-6% ethanol/methylene gradient) with dodging chromatogram, obtains the pale solid title compound.
1HNMR (CDCl
3, 400MHz) δ 7.82 (2H, m), 7.75 (1H, m), 7.70 (1H, s), 7.49 (3H, m), 7.20 (1H, d, J=8.4Hz), 7.06 (1H, s), 5.32 (2H, s), 3.57 (3H, s) and 3.49 (2H, s) ppm.
Step D:2-[1-(naphthalene-2-ylmethyl)-1H-imidazoles-5-yl] acetate
The preparation of hydrochloride
2-[1-(naphthalene-2-ylmethyl)-1H-imidazoles-5-methyl acetate is dissolved in the 2.5N hydrochloric acid (50ml), is heated to 55 ℃, keeps 3 hours.After this, solution is concentrated into dried under vacuum, obtains the white solid title compound.
1H NMR (CD
3OD, 400 MHz) δ 8.92 (1H, s), 7.94 (1H, d, J=8.6Hz), 7.88 (2H, m), 7.83 (1H, s), 7.54 (3H, m), 7.43 (1H, d, J=14Hz), 5.60 (2H, s) and 3.82 (2H, s) ppm.
Step e: 2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-the 1H-imidazoles
-5-yl) ethanoyl]-preparation of 4-(1-naphthoyl)-piperazine dihydrochloride
Product (100mg toward step D; 0.330mmol), 3 (S)-butyl-1-naphthoyl piperazine hydrochloride (100mg; 0.300mmol) and 3-hydroxyl-1; 2; 3-phentriazine-4 (3H)-ketone (HOOBT) (54mg, add in DMF 0.33mmol) (2ml) solution 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) (63mg, 0.33mmol) and triethylamine (161 μ l; 1.1mmol), formed suspension was stirred 18 hours.After this, add saturated NaHCO
3The aqueous solution (7ml) filters the precipitation that is generated.Solids is dissolved in the methylene dichloride again water (25ml) and salt solution (20ml) washing.Vacuum-evaporation removes solvent, and residue is purified with preparation HPLC (chromatography A), obtains title compound after lyophilize.
1HNMR (CDCl
3, 400MHz) (1H, m), (15H, m), (2H, m), (2H, m), (7H, m), (9H, m) ppm. analyzes 1.8-0.2 4.15-2.50 4.79-4.34 5.69-5.50 8.03-7.27 δ 8.98: calculated value C
35H
35N
4O2HCl0.65H
2O:
C,67.30,H,6.16;N,8.97。Measured value: C, 67.25, H, 6.16; N, 9.15.FAB HRMS accurate mass calculated value: C
35H
36N
4O
2545.291652 (MH
+), measured value: 545.292050.
Example 18
2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-1H-imidazoles-5-yl)
Ethyl]-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Steps A: N-methyl-N-methoxyl group-2-[1-(naphthalene-2-ylmethyl)-
1H-imidazoles-5-yl)] preparation of ethanamide
Toward 2-[1-(naphthalene-2-ylmethyl)-1H-imidazoles-5-yl] acetic acid hydrochloride (0.819mg, 2.70mmol) DMF (15ml) solution in add N successively, O-dimethyl hydroxyl ammonia hydrochloric acid salt (293mg, 3.0mmol), 3-hydroxyl-1,2, and 3-phentriazine-4 (3H)-ketone (HOOBT) (489mg, 3.0mmol), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) (575mg, 3.0mmol) and triethylamine (1.67ml, 12.0mmol).This mixture at room temperature stirred 18 hours.Add saturated NaHCO then
3The aqueous solution (30ml) and water (30ml), mixture dichloromethane extraction (2 * 50ml).The organic extract that merges washs with salt solution (50ml), and vacuum-evaporation removes solvent.Residue is purified by dodging chromatogram, with 2-4% ethanol/methylene gradient elution, obtains the oily title compound.
1HNMR (CDCl
3, 400 MHz) δ 7.80 (2H, m), 7.74 (1H, m), 7.56 (1H, s), 7.47 (3H, m), 7.22 (1H, d, J=8.6Hz), 6.97 (1H, s), 5.37 (2H, s), 3.58 (2H, s), 3.51 (3H, s) and 3.12 (3H, s) ppm.
Step B:2-[1-(naphthalene-2-ylmethyl) (1H-imidazoles-5-yl)] second
The preparation of aldehyde
By the past lithium aluminum hydride (40.8mg of sleeve pipe, 1.07mmol) add the product (243mg of steps A in the suspension in be cooled to-45 ℃ tetrahydrofuran (THF) (5ml) with dry ice/acetone batch, 0 895mmol) tetrahydrofuran (THF) (5ml) solution, its adding speed should be able to holding temperature<-35 ℃.Add finish after, allow this solution be warmed to+5 ℃, be cooled to-35 ℃ then again.Water (1ml) solution that adds sal enixum (272mg) in this solution.Mixture at room temperature stirred 30 minutes, passed through diatomite filtration then.The diatomite layer pad washs with ethyl acetate (25ml).The filtrate that merges is used saturated sodium bicarbonate solution (10ml) and water (10ml) washing successively.Organic layer is infused the buttery title compound clearly after with dried over mgso, filtration and evaporation.
1HNMR (CDCl
3, 400MHz) δ 9.50 (1H, t, 2Hz), 7.85-7.70 (3H, m), 7.64 (1H, s), 7.53-7.40 (3H, m), 7.16 (1H, d, J=12Hz), 7.06 (1H, s), 5.20 (2H, s) and 3.53 (2H, m) ppm.
Step C:2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-the 1H-imidazoles
-5-yl) ethyl]-system of 4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Be equipped with
Product (58.4mg toward step B; 0.232mmol) and 3 (S)-butyl-1-naphthoyl piperazine hydrochloride (96.5mg; 0.279mmol) 1; adding 3 molecular sieves (250mg) and sodium triacetoxy borohydride in the solution among 2-ethylene dichloride (10ml) and the DMF (5ml) (236.5mg, 1.12mmol).This mixture at room temperature stirred 18 hours, filtered then.Filtrate is with methylene dichloride (100ml) dilution, with saturated sodium bicarbonate (50ml) washing.With organic layer drying (MgSO
4), filtration and vacuum-evaporation.With dodge chromatography (2-5% ethanol/methylene wash-out), with preparation HPLC (chromatography A) purify, obtain title compound earlier by the back for residue.
1H NMR (CD
3OD, 400 MHz) δ 9.04 (1H, s), 8.17-7.30 (15H, m), 5.65 (2H, s), 4.6-2.2 (11H, m) and 1.6-0.2 (9H, m) ppm.FAB HRMS accurate mass calculated value: C
35H
39N
4O531.312387 (MH
+), measured value 531.313011.
Embodiment 19
1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthalene first
Acyl group)-piperazine two (trifluoroacetic acid) salt
Steps A: N-Boc-O-benzyl Serine-(N '-methoxyl group) methane amide
Under argon shield with N-Boc-O-benzyl Serine (Bachem company; 5.0g, 16.9mmol) and HOBT (2.29g 16.9mmol) is dissolved in the dry DMF (100ml).In this solution, add N, and O-dimethyl hydroxyl amine hydrochlorate (1.98g, 20.3mmol), then at 0 ℃, adding EDC hydrochloride (3.56g, 18.6mmol).Add the 4-methylmorpholine and make pH, this mixture was at room temperature stirred 3 hours to~7 (4.5ml).This solution dilutes with EtOAc, is poured into then among the 0.5N HCl.After EtOAc extraction (2 times), organic layer water and salt water washing successively, drying (MgSO
4) and vacuum-evaporation, obtain light yellow oil.Through column chromatography (silica gel; Hexane/EtOAc 2: 1) purification obtains title compound oil, Rf (silica gel; Hexane/EtOAc 1: 1)=0.45 oil.
Step B:N-Boc-O-benzyl Serine aldehyde
(5.7g, anhydrous diethyl ether 16.9mmol) (20ml) drips of solution is added to LAH, and (0.705g is 18.5mmol) in-50 ℃ of suspension in ether (80ml) with acid amides that steps A obtains.After dropwising, this solution stirred 45 minutes at 0 ℃, and cooling is got back to-50 ℃ then, slowly adds KHSO again
4Solution (4g is in 11ml water).At room temperature this mixture was stirred 1 hour then,, use 10% citric acid solution, saturated NaHCO successively by diatomite filtration
3Solution and salt water washing, dry (MgSO
4) and evaporation, obtain a kind of oil, can be used in Rf (silica gel in the next step same as before; Hexane/EtOAc 2: 1)=0.58.
Step C:1-(2 (R)-N-Boc-amino-3-benzyloxy propyl group)-2 (S)
-butyl-4-(1-naphthoyl)-piperazine
Use Et
3N will derive from piperazine hydrochloride (1.7g, CH 574mmol) of example 1 step e
2Cl
2(25ml) pH regulator to 6 of solution, add successively then new grind and activatory 4 molecular sieves and sodium triacetoxy borohydride (4.85g, 22.9mmol).Be dissolved in 20ml CH 0 ℃ of time dropping with 20 minutes
2Cl
2In the aldehyde that derives from step B (2.08g 747mmol), at room temperature stirs this mixture 16 hours then.After this, this mixture is by diatomite filtration, with EtOAc dilution, use H successively
2O, KHSO
4Solution, NaHCO
3Solution and salt water washing.Dry (MgSO
4) after solution after vacuum-evaporation, obtain a kind of light yellow oil, pass through column chromatography (silica gel again; Hexane/EtOAc 1: 1) purification obtains spumescence title compound, Rf (silica gel; Hexane/EtOAc 2: 1)=0.15.
Step D:1-(2 (R)-N-Boc-amino-3-hydroxypropyl)-2 (S)
-butyl-4-(1-naphthoyl)-piperazine
(700mg 1.25mmol) is dissolved among the MeOH that 20ml contains 150 μ l acetate, adds 20% Pd (OH) then with the benzylic ether of step C
2/ charcoal (500mg) is with this mixture hydrogenation 16 hours under 50psi (pound/square inch) pressure.Behind diatomite filtration, remove solvent, residue is purified (EtOAc/ hexane 1: 1,5% MeOH/EtOAc then) by silica gel column chromatography, obtains the oily title compound.
Step e: 1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
EtOAc (10ml) solution of the N-Boc amine (140mg) of step D is handled until saturated with HCl (gas).After 5 minutes, clean this solution, obtain a kind of solid after removing solvent with argon gas, with it further with preparation HPLC (the C-18 post of purifying; H
2O/CH
3CN contains 0.1% TGA; Gradient).Should be water-soluble freezing, obtain the Powdered title compound of a kind of water-absorbent after the freeze-drying.FAB mass spectrum m/z=370 (M+1).Analytical calculation value C
22H
32N
3O
22.35TFA:
C, 50.31; H, 5.27; N, 6.59 measured values: C, 50.28; H, 549; N, 6.70
Example 20
1-(2 (R)-amino-4-hydroxy butyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine dihydrochloride
According to the program of example 19 steps A-E, but with N-Boc-O-benzyl homoserine (Bachem) as starting raw material, obtain the title compound of dihydrochloride form.FAB mass spectrum m/z=384 (M+1).Analyze: calculated value C
23H
33N
3O
21.5HCl:
C, 54.04; H, 7.20; N, 8.22 measured values: C, 53.95; H, 7.23; N, 8.50.
Example 21
1-(2-amino-3-(2-benzyl chloro phenyl) propyl group)-2 (S)-butyl-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
Steps A: D, L-N-Boc-is former-L-Tyrosine methyl ester
With 2 steps ((Boc)
2O/K
2CO
3THF/H
2O solution is used the EtOAc solution of diazomethane then) from D, the former tyrosine of L-(Sigma company) makes the crystalline solid title compound.
Step B:3-(2-hydroxy phenyl)-2-(N-Boc-amino) propyl alcohol
Toward the ester of steps A (1.34g, 4.54mmol) add in the solution in 0 ℃ THF (20ml) in batches LAH (400mg, 10.5mmol).At room temperature after 4 hours, dropwise add 0.4ml H successively
2O, 0.4ml 1N NaOH and 1.2ml H
2O.This soup compound was stirred 1 hour,, use THF drip washing by diatomite filtration, remove solvent after residue through chromatogram purification (silica gel; Hexane/EtOAc 1: 1), obtain the title compound of solid form.Rf (silica gel; Hexane/EtOAc 1: 1)=0.45.
Step C:3-(2-benzyl hydrogen base phenyl)-2-(N-Boc-amino) propyl alcohol
With the alcohol of step B (280mg, 1.05mmol), bromotoluene (150 μ l, 1.26mmol) and Cs
2CO
3(513mg, 1.57mmol) mixture in DMF (10ml) at room temperature reaches under the argon shield and stirred 16 hours.Then this mixture is poured in the water, with EtOAc extraction 2 times, first water is used the salt water washing then, drying (MgSO
4) and the evaporation after obtain a kind of oil.This oil is through chromatogram purification (silica gel; Hexane/EtOAc 2: 1) obtains the oily title compound after.Rf (silica gel; Hexane/EtOAc 2: 1)=0.36.
Step D:3-(2-benzyloxy phenyl)-2-(N-Boc-amino) propyl alcohol
(280mg is 0.78mmol) at 3mlDMSO, 3ml CH for the alcohol of past step C under room temperature and argon shield
2Cl
2With 0.55ml Et
3Add pyridine SO in the solution among the N
3(500mg 3.14mmol), stirs this mixture 1 hour title complex then.This solution is poured into saturated NaHCO
3In the solution, with EtOAc extraction 2 times, water and salt water washing successively, dry (MgSO
4), under vacuum, concentrate then.The oily title compound that obtains thus can be used for next step same as before.Rf (silica gel; Hexane/EtOAc 4: 1)=0.41.
Step e: 1-(2-N-Boc-amino-3-(2-benzyloxy phenyl) third
Base 2 (S)-butyl-4-(1-naphthoyl)-piperazine
Adopt the described method of example 19 step C to make the aldehyde of step D and piperazine hydrochloride coupling of example 1 step e by standard reductive alkylation.Through chromatogram purification (silica gel; Hexane/EtOAc 3: 2) obtain title compound, its form is 1: 1 a non-enantiomer mixture.Rf (silica gel; Hexane/EtOAc=0.51 and 0.45.
Step F: 1-(2-amino-3-(2-benzyloxy phenyl) propyl group)-2 (S)
-butyl-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
EtOAc (15ml) solution of the N-Boc amine (70mg) of step e is handled until saturated with HCl (gas).After 15 minutes, clean this solution, remove solvent then and obtain a kind of solid with argon gas.With preparation HPLC purification (C-18 post, H
2O/CH
3CN contains 0.1% TFA; Gradient elution), after lyophilize, obtain Powdered title compound.The FAB mass spectrum, m/z=536 (M+1).Analytical calculation value C
35H
41N
3O
22.2TFA0.35H
2O:
C, 59.68; H, 5.58; N, 5.30 measured values: C, 59.70; H, 5.60; N, 5.56.
Example 22
1-(2-amino-3-(2-hydroxy phenyl) propyl group)-2 (S)-butyl-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt, diastereomer A
Steps A: 1-(2-N-Boc-amino-3-(2-hydroxy phenyl) propyl group)
-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2-N-Boc-amino-3-(2-benzyloxy phenyl) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine (derives from example 19, step e; 290mg, 0.5mmol), acetate (60 μ l, 1.0mmol) and 20% Pd (OH)
2The mixture of/charcoal (100mg) in MeOH (20ml) hydrogenation 5 hours under 67psi pressure.Solution is by diatomite filtration, obtains a kind of oil after removing solvent, and this oil demonstrates 2 spot that obviously separate on silica gel thin-layer chromatography.Column chromatography (silica gel; Hexane: EtOAc 1: 1) provide:
A) the diastereomer A of title compound, Rf (silica gel; Hexane/EtOAc 1: 1)=0.49.
B) the diastereomer B of title compound, Rf (silica gel; Hexane/EtOAc 1: 1)=0.35.
Step B:1-(2-amino-3-(2-hydroxy phenyl) propyl group)-2 (S)-
Butyl-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt, diastereomer A
Derive from the N-Boc amine of steps A, promptly diastereomer A uses HCl (gas) deprotection in EtOAc.Be prepared HPLC (C-18 post after removing solvent; H
2O/CH
3CN contains 0.1% TFA; Gradient) purifies, obtain (after the freeze-drying) Powdered title compound.The FAB mass spectrum, m/z=446 (M+1) analytical calculation value C
28H
35N
3O
22TFA:
C, 57.05; H, 5.54; N, 6.24 measured values: C, 57.08; H, 5.64; N, 6.32.
Example 23
1-[3-(4-imidazolyl) propyl group]-2 (S)-butyl-4-(1-naphthoyl)
-piperazine two (trifluoroacetic acid) salt
Steps A: 3-(4-imidazolyl) ethyl propionate
Adopt standard chemical process, make this title compound from urinating sharp acid (Aldrich company) with 2 steps (, in ethanol, carrying out hydrogenation with 10%Pd-C then) with HCl esterification in ethanol.
1H?NMR(CDCl
3):δ1.23(3H,t),2.65(2H,t),2.94(2H,t),4.15(2H,q),6.81(1H,S),7.56(1H,s).
Step B:3-(4-imidazolyl) propyl alcohol
In 30 minutes toward derive from steps A ester (120g, 71.4mmol) add in the solution in 0 ℃ anhydrous THF (230ml) in batches LAH (2.99g, 78.6mmol).Mixture at room temperature stirs 2h, and cooling is got back to 0 ℃ then, and it is (careful dropwise to add entry (4.2ml)! ).Then drip 10.6ml 1N NaOH, the gained soup compound at room temperature stirred 1 hour.By behind the diatomite filtration with EtOAc washing, infused oily title compound (8.16g) clearly after removing solvent.
1H?NMR(CD
3OD):δ1.84(2H,pentet),2.68(2H,t),3.58(2H,t),6.88(1H,s),7.80(1H,s).
Step C:3-(4-N-Boc-imidazolyl) propyl alcohol
Derive from step B imidazoles (166mg, 1.32mmol), (Boc) 2O (302mg, 1.38mmol) and K
2CO
3(190mg 1.38mmol) stirred 2 hours in THF (10ml).Filter final vacuum and remove solvent, obtain desired oily compound.Rf (silica gel; 5% MeOH/CHCl
3)=0.17.This oil can be used for next step same as before.
Step D:1-[3-(4-imidazolyl) propyl group]-2 (S)-butyl-4-(1-
Naphthoyl)-piperazine two (trifluoroacetic acid) salt
With derive from step C alcohol (~1.32mmol) be dissolved in 4ml DMSO, 4ml CH
2Cl
2With 0.92ml Et
3Among the N, add pyridine SO then in batches
3Title complex (600mg, 5.28mmol).After 3 hours, mixture is poured among the EtOAc, uses saturated NaHCO successively
3Solution and salt solution extraction obtain corresponding aldehyde after the drying evaporation, and need not further purifies just can use.
According to the described program of example 19 step C, make this aldehyde and the piperazine coupling that derives from example 1 step e by standard reductive alkylation, again through column chromatography purification (silica gel; 5% Me0H/CHCl
3) obtain product, this product is dissolved in 10ml uses among the saturated EtOAc of HCl (gas).Remove solvent, residue is with preparing HPLC (C-18; H
2O/CH
3CN contains 0.1% TFA; Gradient) purifies.The freezing aqueous solution provides a kind of hygroscopic powder shape title compound after lyophilize.The FAB mass spectrum, m/z=405 (M+1) analyzes: calculated value C
25H
32N
4O2.35TFA 0.4H
2O:
C, 52.48; H, 5.21; N, 8.24 measured values: C, 52.45; H, 5.22; N, 8.27.
Example 24
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(1-naphthyl methyl)
Imidazoles-5-ylmethyl]-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.046g 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 1-brooethyl naphthalene.Preparing HPLC through anti-phase purifies (with 30%-75% acetonitrile/0.1% TFA; The 0.1%TFA aqueous solution of 70%-25% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)517。Analyze: calculated value C
34H
36N
4O0.05H
2O2.0TFA:
C,60.55;H,5.22;N,7.43。Measured value: C, 60.48; H, 5.12; N, 7.42.
Example 25
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-naphthyl methyl)
Imidazoles-5-ylmethyl]-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.046g 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 2-brooethyl naphthalene.Preparing HPLC through anti-phase purifies (with 30%-75% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 70%-25% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)517。Analyze: calculated value C
34H
36N
4O1.7H
2O2.0TFA:
C, 58.87; H, 5.38; N, 7.23 measured values: C, 58.90; H, 4.93; N, 7.13.
Example 26
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.041g 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with the 4-cyano-benzyl bromide.Preparing HPLC through anti-phase purifies (with 25%-65% acetonitrile/0.1% TFA; The 0.1%TFA aqueous solution of 75%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)492。Analyze: calculated value C
31H
33N
5O0.35H
2O2.0TFA:
C, 57.91; H, 4.96; N, 9.65 measured values: C, 57.93; H, 4.91; N, 9.55.
Example 27
2 (S)-normal-butyl-1-[1-(4-methoxy-benzyl) imidazoles-5-ylmethyl]-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and 4-methoxy-benzyl chlorine (0.041ml; 0.21mmol); and in reaction mixture, add potassiumiodide (100mg), made title compound.Preparing HPLC through anti-phase purifies (with 25%-65% acetonitrile/0.1%TFA; The 0.1% TFA aqueous solution of 75%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)497。Analyze: calculated value C
31H
36N
4O
21.7H
2O2.0TFA:
C, 53.40; H, 5.30; N, 7.12 measured values: C, 53.37; H, 4.78; N, 7.00.
Example 28
2 (S)-normal-butyl-1-[1-(3-methyl-2-butene base) imidazoles-5-Ji Jia
Base]-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.024ml 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 4-bromo-2-methyl-2-butene.Preparing HPLC through anti-phase purifies (with 5%-95% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 95%-5% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)445。Analyze: calculated value C
28H
36N
4O1.8H
2O2.0 TFA:
C, 54.51; H, 5.95; N, 7.95 measured values: C, 54.54; H, 5.39; N, 7.73.
Example 29
2 (S)-normal-butyl-1-[1-(4-luorobenzyl) imidazoles-5-ylmethyl]-4-
(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.026ml 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with the 4-fluoro benzyl bromide.Preparing HPLC through anti-phase purifies (with 25%-65% acetonitrile/0.1% TFA; The 0.1%TFA aqueous solution of 75%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)485。Analyze: calculated value C
30H
33FN
4O3.0H
2O2.0TFA:
C, 53.26; H, 5.39; N, 7.31 measured values: C, 53.21; H, 4.56; N, 7.08.
Example 30
2 (S)-normal-butyl-1-[1-(4-benzyl chloride base) imidazoles-5-ylmethyl]-4-
(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and the 4-chlorobenzyl chloride (0.034mg 0.21ml), and adds sodium iodide (100mg) in reaction mixture.Made title compound.Preparing HPLC through anti-phase purifies (with 25%-65% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 75%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)501。Analyze: calculated value C
30H
33ClN
4O4.8H
2O2.0TFA:
C, 50.07; H, 5.51; N, 6.87 measured values: C, 50.10; H, 4.25, N, 6.48.
Example 31
1-[1-(4-bromobenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-
(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and the 4-bromo benzyl bromo (0.053mg 0.21ml), and adds sodium iodide (100mg) in reaction mixture.Made title compound.Preparing HPLC through anti-phase purifies (with 30%-65% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 70%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)545。Analyze: calculated value C
30H
33BrN
4O1.7H
2O2.0TFA:
C, 50.78; H, 4.81; N, 6.97 measured values: C, 50.81; H, 4.39; N, 6.88.
Example 32
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethyl benzyl
Base) imidazoles-5-ylmethyl]-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.053mg 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 4-trifluoromethyl benzyl bromine.Preparing HPLC through anti-phase purifies (with 30%-65% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 70%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)535。Analyze: calculated value C
30H
33BrN
4O2.0TFA:
C, 55.12, H, 4.63; N, 7.35 measured values: C, 57.46; H, 4.98; N, 7.84.
Example 33
2 (S)-normal-butyl-1-[1-(4-methyl-benzyl) imidazoles-5-ylmethyl]-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and 4-methyl-benzyl bromine (0.029ml; 0.21mmol); but in reaction mixture, add sodium iodide (100mg), made title compound.Preparing HPLC through anti-phase purifies (with 30%-65% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 70%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)481。Analyze: calculated value C
31H
36N
4O2.6H
2O2.0TFA:
C, 55.64; H, 5.76; N, 7.42 measured values: C, 55.61; H, 5.09; N, 7.43.
Example 34
2 (S)-normal-butyl-1-[1-(3-methyl-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.029mg 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 3-methyl-benzyl bromine.Preparing HPLC through anti-phase purifies (with 25%-65% acetonitrile/0.1% TFA; The 0.1%TFA aqueous solution of 75%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)481。Analyze: calculated value C
31H
36N
4O2.0TFA:
C, 67.26; H, 6.92; N, 10.12 measured values: C, 69.60; H, 6.98; N, 10.51.
Example 35
1-[1-(4-phenylbenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyls-4
-(1-naphthoyl)-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs, from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-(0.124g, 0.200mmol) (0.029mg 0.21mmol) has made title compound to 4-(1-naphthoyl)-piperazine with 4-phenylbenzyl bromine.Preparing HPLC through anti-phase purifies (with 30%-65% acetonitrile/0.1% TFA; The 0.1%TFA aqueous solution of 70%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB ms(m+1)543。Analyze: calculated value C
36H
38N
4O4.95H
2O2.0TFA:
C,55.87;H,5.85;N,6.52。Measured value: C, 55.55; H, 4.58; N, 6.23.
Example 36
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-phenylethyl)
Imidazoles-5-ylmethyl]-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and 2-phenylethyl bromine (0.029ml; 0.21mmol); but add sodium iodide (120mg); and refluxed 12 hours, made title compound.Preparing HPLC through anti-phase purifies (with 30%-65% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 70%-35% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)481。Analyze: calculated value C
36H
38N
4O4.20H
2O2.0TFA:
C, 53.60; H, 5.96; N, 7.14. measured value: C, 53.54; H, 4.86; N, 6.86.
Example 37
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethoxy)
Imidazoles-5-ylmethyl]-piperazine two (trifluoroacetic acid) salt
According to example 4 described programs; from 2 (S)-normal-butyl-1-[5-(3-trityl imidazole base) methyl]-4-(1-naphthoyl)-piperazine (0.124g; 0.200mmol) and 4-trifluoromethoxy bromine (0.032ml; 0.21mmol); but add sodium iodide (120mg); and refluxed 12 hours, made title compound.Preparing HPLC through anti-phase purifies (with 35%-70% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 65%-30% carried out gradient elution 50 minutes) and lyophilize after obtain title compound.FAB?ms(m+1)551。Analyze: calculated value C
31H
33F
3N
4O
24.00H
2O2.0TFA:
C, 49.42; H, 5.09; N, 6.59. measured value: C, 48.95; H, 4.06; N, 6.26.
Example 38
1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }-2 (S)
The preparation of-normal-butyl-4-(1-naphthoyl)-piperazine trifluoroacetate
Steps A: the preparation of 1H-imidazoles-4-methyl acetate hydrochloride
(4.00g, methyl alcohol 24.6mmol) (100ml) solution is saturated with hydrogen chloride gas for 1H-imidazoles-4-acetic acid hydrochloride.Formed solution at room temperature left standstill 18 hours.Solvent obtains the title compound of white solid after vacuum-evaporation.
1H NMR (CDCl
3, 400 MHz) δ 8.85 (1H, s), 7.45 (1H, s), 3.89 (2H, s) and 3.75 (3H, s) ppm.
The preparation of step B:1-(trityl)-1H-imidazol-4 yl methyl acetate
Toward the product that derives from steps A (24.85g, add in DMF 0.141mmol) (115ml) solution triethylamine (57.2ml, 0.412mmol) and trityl bromide (55.3g, 0.171mol), with gained suspension stirring 24 hours.Use ethyl acetate (EtOAc) (1 liter) and water (350ml) that reaction mixture is diluted then.The saturated NaHCO of organic phase
3The aqueous solution (350ml) washing, dry (Na
2SO
4), and carry out vacuum-evaporation.Residue is with dodging chromatogram purification (SiO
2, the 0-100% ethyl acetate/hexane; Gradient elution), obtain the title compound of white solid.
1H NMR (CDCl
3, 400 MHz) δ 7.35 (1H, s), 7.31 (9H, m), 7.22 (6H, m), 6.76 (1H, s), 3.68 (3H, s) and 3.60 (2H, s) ppm.
Step C:[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] methyl acetate
Preparation
(8.00g, (4.10g 20.92mmol), heated 3 hours at 55 ℃ then to add the bromine p-tolunitrile in acetonitrile 20.9mmol) (70ml) solution toward the product that derives from step B.Make the reaction mixture cool to room temperature then, filter and collect the imidazole salts (white precipitate) that is generated.Filtrate was 55 ℃ of heating 18 hours.The reaction mixture cool to room temperature, and carry out vacuum-evaporation.In residue, add EtOAc (70ml), filter and collect formed white depositions.The imidazole salts that is precipitated out is merged, be suspended in the methyl alcohol (100ml) reflux 30 minutes.Then, under vacuum, remove solvent.The gained residue is suspended among the EtOAc (75ml), filters to isolate solids, and washs (EtOAc).The saturated NaHCO of this solids
3The aqueous solution (300ml) and CH
2Cl
2(300ml) handle, at room temperature stirred 2 hours.Tell organic layer, drying (MgSO
4), vacuum-evaporation, obtain the white solid title compound.
1HNMR (CDCl
3, 400 MHz) δ 7.65 (1H, d, J=8Hz), 7.53 (1H, s), 7.15 (1H, d, J=8Hz), 7.04 (1H, s), 5.24 (2H, s), 3.62 (3H, s) and 3.45 (2H, s) ppm.
Step D:[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] preparation of acetate
(4.44g, (17.4ml 17.4mmol) at room temperature stirs 18 hours to [1-(4-cyano group benzyl)-1H-imidazoles-5-yl] methyl acetate for (100ml) solution of THF 17.4mmol) and 1M lithium hydroxide.Add 1M HCl (17.4ml), vacuum-evaporation removes THF.This aqueous solution freeze-drying is obtained containing the white solid title compound of lithium chloride.
1H NMR (CD
3OD, 400 MHz) δ 8.22 (1H, s), 7.74 (1H, d, J=8.4Hz), 7.36 (1H, d, J=8.4Hz), 7.15 (1H, s), 5.43 (2H, s) and 3.49 (2H, s) ppm.
Step e: 1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }
The preparation of-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine trifluoroacetate
Toward the acid (100mg that derives from step D, 0.35mmol), example _ step _ amine hydrochloride (117mg, 0.35mmol), HOOBT (58mg, triethylamine (0.123ml 0.35mmol), 0.88mmol) DMF (2ml) solution in add EDC (75mg, 0.38mmol).Under agitation at room temperature reacted 16 hours, with the EtOAc dilution, organic layer is used saturated NaHCO successively
3The aqueous solution and salt water washing, dry (Na
2SO
4), and carry out vacuum-evaporation.Residue is with preparing HPLC purification (C-18; 95: 5-5: water/CH of 95
3CN contains 0.1% trifluoroacetic acid; Gradient elution).Obtain the white solid title compound after the level lease making lyophilize of collecting.
1H NMR (CD
3OD, 400 MHz) δ 9.00-8.90 (1H, m), 8.05-7.94 (2H, m), 7.94-7.40 (10H, m), 5.60-5.40 (2H, m), 5.00-2.80 (9H, m), 1.90-1.15 (4H, m) and 1.05-0.40 (5H, m) ppm. analyzes: calculated value: C
32H
33N
5O
21.40TFA; 0.55 H
2O:
C, 60.65; H, 5.19; N, 10.16. measured value: C, 60.66; H, 5.17; N, 10.06.
Example 39
5 (S)-normal-butyl-1-(2, the 3-3,5-dimethylphenyl)-4-(4-imidazolyl methyl)
Piperazine-2-ketone two (trifluoroacetic acid) salt
Steps A: N-methoxyl group-N-methyl-2 (S)-(t-butoxycarbonyl amino)-oneself
Acid amides
With 2 (S)-(t-butoxycarbonyl amino) caproic acid (24.6g; 0.106mol), N; O-dimethyl hydroxyl amine hydrochlorate (15.5g; 0.15mol), EDC hydrochloride (22.3g; 0.117mol) and HOBT (14.3g, 0.106mol) anhydrous, the degassing DMF (300ml) in stir under nitrogen protection at 20 ℃.Add N-methylmorpholine and make pH=7.Under agitation react a night, steam DMF under high vacuum, residue distributes between ethyl acetate and 2% sal enixum.Organic phase is used saturated sodium bicarbonate, water and salt water washing successively, uses dried over mgso then.Obtain title compound after under vacuum, removing solvent.
Step B:2 (S)-(t-butoxycarbonyl amino) hexanal
(5.00g, ether 0.131mol) (250ml) suspension is cooled to-45 ℃ to the lithium aluminum hydride of under nitrogen protection mechanical stirring.(holding temperature is lower than-35 ℃ simultaneously for 28.3g, ether 0.103mol) (125ml) solution to add the product that derives from steps A.After interpolation finishes, will react (mixture) and be warmed to 5 ℃, and then be cooled to-45 ℃.(holding temperature is lower than-5 ℃ for 27.3g, the 0.200mol) aqueous solution, and after the termination, reaction (mixture) was at room temperature stirred 1 hour slowly to add sal enixum.By diatomite filtration, with the ether evaporation, resistates distributes between ethyl acetate and 2% sal enixum with mixture.Through with the saturated brine washing,, obtain title compound with dried over mgso and after removing solvent.
Step C:N-(2, the 3-3,5-dimethylphenyl)-2 (S)-(t-butoxycarbonyl amino)
-hexylamine
Under nitrogen protection, (8.32ml 68.3mmol) is dissolved in the ethylene dichloride with 23 dimethyl aniline.Add acetate and make pH=5, (17.2g is 80.8mmol) with the molecular sieve of pulverizing (4g) to add sodium triacetoxy borohydride.At 20 ℃, dropwise slowly add product (13.3g, ethylene dichloride 62.1mmol) (80ml) solution that derives from step B.Reaction (mixture) is stirred and is spent the night, and uses the saturated sodium bicarbonate solution stopped reaction then.Remove water layer, organic layer washs with saturated brine, uses dried over mgso.With obtaining title compound after the hexane crystallization.
Step D:4-tertbutyloxycarbonyl-5 (S)-normal-butyl-1-(2, the 3-dimethyl benzene
Base) piperazine-2-ketone
Derive from step C product (8.50g, ethyl acetate 26.5mmol) (250ml) solution with saturated sodium bicarbonate (150ml) 0 ℃ of fierce stirring.(2.33ml, 29.1mmol), reaction (mixture) was stirred 1 hour at 0 ℃ to add chloroacetyl chloride.Be separated two, ethyl acetate is used dried over mgso with the saturated brine washing.Crude product is dissolved among the DMF (300ml) under nitrogen protection, and it is cooled to 0 ℃.Add sodium hydride (1.79g, 60% oily dispersion liquid 44.9mmol) are emitted speed to keep moderate hydrogen in batches.After 30 minutes, add extra sodium hydride (0.8g) again.To react (mixture) restir 30 minutes, use the saturated ammonium chloride termination reaction then.Vacuum steams DMF, and residue distributes between ethyl acetate and water.Organic phase is water and saturated brine washing successively, uses dried over mgso.Crude product is purified in the enterprising circumstances in which people get things ready for a trip spectrum of silicagel column, with 20-30% ethyl acetate/hexane wash-out, obtains title compound.
Step e: 5 (S)-normal-butyl-1-(2, the 3-3,5-dimethylphenyl)-4-[4-(1
-trityl imidazole base) methyl] piperazine-2-ketone
(0.570g, ethyl acetate 1.58mmol) (50ml) solution is cooled to-15 ℃ under nitrogen protection to derive from the product of step D.Bubbling fed HCl gas 15 minutes, and this reaction soln is warmed to 0 ℃, kept 2 hours.Under vacuum, remove solvent, the gained solids is dissolved in the ethylene dichloride (20ml).Add sodium triacetoxy borohydride (0.502g, 2.37mmol) and 1-trityl-4-imidazolyl formaldehyde (0.534g, 1.58mmol).Reaction (mixture) is spent the night 20 ℃ of stirrings, is poured in the saturated sodium bicarbonate solution then.Organic phase is used dried over mgso after washing with saturated brine.Carry out silica gel column chromatography with 4% ethanol/methylene as elutriant and purify, obtain title compound.
Step F: 5 (S)-normal-butyl-1-(2, the 3-3,5-dimethylphenyl)-4-(4-
Imidazolyl methyl) piperazine-2-ketone two (trifluoroacetic acid) salt
(0.233g adds the trifluoroacetic acid (2ml) of triethyl silicane (0.254ml) in methylene dichloride 0.40mmol) (6ml) solution, reaction (mixture) was stirred 2 hours at 20 ℃ toward the product that derives from step e.Under vacuum, remove volatile matter, allow residue between hexane and water-methanol two-phase, distribute.Water is injected preparation HPLC post, with 15%-60% acetonitrile/0.1%TFA; The 0.1% TFA aqueous solution mixing gradient elution of 85%-40% 50 minutes, thus obtain purifying.After lyophilize, isolate title compound.FAB?ms(m+1)341。Analyze: calculated value C
20H
28N
4O2.0TFA:
C, 50.80; H, 5.15; N, 9.87. measured value: C, 51.31; H, 5.41; N, 10.11.
Example 40
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1
-(2, the 3-3,5-dimethylphenyl) piperazine-2-ketone two (trifluoroacetic acid) salt
At 20 ℃ with 4-cyano-benzyl bromide (0.043g, 0.22mmol) join 5 (S)-normal-butyl-1-(2 that derive from example 39 step e, the 3-3,5-dimethylphenyl)-and 4-[4-(1-trityl imidazole base) methyl] (0.120g is in acetonitrile 0.21mmol) (10ml) solution for piperazine-2-ketone.After 48 hours, vacuum removal solvent, crude product are dissolved in the methylene dichloride (6ml).Add triethyl silicane (0.13ml) and trifluoroacetic acid (2ml), reaction (mixture) was stirred 2 hours at 20 ℃.The vacuum removal volatile matter, residue distributes between hexane and water-methanol two-phase.Water is injected into anti-phase and prepares in the HPLC post, with 30%-60% acetonitrile/0.1%TFA; The 0.1% TFA aqueous solution mixing gradient elution of 70%-40% 50 minutes, thus obtain purifying.After lyophilize, from water-acetonitrile solution, isolate title compound.FAB?ms(m+1)456。Analyze: calculated value C
28H
33N
5O0.7H
2O2.0TFA:
C, 55.28; H, 5.13; N, 10.07. measured value: C, 55.27; H, 5.20; N, 10.41.
Example 41
4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2, the 3-diformazan
The base phenyl)-5 (S)-(2-methoxy ethyl) piperazine-2-ketone two (trifluoroacetic acid) salt
Steps A: N-methoxyl group-N-methyl-4-benzyloxy-2 (S)-(tertiary butyloxycarbonyl
Base is amino) butyramide
According to example 39, the described program of steps A, use EDCHCl (0.680g, 3.55mmol), HOBT (0.436g, 3.23mmol) and N, (0.473g, 4.85mmol) (1.00g 3.23mmol) changes into title compound to the O-dimethyl hydroxylamine hydrochloride under pH 7 conditions in DMF (50ml) with 4-benzyloxy-2 (S)-(t-butoxycarbonyl amino) butyric acid.Through obtaining being the title compound of transparent adhesive tape form after the aftertreatment.
Step B:4-(1-benzyloxy ethyl)-2 (S)-(t-butoxycarbonyl amino) fourth
Aldehyde
According to example 39, the described program of step B with the reduction of steps A product, just makes this title compound with lithium aluminum hydride.
Step C:N-(2, the 3-3,5-dimethylphenyl)-4-(2-benzyloxy ethyl)-
2-(S)-(t-butoxycarbonyl amino) butylamine
According to example 39, the described program of step B, with 2,3-xylidine (0.505ml, 4.14mmol), sodium triacetoxy borohydride (1.20g, the molecular sieve of pulverizing 5.65mmol) (1g) in ethylene dichloride (20ml) under the condition of pH 5 product from step C prepared this title compound.This title product is to purify through silica gel column chromatography, with what obtain behind the 15% ethyl acetate/hexane wash-out.
Step D:5 (S)-(2-benzyloxy ethyl)-4-tertbutyloxycarbonyl-1-(2,3
-3,5-dimethylphenyl) piperazine-2-ketone
This title compound is according to example 39, the described program of step D, with chloroacetyl chloride (0.21ml, 2.57mmol) from the preparation of the product of step C in ethyl acetate/saturated sodium bicarbonate of 1: 1 of 60ml, then allow crude product and sodium hydride (0.373g, 60% oily dispersion liquid 9.32mmol) reacts in DMF (30ml).Through after the aftertreatment, crude product carries out silica gel column chromatography purifies, and with 30% ethyl acetate/hexane wash-out, obtains title compound.
Step e: 4-tertbutyloxycarbonyl-1-(2, the 3-3,5-dimethylphenyl)-5 (S)-(2
-hydroxyethyl) piperazine-2-ketone
The product of step D is dissolved in the methyl alcohol (40ml), adds 10% Pd/C (0.160g).Under the hydrogen pressure of 60 psi and under shaking, react a night.Remove by filter catalyzer, obtain title compound after the solvent evaporation.
Step F: 4-tertbutyloxycarbonyl-1-(2, the 3-3,5-dimethylphenyl)-5 (S)-(2
-methoxy ethyl) piperazine-2-ketone
(0.241g 0.688mmol) is dissolved in and contains methyl-iodide (0.21ml among DMF 3.44mmol) (10ml), with this solution stirring, makes it be cooled to 0 ℃ under nitrogen protection with the product of step e.(0.070g, 60% oily dispersion liquid 1.72mmol), under agitation reacted 1 hour to add sodium hydride.The water termination reaction, vacuum removal DMF.Residue distributes between ethyl acetate and water, and organic phase is washed with saturated brine, uses dried over mgso.Crude product is purified with silica gel column chromatography, with 40% ethyl acetate/hexane wash-out, obtains title compound.
Step G:1-(2, the 3-3,5-dimethylphenyl)-5 (S)-(2-methoxy ethyl)
-4-[4-(1-trityl imidazole base) methyl] piperazine-2-ketone
According to example 39, the described program of step e changes into title compound with the product of step F, and different is to use 30% trifluoroacetic acid to begin deprotection 1 hour in methylene dichloride (10ml).The vacuum removal volatile matter, residue is dissolved in the ethylene dichloride.Add triethylamine, make pH=5.Add the triacetyl sodium borohydride (0.100g, 0.468mmol) and 1-trityl-4-imidazolyl formaldehyde (0.1164g, 0.343mmol).Reaction (mixture) is spent the night 20 ℃ of stirrings, is poured in the saturated sodium bicarbonate solution then.Dried over mgso is used in organic phase salt water washing.Carry out column chromatography with 5% methyl alcohol/chloroform give elutriant and purify, obtain title compound.
Step H:4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2,
The 3-3,5-dimethylphenyl)-5 (S)-(2-methoxy ethyl) piperazine-2-ketone two (trifluoro second
Acid) salt
According to example 40 described programs, with 4-cyano-benzyl bromide (0.061g, 0.312mmol) in acetonitrile (10ml), make the product (0.182g of step G, 0.312mmol) change into title compound, then allow this thick imidazole salts and triethyl silicane (0.13ml) and trifluoroacetic acid (2ml) in methylene dichloride (6ml), react.Prepare HpLC with anti-phase and purify, with 0%-70% acetonitrile/0.1% TFA; The 0.1% TFA aqueous solution of 100%-30% carries out mixing in 60 minutes gradient elution.After lyophilize, from water, isolate title compound.FAB ms(m+1)458。Analyze: calculated value C
27H
31N
5O
20.35H
2O2.0TFA:
C, 53.81; H, 4.91; N, 10.21. measured value: C, 53.83; H, 4.95; N, 10.29.
Example 42
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-
Imidazolyl methyl]-5-[2-(methylsulfonyl) ethyl]-system of 2-piperazine ketone dihydrochloride
Be equipped with
Steps A: the preparation of 1-trityl-4-(methylol)-imidazoles
At room temperature toward 4-(methylol) imidazole hydrochloride (35.0g, add in dry DMF 260mmol) (250ml) solution triethylamine (90.6ml, 650mmol).From this solution, be settled out a kind of white solid.Dropwise add chlorine tritane (76.1g, DMF 273mmol) (500ml) solution.Reaction mixture was stirred 20 hours, be poured on then on ice, filter, wash with frozen water.Formed product filters with Leng diox furnishing soup compound, and vacuum-drying obtains the title compound of white solid form, and its purity is enough to and can uses in next step.
The preparation of step B:1-trityl-4-(acetoxy-methyl)-imidazoles
The alcohol of steps A (260mmol prepares above) is suspended in the 500ml pyridine.(74ml 780mmol), under agitation reacted 48 hours, and material becomes even in this process dropwise to add diacetyl oxide.This solution is poured among 2 liters of EtOAc, water (3 * 1 liters), the 5% HCl aqueous solution (2 * 1 liters), saturated sodium bicarbonate aqueous solution and salt water washing successively, dry then (Na
2SO
4), filter and carry out vacuum concentration, obtain crude product.Isolate the acetate of white powder form, its purity is enough to and can uses in next step reaction.
Step C:1-(4-cyano group benzyl)-5-(acetoxy-methyl)-imidazoles hydrogen
The preparation of bromate
The product of step B (85.8g, 225mmol) and α-bromo-paratolunitrile (50.1g, 232mmol) solution in 500ml EtOAc stirred 20 hours at 60 ℃, formed a kind of light-yellow precipitate in this process.To react (mixture) cool to room temperature, obtain bromination imidazole salts solid after the filtration.Filtrate is concentrated into the 200ml volume under vacuum, 60 ℃ of heating 2 hours, be cooled to room temperature again, and filter once more.Filtrate is concentrated into the 100ml volume under vacuum, again 60 ℃ of heating 2 hours, be cooled to room temperature again, concentrates under vacuum, obtains a kind of light yellow solid.All these solid matters are merged, be dissolved in the 500ml methyl alcohol, be warmed to 60 ℃ then.After 2 hours, solution concentrates under vacuum again, obtains a kind of white solid, with the hexane development, removes soluble substance.Under vacuum, remove residual solvent, obtain the title product hydrobromate of white solid form, need not further purification and just can be used in the next step.
The preparation of step D:1-(4-cyano group benzyl)-5-(methylol)-imidazoles
0 ℃ toward the acetic ester of step C (50.4g, 150mmol) add in the solution in 1.5 liters of 3: 1 THF/ water lithium hydroxide monohydrate (18.9g, 450mmol).After 1 hour, reaction mixture is concentrated under vacuum, with EtOAc (3 liters) dilution, water, saturated NaHCO successively
3The aqueous solution and salt water washing.Solution drying (Na
2SO
4), obtain a kind of crude product of light yellow bulk solids form behind filtration and the vacuum concentration, its purity is enough to be used in the next step, therefore need not further purification.
The preparation of step e: 1-(4-cyano group benzyl)-5-imidazole formaldehyde
At room temperature (21.5g, (56ml 402mmol), adds SO to the alcohol of past step D then to add triethylamine in DMSO 101mmol) (500ml) solution earlier
3-pyridine complex (40.5g, 254mmol).After 45 minutes, reaction mixture is poured among 2.5 liters of EtOAc water (4 * 1 liters) and salt water washing, drying (Na
2SO
4), the aldehyde of the powder type that obtains behind filtration and the vacuum concentration being white in color, its purity is enough to be used in subsequently the step (step L), therefore need not further purification.
Step F: (S)-2-(t-butoxycarbonyl amino)-N-methoxyl group-N-first
The preparation of-4-(methylthio group) butyramide
Under nitrogen protection at 20 ℃ with L-N-Boc-methionine(Met) (30.0g; 0.120mol), N, the O-dimethyl hydroxylamine hydrochloride (14.1g, 0.144mol), DEC hydrochloride (27.7g; 0.144mol) and HOBT (19.5g, 0.144mol) stirring together in dry DMF (300ml).Add N again, (2.3g, 23mmol), make pH is 7-8 to the O-dimethyl hydroxylamine hydrochloride.Reaction is under agitation spent the night, and DMF is distilled to half of original volume under high vacuum, and residue is at ethyl acetate and saturated NaHCO
3Distribute between the solution.Organic phase is used saturated sodium bicarbonate, water, 10% citric acid and salt water washing successively, uses dried over sodium sulfate then.Obtain title compound behind the vacuum removal solvent.
Step G:(S)-2-(t-butoxycarbonyl amino)-4-(methylthio group) butyraldehyde
Preparation
At room temperature (5.02g, ether 0.132mol) (500ml) suspension stirred 1 hour with lithium aluminum hydride.Under nitrogen protection, this solution is cooled to-50 ℃, add ether (200ml) solution of step F product (39.8g, about 0.120mol) with 30 fens clock times, and holding temperature is lower than-40 ℃.After adding, will react (mixture) and be warmed to 5 ℃, and then be cooled to-45 ℃.Thin-layer chromatographic analysis discloses reaction not exclusively.Again solution is warmed to 5 ℃, stirred 30 minutes, be cooled to-50 ℃ then.Slowly add sal enixum (72g, water 0.529mol) (200ml) solution, and holding temperature is lower than-20 ℃.With mixture be warmed to 5 ℃, by obtaining the aldehyde of title behind diatomite filtration and the vacuum concentration.
Step H:(S)-2-(t-butoxycarbonyl amino)-N-(3-chloro-phenyl-)
The preparation of-4-(methylthio group) butylamine
Under nitrogen protection; toward the 3-chloroaniline (10.3ml, 97.4mmol), the product of step G (23.9g, 97.4mmol) and acetate (27.8ml; 487mmol) add in the solution in ethylene dichloride (250ml) sodium triacetoxy borohydride (41.3g, 195mmol).Reaction is under agitation spent the night, and uses the saturated sodium bicarbonate solution termination reaction then.Solution CHCl
3Dilution, organic phase is water, 10% citric acid and salt water washing successively.The solution dried over sodium sulfate obtains crude product behind vacuum concentration, it is carried out silica gel column chromatography purify, and with 20% ethyl acetate/hexane wash-out, obtains title compound.
Step I:(S)-4-(uncle Ding Qing carbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(methylthio group) ethyl] piperazine-2-ketone
With the product of step H (22.0g, ethyl acetate 63.8mmol) (150ml) solution with saturated sodium bicarbonate (150ml) 0 ℃ of fierce stirring.(5.6ml, 70.2mmol), reaction mixture stirred 2 hours at 0 ℃ dropwise to add chloroacetyl chloride.Be separated two, ethyl acetate is mutually with using dried over sodium sulfate after 10% citric acid and the saturated brine washing.Gained crude product (27.6g) is dissolved among the DMF (300ml) behind vacuum concentration, is cooled to 0 ℃ then under argon shield.(63.9g 196mmol), under agitation reacted 2 days, allowed it be warmed to room temperature to add cesium carbonate.(10g 30mmol), under agitation reacted 16 hours to add another part cesium carbonate.Vacuum distilling goes out DMF, and residue distributes between ethyl acetate and water.Organic phase is used dried over sodium sulfate after washing with saturated brine.Crude product carries out silica gel column chromatography purifies, and with 20-25% ethyl acetate/hexane wash-out, obtains title compound.
Step J:(S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(methylsulfonyl) ethyl] piperazine-2-ketone
(14.2g, methyl alcohol 37mmol) (300ml) solution is cooled to 0 ℃, adds Magnesium monoperoxyphthalate (54.9g, methyl alcohol 111mmol) (210ml) solution with 20 fens clock times with the product of step I.Remove ice bath, allow solution be warming up to room temperature.After 45 minutes,, add 2N Na then with reaction mixture vacuum concentration half to original volume
2S
2O
3Solution makes reaction terminating.Solution is poured into EtOAc and saturated NaHCO
3In the solution, organic phase salt water washing, drying (Na
2SO
4), obtain the crude product sulfone behind filtration and the vacuum concentration.It is carried out silica gel column chromatography purify,, obtain title compound with 60-100% ethyl acetate/hexane wash-out.
Step K: (S)-1-(3-chloro-phenyl-)-5-[2-(methylsulfonyl) second
Base] preparation of piperazine-2-ketone
0 ℃ with anhydrous HCl gas bubbling feed the Boc-protection of step J piperazine ketone (1.39g, 3, in EtOAc 33mmol) (30ml) solution.The gained saturated solution was stirred 35 minutes, behind vacuum concentration, obtain the hydrochloride of white powder.This material is suspended among the EtOAc, uses rare NaHCO
3Solution-treated.Water extracts with EtOAc, and drying (Na is carried out in the salt water washing of the organic mixture of merging then
2SO
4), filtration and vacuum concentration.Resulting amine concentrates from toluene again, obtains being applicable to the title substance of next step.
Step L:(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)
-5-imidazolyl methyl]-5-[2-(methylsulfonyl) ethyl]-2-piperazine ketone dihydrochloride
Preparation
Toward the amine of step K (898mg, 2.83mmol) and the imidazole formaldehyde of step e (897mg, 4.25mmol) at 15ml 1, add in the solution in the 2-ethylene dichloride sodium triacetoxy borohydride (1.21g, 57.mmol).Under agitation reacted 23 hours, and used saturated NaHCO at 0 ℃ then
3The solution termination reaction.Solution is poured into CHCl
3In, water layer CHCl
3Strip.The organism that the merges dry (Na of the laggard row of salt water washing
2SO
4), filtration and vacuum concentration.Products therefrom is used silica gel column chromatography (95: 5: 0.5-90: 10: 0 EtOAc: MeOH: NH
4Cl) purify, the product that obtains is called in the EtOAc/ methyl alcohol, handles with 2.1 equivalent 1M HCl/ diethyl ether solutions then.Behind vacuum concentration, isolate the product dihydrochloride of white powder.
Example 43
(S)-1-(3-chloro-phenyl--4-[1-(4-cyano group benzyl)-5-miaow
The azoles ylmethyl]-5-[2-(ethylsulfonyl) ethyl]-preparation of 2-piperazine ketone dihydrochloride
Steps A: (S)-preparation of N-(tertbutyloxycarbonyl) homoserine lactone
Toward (S)-homoserine lactone hydrochloride (11.0g, 79.9mmol) and Di-tert butyl pyrocarbonate (19.2g, 88.0mmol) in the solution in the methylene dichloride of 0 ℃ of 160ml with time of 3 minutes adding diisopropyl ethyl amine (13.9ml, 79.9mmol).Allow this solution be warmed to temperature.After 3 hours, add another part Di-tert butyl pyrocarbonate (1.75g, 8.0mmol) and diisopropyl ethyl amine (0.70ml, 4.0mmol), mixture restir 2.5 hours.Solution is used 10% citric acid, saturated NaHCO successively
3With the salt water washing, carry out drying (Na then
2SO
4), filtration and vacuum concentration.The gained material is purified with silica gel column chromatography (50% EtOAc/ hexane), obtains pure title compound.
Step B:(S)-preparation of N-(tertbutyloxycarbonyl) homoserine lactonaphthol
(7.0g, (72.0ml, 1M in THF 72mmol), keep temperature of reaction and are lower than-72 ℃ the lactone of past steps A simultaneously 35mmol) dropwise to add diisobutylaluminium hydride in the solution in 175ml-78 ℃ THF.After 3 hours, add another part diisobutylaluminium hydride (10.0ml, 10mmol), add again after 1 hour another part (20.0ml, 20mmol).Through after 1 hour,,, be warming up to room temperature then more then with saturated sodium tartrate potassium solution termination reaction with-78 ℃ EtOAc.Solution is poured among the EtOAc, with the dry (Na of the laggard row of salt water washing
2SO
4), filtration and vacuum concentration.The gained material obtains the title lactonaphthol with silica gel column chromatography (50% EtOAc/ hexane).
Step C:(S)-3-(tertbutyloxycarbonyl)-N-(3-chloro-phenyl-)-4
The preparation of-hydroxyl-1-butylamine
Toward the lactonaphthol of step B (4.49g, 22.2mmol) and the 3-chloroaniline (2.58ml, 24.4mmol) add in the solution in the methylene dichloride under the 50ml room temperature acetate (1.27ml, 22.2mmol).After 10 minutes, add sodium triacetoxy borohydride (6.59g, 31.1mmol), with this solution stirring 1.5 hours.Use saturated NaHCO
3Aqueous solution termination reaction is used CH
2Cl
2Two-phase is isolated in dilution.Organism drying (Na
2SO
4), obtain a kind of solid behind filtration and the vacuum concentration, obtain the described amine of title after with silica gel column chromatography (EtOAc/ hexane) it being purified.
Step D:(S)-and N-[2-(t-butoxycarbonyl amino)-4-hydroxyl butyl]-2
The preparation of-chloro-N-(3-chloro-phenyl-) ethanamide
(5.29g 16.9mmol) is dissolved in the saturated NaHCO of 60ml EtOAc and 60ml to the anils of step C
3In the solution, be cooled to 0 ℃ then.Under fierce the stirring, and the dropping chloroacetyl chloride (1.48ml, 18.5mmol).After 2 hours, water and EtOAc diluted reaction mixture, organic layer salt water washing, drying (Na
2SO
4), obtain the chlor(o)acetamide of title behind filtration and the vacuum concentration, need not further purifies just can use.
Step e: (S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-(2-hydroxyethyl) piperazine-2-ketone
Toward the chlor(o)acetamide of step D (6.32g, 16.1mmol) add in the DMF solution of 0 ℃ of 80ml cesium carbonate (15.8g, 48.3mmol).This solution stirring is shown that until thin-layer chromatographic analysis starting material is exhausted till (about 5 hours).Solution is poured among the EtOAc water and salt water washing, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration, with silica gel column chromatography (90: 1: 0-95: 5: 0.15 CHCl
3: MeOH: NH
4OH) purification obtains containing the product of a small amount of DMF impurity.
Step F: (S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(mesyloxy) ethyl] piperazine-2-ketone
Toward the alcohol of step e (3.58g, add in 0 ℃ of dichloromethane solution of 50ml 10.1mmol) diisopropyl ethyl amine (3.5ml, 20.2mmol), then add methylsulfonyl chloride (0.936ml, 12.1mmol).With this solution stirring 45 minutes, use 10% citric acid termination reaction then.With the salt water washing of this solution, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration, need not further purification and just can be used in the next step.
Step G:(S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(ethylmercapto group) ethyl] piperazine-2-ketone
The methylsulfonyl thing of past step F (3.6g, and adding sulfur alcohol sodium in the DMF solution that 100ml 8.3mmol) is 0 ℃ (1.4g, 16.6mmol).After 2 hours, reaction mixture is poured among the EtOAc, uses saturated NaHCO
3With the salt water washing, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration, need not further purification and just can be used in the next step.
Step H:(S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(ethylsulfonyl) ethyl] piperazine-2-ketone
(3.12g adds Magnesium monoperoxyphthalate (11.6g, 23.5mmol) solution in the methyl alcohol under the 50ml room temperature to the product of past step G in methyl alcohol 7.82mmol) (50ml) solution.After 45 minutes, add 2N Na
2S
2O
3Solution makes reaction terminating.Reaction mixture is poured into EtOAc and saturated NaHCO
3In the solution, organic layer salt water washing, drying (Na
2SO
4), obtain the crude product sulfone behind filtration and the vacuum concentration.It is carried out silica gel column chromatography purify,, obtain title compound with 2% methyl alcohol/chloroform wash-out.
Step I:(S)-1-(3-chloro-phenyl-)-5-[2-(ethylsulfonyl) second
Base] preparation of piperazine-2-ketone
(1.75g is in 0 ℃ of EtOAc solution of 20ml 4.06mmol) anhydrous HCl gas bubbling to be fed the piperazine ketone of Boc protection of step H.Formed saturated solution was stirred 30 minutes, behind vacuum concentration, obtain the title compound hydrochloride of white powder.This material is suspended among the EtOAc, uses rare NaHCO then
3The aqueous solution is handled.Water extracts with EtOAc, the organic mixture of the merging dry (Na of the laggard row of salt water washing
2SO
4), filtration and vacuum concentration.The described amine of resulting title concentrates from toluene again.Obtain being applicable to the title compound of next step.
Step J:(S)-1-(3-chloro-phenyl--4-[1-(4-cyano group benzyl)
-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) ethyl]-2-piperazine ketone dihydrochloride
Preparation
Toward the amine of step I (480mg, 1.45mmol), the imidazole formaldehyde of example 42 step e (460mg, 2.2mmol) and acetate (0.415ml, 10ml 1 7.25mmol), add in the 2-dichloroethane solution sodium triacetoxy borohydride (615mg, 2.9mmol).Under agitation reacted 18 hours, and used saturated NaHCO at 0 ℃ then
3The solution termination reaction.Solution is poured into CH
2Cl
2In, the organic phase dry (Na of the laggard row of salt water washing
2SO
4), filtration and vacuum concentration.Products therefrom silica gel column chromatography (2-5% MeOH:CHCl
3) purify, obtain expecting product and less polarity boron complexes.A kind of compound dissolution in back in methylene dichloride (1ml) and benzene (5ml), was handled 18 hours with Tri N-Propyl Amine (1ml), under vacuum, concentrated then.Residue silica gel column chromatography (2-5% MeOH:CHCl
3) purify, merge with preceding a collection of product, it is dissolved in the EtOAc/ methyl alcohol, handle with 2.1 equivalent 1M HCl/ diethyl ether solutions.Behind vacuum concentration, isolate the product hydrochloride of white powder.
Example 44
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-
Imidazolyl methyl]-5-[2-(ethylsulfonyl) methyl]-system of 2-piperazine ketone dihydrochloride
Be equipped with
Steps A: (S)-2-(t-butoxycarbonyl amino)-N-(3-chloro-phenyl-)
-3-[(trityl) sulfo-]-preparation of 1-propylamine
(0.709ml adds the 4 molecular sieves that 1.2g pulverizes in the dichloromethane solution under 30ml room temperature 6.70mmol) toward the 3-chloroaniline.(3.35g 16.7mmol), then drips N-methylmorpholine, makes pH reach 6.5 to add sodium triacetoxy borohydride.(3.15g, 7.04mmol) (according to people such as S.L.Graham: pharmaceutical chemistry magazine (1994) the 37th volume, the preparation of method described in the 725-732 page or leaf) was with this solution stirring 48 hours to add L-S-trityl-N-Boc-half Guang ammonium aldehyde.Use saturated NaHCO
3Aqueous solution termination reaction with the EtOAc dilution, is separated 2.Organism salt water washing, drying (Na
2SO
4), obtain a kind of oil behind filtration and the vacuum concentration, recycle silicon glue column chromatography (15% EtOAc/ hexane) is purified it, obtains the amine of title.
Step B:(S)-N-[2-(t-butoxycarbonyl amino)-3-((trityl)
Sulfo-) propyl group]-preparation of 2-chloro-N-(3-chloro-phenyl-) ethanamide
(2.77g 4.95mmol) is dissolved in the saturated NaHCO of 73ml EtOAc and 73ml with the anils of steps A
3In the solution, be cooled to 0 ℃ then.Under fierce the stirring, drip chloroacetyl chloride (0.533ml, 6.69mmol).After 3 hours, water and EtOAc dilute reaction mixture, organic layer salt water washing, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration, the chlor(o)acetamide of title, need not further purifies just can use.
Step C:(S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[S-(trityl) thiomethyl] piperazine-2-ketone
Add in the 53ml0 ℃ of DMF solution of the chlor(o)acetamide (3.29g crude product, 4.95mmol in theory) of step B cesium carbonate (4.84g, 14.85mmol).With this solution stirring 48 hours, allow it be warmed to room temperature.Solution is poured among the EtOAc water and salt water washing, drying (Na
2SO
4), obtain the oily crude product behind filtration and the vacuum concentration.With its purification, obtain white solid product with silica gel column chromatography (20% EtOAc/ hexane).
Step D:(S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-(thiomethyl) piperazine-2-ketone
(625mg 1.04mmol) is warmed to 30 ℃ at the EtOAc (38ml) of the degassing and the solution in the ethanol (12ml) with the piperazine ketone of step C.Add AgNO
3(177mg, 1.04mmol) and pyridine (0.084ml, 8ml ethanolic soln 1.04mmol) is heated to backflow then.After 45 minutes, reaction mixture is concentrated under vacuum, be dissolved in again then among the 26ml degassing EtOAc.With H
2S gas bubbling fed this solution 2.5 minutes, added gac after 4 minutes.This material by diatomite filtration, is used the EtOAc drip washing of the degassing, vacuum concentration, and then CH from outgasing
2Cl
2In concentrate, the crude product that obtains need not further to purify just can use.
Step e: (S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[(ethylmercapto group) methyl] piperazine-2-ketone
The 3ml THF solution of the mercaptan (about 1.04mmol) of step D is joined NaH through sleeve pipe, and (51.4mg, 60% suspension in mineral oil is in 0 ℃ of THF suspension of 2ml 1.28mmol).After 10 minutes, add methyl iodide (0.079ml, 0.988mmol), with this solution stirring 1.5 hours.Reaction mixture is poured among the EtOAc, uses saturated NaHCO
3With the salt water washing, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration.With silica gel column chromatography (1% MeOH/CH
2Cl
2) purify, obtain title product.
Step F: (S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[(ethylsulfonyl) methyl] piperazine-2-ketone
(217mg adds Magnesium monoperoxyphthalate (835mg, 2ml MeOH solution 1.69mmol) to the thioether of past step e in 0 ℃ of MeOH solution of 3ml 0.563mmol).Reaction is under agitation spent the night, and allows it be warmed to room temperature.Solution is cooled to 0 ℃, adds 4ml 2NNa
2S
2O
3Solution makes reaction terminating, concentrates under vacuum then.Residue is at EtOAc and saturated NaHCO
3Distribute organic phase salt water washing, drying (Na between the solution
2SO
4), obtain white waxy solid crude product sulfone behind filtration and the vacuum concentration.
Step G:(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)
-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) methyl]-2-piperazine ketone two hydrochloric acid
The preparation of salt
(224mg adds 2.5ml trifluoroacetic acid (TFA) to the piperazine ketone of the Boc-protection of past step F in ℃ dichloromethane solution of 5ml0 0.538mmol).After 45 minutes, reaction mixture is concentrated under vacuum, carry out component distillation to remove excessive TFA with benzene then.Residue is dissolved in 4ml 1, in the 2-ethylene dichloride, is cooled to 0 ℃ then.Add the Powdered molecular sieves of 4 (340mg) in this solution, (285mg 1.34mmol) with several triethylamines, makes pH=6 then to add sodium triacetoxy borohydride.Adding derives from example 42, and (125mg 0.592mmol), under agitation reacts at 0 ℃ the imidazole formaldehyde of step e.After 2 days, reaction mixture is poured among the EtOAc, uses rare NaHCO
3Drying (Na is carried out in the aqueous solution and salt water washing then
2SO
4), filtration and vacuum concentration.Crude product is dissolved in the methyl alcohol, is injected in the preparation HPLC post, with 15%-50% acetonitrile/0.1 TFA; The 0.1% TFA aqueous solution of 85%-50% carries out 60 minutes mixing gradient elution, thereby with its purification.Behind vacuum concentration, products therefrom is at methylene dichloride and NaHCO
3Distribute water CH between the aqueous solution
2Cl
2Extraction.Organic solution salt water washing, drying (Na
2SO
4), filter, be concentrated into and obtain the product free alkali after doing, it is dissolved in CH
2Cl
2In, handle with 2.1 equivalent 1M HCl/ diethyl ether solutions.Behind vacuum concentration, isolate the product dihydrochloride of white powder.
Example 45
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazoles
Ylmethyl]-5-[N-ethyl-2-kharophen]-preparation of 2-piperazine ketone dihydrochloride
Steps A: (S)-4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-5
The preparation of-[2-(oxo) ethyl] piperazine-2-ketone
Past oxalyl chloride (0.608ml, and usefulness adding in 2-3 minute DMSO in-78 ℃ of dichloromethane solutions 6.97mmol) (0.990ml, 13.9mmol).Under agitation reacted 10 minutes, and added alcohol (2.06g, 10ml dichloromethane solution 5.81mmol), and keep temperature of reaction to be lower than-70 ℃ of example 43 step e then with 5 fens clock times.Reaction mixture was stirred 10 minutes, add triethylamine (2.43ml) then, reaction mixture stirred 5 minutes at-78 ℃, allowed it be warmed to room temperature then.After 45 minutes, solution is poured in the methylene dichloride, uses saturated NH successively
4Cl solution, 10% citric acid solution, water and salt water washing, this solution drying (Na
2SO
4), obtain the aldehyde of title behind filtration and the vacuum concentration.
Step B:(S)-4-(tertbutyloxycarbonyl)-5-(carboxymethyl)-1-(3
-chloro-phenyl-) preparation of piperazine-2-ketone
Aldehyde (1.52g toward steps A, 4.31mmol) add Textone (585mg in the solution at room temperature in 2-methyl-2-propyl alcohol (50ml) and 2-methyl-2-butene (10ml), 5.17mmol) and SODIUM PHOSPHATE, MONOBASIC (595mg, 4.31mmol) solution in 10ml water.The reaction mixture yellowing slowly faded in 45 minutes then, became the pale pink look.Solution is poured among the EtOAc, with saturated sodium sulfite solution washing, water layer 2.75M KHSO
4Solution is acidified to pH3, extracts several times with EtOAc.Organic extract drying (the Na that merges
2SO
4), obtain the carboxylic acid of title behind filtration and the vacuum concentration.
Step C:(S)-4-(tertbutyloxycarbonyl)-5-[N-ethyl-2-acetyl
Amino]-preparation of 1-(3-chloro-phenyl-) piperazine-2-ketone
The product of step B (200mg, 0.56mmol), ethylamine hydrochloride (114mg, 1.4mmol), the EDC hydrochloride (140mg, 0.73mmol) and the HOBT hydrate (113mg 0.84mmol) stirs in 0 ℃ dry DMF (3ml) under nitrogen protection together.After 1 hour, solution is warmed to room temperature, and stirring is spent the night.Vacuum removal DMF, residue distributes between ethyl acetate and water.Organic phase is used 10% citric acid, saturated sodium bicarbonate, water and salt water washing successively, uses dried over sodium sulfate.Obtain title compound behind the vacuum removal solvent.
Step D:(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-
The 5-imidazolyl methyl]-5-[N-ethyl-2-kharophen]-2-piperazine ketone dihydrochloride
Preparation
With being similar to example 42, the method described in step K and the L, (184mg 0.47mmol) has made title product from the product of step C.This product comes out with the white solid isolated in form.
Example 46
(±)-5-(2-butyne base)-1-(3-chloro-phenyl-)-4-[1-(4
-cyano group benzyl)-the 5-imidazolyl methyl]-preparation of 2-piperazine ketone dihydrochloride
The preparation of steps A: 1-(methylsulfonyl)-2-butyne
Toward 2-butyne alcohol (10.0ml, add in 0 ℃ of dichloromethane solution of 200ml 134mmol) methylsulfonyl chloride (23.4g, 134mmol), then drip diisopropyl ethyl amine (30ml, 174mmol).1.5 after hour, this solution is poured into 0.5N KHSO
4In the solution, organic layer salt water washing.Solution drying (Na
2SO
4), obtain title product behind filtration and the vacuum concentration.
Step B:(±)-the 2-[(phenmethyl) imino-]-preparation of 4-hexynoic acid ethyl ester
Toward glycine ethyl ester hydrochloride (10.11g, add in 200ml dichloromethane solution 72.4mmol) phenyl aldehyde (7.36ml, 72.4mmol), triethylamine (20.0ml, 143mmol) and sal epsom (6g).This solution was at room temperature stirred 16 hours, filter, under vacuum, concentrate then by frit.Residue distributes between ether and water, organic layer salt water washing.Solution drying (Na
2SO
4), obtain a kind of light yellow oil behind filtration and the vacuum concentration.(9.90g 51.8mmol) is dissolved among the 200ml THF, is cooled to-78 ℃ under nitrogen atmosphere to get the part of this oil.(51.8ml, 1M 51.8mmol), obtain a kind of shiny red solution dropwise to add the THF solution of potassium tert.-butoxide.After 20 minutes, (8.05g, 20ml THF solution 54.4mmol) allows this solution be warmed to room temperature to splash into the methylsulfonyl thing that derives from steps A by sleeve pipe.After 2 hours, reaction mixture is poured among the EtOAc, used saturated NaHCO successively
3Solution and salt water washing drying (Na
2SO
4), obtain title product behind filtration and the vacuum concentration.
Step C:(±)-the 2-[(tertbutyloxycarbonyl) amino]-system of 4-hexynoic acid ethyl ester
Be equipped with
The solution of step B product (about 51.8mmol) at room temperature stirs in the 5%HCl aqueous solution (100ml).After 12 hours, under vacuum, this solution concentration provided a kind of orange oil.This product is dissolved among the 50ml THF, at room temperature adds saturated NaHCO then
3Solution (50ml), then add Di-tert butyl pyrocarbonate (11.3g, 51.8mmol).After 6 hours, reaction mixture is poured among the EtOAc, used saturated NaHCO
3Solution and salt water washing, drying (Na
2SO
4), obtain title compound behind filtration and the vacuum concentration.
Step D:(±)-the 2-[(tertbutyloxycarbonyl) amino]-preparation of 4-hexynoic acid
0 ℃ add in the solution of step C product (about 51.8mmol) in THF (100ml) and water (20ml) lithium hydroxide monohydrate (6.5g, 155mmol).This solution was stirred 1 hour at 0 ℃, be warmed to room temperature then.After 48 hours, this solution is concentrated under vacuum.Aqueous mixture extracts with EtOAc, 0 ℃ with 10% HCl acidified aqueous solution, use 3 parts of dichloromethane extractions then.Dichloromethane extract drying (the Na that merges
2SO
4), obtain a kind of orange oily title product behind filtration and the vacuum concentration.
Step e: (±)-2-(t-butoxycarbonyl amino)-N-methoxyl group-N-first
The preparation of base-4-hexin acid amides
Product (the 10.58g of step D; 46.6mmol), N, the O-dimethyl hydroxylamine hydrochloride (9.09g, 93.2mmol), HOBT hydrate (9.44g; 69.9mmol) and triethylamine (13.0ml, 93.2mmol) stirring together in 0 ℃ dry DMF (150ml) under nitrogen protection.(11.5g 60.0mmol), under agitation reacted 3 hours to add the EDC hydrochloride.Solution distributes between 2: 1 ethyl acetate/hexane and water, successively water, the 10% HCl aqueous solution, saturated NaHCO
3Dried over sodium sulfate is used in solution and salt water washing then.Obtain orange oily title compound behind the vacuum removal solvent.
The preparation of step F: (±)-2-(t-butoxycarbonyl amino)-4-hexin aldehyde
(1.56g, ether 41.1mmol) (150ml) suspension at room temperature stirred 30 minutes lithium aluminum hydride.Under nitrogen atmosphere, this solution is cooled to-55 ℃, adds step e product (11.10g, ether 41.1mmol) (150ml) solution, and holding temperature is lower than-50 ℃ with 15 fens clock times.After adding, reaction mixture is warmed to 5 ℃, is cooled to-40 ℃ then.The 25ml aqueous solution that slowly adds sal enixum (21.8g) keeps temperature to be lower than-35 ℃.Mixture is warmed to room temperature, stirs 1 hour by obtaining the aldehyde of title behind diatomite filtration and the vacuum concentration.
Step G:(±)-2-(t-butoxycarbonyl amino)-N-(3-chloro-phenyl-)
-4-butine amine
Toward 3 chloroaniline (4.33ml under nitrogen atmosphere, 40.9mmol), add in the product (about 41mmol) of step F and 0 ℃ of solution of 4 molecular sieves (10g) in ethylene dichloride (100ml) pulverized sodium triacetoxy borohydride (12.9g, 61.5mmol).Under agitation reacted 1 hour, and be warmed to room temperature then.After 3 hours solution is poured among the EtOAc, successively water, saturated NaHCO
3Solution and salt water washing.This solution obtains crude product behind dried over sodium sulfate and vacuum concentration.
Step H:(±)-N-[2-(t-butoxycarbonyl amino)-4-hexin base]-2
The preparation of-chloro-N-(3-chloro-phenyl-) ethanamide
Step G product (1.68g, 5.22mmol) and triethylamine (1.2ml, 15ml CH 8.61mmol)
2Cl
2Solution is cooled to 0 ℃.(0.457ml 5.74mmol), under agitation reacts at 0 ℃ to splash into chloroacetyl chloride.After 30 minutes, splash into another part chloroacetyl chloride (0.20ml) and triethylamine (0.5ml).After 30 minutes, reaction mixture is poured among the EtOAc, with the 10% HCl aqueous solution, saturated NaHCO
3The aqueous solution and salt water washing.Solution drying (Na
2SO
4), obtain a kind of brown oil behind filtration and the vacuum concentration.Obtain title product after with silica gel column chromatography (20-35% EtOAc/ hexane) it being purified.
Step I:(±)-4-(tertbutyloxycarbonyl)-5-(2-butyne base)-1-
The preparation of (3-chloro-phenyl-)-2-piperazine ketone
(1.68g adds Cs in 0 ℃ of anhydrous DMF solution of 15ml 4.23mmol) to the product of past step H
2CO
3(3.08g, 9.48mmol).With this solution stirring 30 minutes, allow it be warmed to room temperature then.After 14 hours, reaction mixture is poured in the 50% EtOAc/ hexane water and salt water washing, drying (Na
2SO
4), obtain crude product behind filtration and the vacuum concentration.Obtain title product after with silica gel column chromatography (20-40%EtOAc/ hexane) it being purified.
Step J:(±)-5-(2-butyne base)-1-(3-chloro-phenyl-)-4-
The preparation of [1-(4-cyano group benzyl)-5-imidazolyl methyl]-2-piperazine ketone dihydrochloride
Piperazine ketone (1.03g, adding 4ml trifluoroacetic acid (TFA) in ℃ dichloromethane solution of 7ml0 2.85mmol) toward the Boc protection that derives from step I.After 4 hours, reaction mixture is warmed to room temperature, and restir 6 hours.Solution is carried out vacuum concentration, carries out component distillation to remove excessive TFA with benzene.A part of residue is dissolved in 6ml 1, in the 2-ethylene dichloride, and is cooled to 0 ℃.Add the molecular sieve (600mg) that 4 pulverize in this solution, then add sodium triacetoxy borohydride (214mg, 1.02mmol).(186mg 0.881mmol), under agitation reacts at 0 ℃, after 24 hours, reaction mixture is poured among the EtOAc, uses rare NaHCO to add the imidazole formaldehyde that derives from example 42 step e
3Dry (the Na of the laggard row of the aqueous solution and salt water washing
2SO
4), filtration and vacuum concentration.With silica gel column chromatography (2-5%MeOH: CH
2Cl
2) obtain a kind of white foam body after the purification, with its molten CH
2Cl
2In, handle with 2.1 equivalent 1M HCl/ diethyl ether solutions.Behind vacuum concentration, isolate the product dihydrochloride of white powder.
Example 47
1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl) imidazolyl methyl]-2
-piperazine ketone dihydrochloride
The preparation of steps A: N-(3-chloro-phenyl-) ethylenediamine-hydrochloride
(30.0ml dropwise adds 4N HCl 1 in 0 ℃ of dichloromethane solution of 500ml 284mmol), the solution in the 4-diox (80ml, 320mmol HCl) toward the 3-chloroaniline.This solution is warmed to room temperature, under vacuum, is concentrated into the dried white powder that obtains then.With this powder and 2-oxazolidone (24.6g, 282mmol) together under nitrogen atmosphere 160 ℃ of heating 10 hours, solids fusing in this process, and observed gas and emitted.After the reaction mixture cooling, form light brown solid crude product diamine hydrochloride.
The preparation of step B:N-(tertbutyloxycarbonyl)-N '-(3-chloro-phenyl-) quadrol
The amine hydrochlorate (about 282mmol, the coarse raw materials for preparing above) of steps A is dissolved in 500mlTHT and the saturated NaHCO of 500ml
3In the aqueous solution, be cooled to 0 ℃, add then Di-tert butyl pyrocarbonate (61.6g, 282mmol).After 30 hours, reaction mixture is poured among the EtOAc water and salt water washing, drying (Na
2SO
4), obtain brown oily title carbamate behind filtration and the vacuum concentration, need not further purification and just can be used in the next step.
Step C:N-[2-(uncle Ding Qing formamyl) ethyl]-N-(3-chlorobenzene
Base)-preparation of 2-chlor(o)acetamide
Step B product (77g, about 282mmol) and triethylamine (67ml, 500ml CH 480mmol)
2Cl
2Solution is cooled to 0 ℃.(25.5ml 320mmol), keeps 0 ℃, under agitation reacts to splash into chloroacetyl chloride.After 3 hours, splash into another part chloroacetyl chloride (3.0ml).After 30 minutes, reaction mixture is poured among the EtOAc (2 liters), successively water, saturated NH
4The Cl aqueous solution, saturated NaHCO
3The salt water washing of the aqueous solution.Solution drying (Na
2SO
4), obtain brown buttery title chlor(o)acetamide behind filtration and the vacuum concentration, need not further purification and just can be used in the next step.
Step D:4-(tertbutyloxycarbonyl)-1-(3-chloro-phenyl-)-2-piperazine ketone
Preparation
In the 700ml anhydrous DMF solution of the chlor(o)acetamide that derives from step C (about 282mmol), add K
2CO
3(88g 0.64mmol), places 70-75 ℃ oil bath to heat 20 hours this solution, and cool to room temperature concentrates under vacuum then, removes about 500ml DMF.In the remaining material impouring 33% EtOAc/ hexane, water and salt water washing, drying (Na
2SO
4), obtain brown oily product behind filtration and the vacuum concentration.With its purification, obtain pure products with silica gel column chromatography (25-50%EtOAc/ hexane), and the product sample (HPLC purity assay about 65%) that contains small amount of polar impurity.
The preparation of step e: 1-(3-chloro-phenyl-)-2-piperazine ketone
(17.19g, 55.4mmol) in the solution in-78 ℃ 500ml EtOAc, formed saturated solution is warmed to 0 ℃ to the piperazine ketone that the Boc that anhydrous HCl gas bubbling feeding is derived from step D protects, and stirs 12 hours.Bubbling feeds nitrogen to drive away excessive HCl in the reaction mixture, then this mixture is warmed to room temperature.Solution obtains the hydrochloride of white powder behind vacuum concentration.It is dissolved in 300ml CH
2Cl
2In, and handle with the rare o aqueous solution.Water CH
2Cl
2(8 * 300ml) extractions are till thin-layer chromatographic analysis shows extraction fully.Organic mixture drying (the Na that merges
2SO
4), obtain the unhindered amina of the light brown oily of title behind filtration and the vacuum concentration.
Step F: 1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-
Imidazolyl methyl]-preparation of 2-piperazine ketone dihydrochloride
Toward 0 ℃ 1 of the 200ml of the amine (55.4mmol prepares above) of step e, the 2-dichloroethane solution adds 4 mealy molecular sieves (10g), then add sodium triacetoxy borohydride (17.7g, 83.3mmol).Adding derives from example 42, and (11.9g 56.4mmol) under agitation reacts at 0 ℃ the imidazole formaldehyde of step e.After 26 hours, in reaction mixture impouring EtOAc, use rare NaHCO
3Solution washing, water layer is stripped with EtOAc.The organism that the merges dry (Na of the laggard row of salt water washing
2SO
4), filtration and vacuum concentration.Products therefrom is dissolved in benzene/CH of 5: 1 of 500ml
2Cl
2In, add propylamine (20ml) then.Mixture was stirred 12 hours, behind vacuum concentration, obtain a kind of light yellow foam.With silica gel column chromatography (2-7% MeOH/CH
2Cl
2) with its purification, resulting white foam is dissolved in CH
2Cl
2In, handle with 2.1 equivalent 1M HCl/ diethyl ether solutions.Behind vacuum concentration, isolate the product dihydrochloride of white powder.
Example 48
5 (S)-butyl-4-[1-(4-cyano group benzyl)-2-methyl-5-imidazolyl first
Base]-1-(2, the 3-3,5-dimethylphenyl)-piperazine-2-ketone dihydrochloride
Steps A: 4-bromo-glyoxal ethyline-5-formaldehyde
According to S.P.Watson: synthesising communication, 22, method described in the 2971-2977 (1992) prepares 4-bromo-5-methylol-glyoxal ethyline.(4.18g, solution 21.9mmol) refluxed 16 hours in 1: 1 methylene dichloride/diox (200ml) with Manganse Dioxide (16.1g) 4-bromo-5-methylol-glyoxal ethyline.Cooled reaction mixture obtains the light yellow solid title compound by diatomite filtration after concentrating.
1H?NMR(CDCl
3,300MHz)δ9.57(1H,s),2.52(3H,s)。
Step B:4-bromo-1-(4-cyano group benzyl)-glyoxal ethyline-5-first
Aldehyde
(1.05g, (1.02g is in N,N-DIMETHYLACETAMIDE 5.39mmol) in (15ml) solution 5.39mmol) to join 4-bromo-glyoxal ethyline-5-formaldehyde with the 4-cyano-benzyl bromide.This solution is cooled to-10 ℃, and the adding powdered potassium carbonate (0.745g, 5.39mmol).Under agitation-10 ℃ of reactions 2 hours, again 20 ℃ of reactions 4 hours.The reaction mixture dilute with water is used ethyl acetate extraction.Organic phase is water and saturated brine washing successively, uses dried over mgso.After solvent evaporation, obtain a kind of white solid.
1H?NMR(CDCl
3,400MHz)δ9.68(1H,s),7.64(2H,d,J=7Hz),7.15(2H,d,J=7Hz),5.59(2H,s),2.40(3H,s)。
Step C:1-(4-cyano group benzyl)-glyoxal ethyline-5-formaldehyde
4-bromo-1-(4-cyano group benzyl)-glyoxal ethyline-5-formaldehyde (1.33g, 4.37mmol) and imidazoles (0.600g, 8.74mmol) solution in 1: 1 ethyl acetate/ethanol (150ml) stirs with 10% palladium/charcoal (0.020g) catalyzer under 1 atm hydrogen pressure.After 2 hours, reaction mixture obtains the white solid title compound by diatomite filtration after concentrating.
1H?NMR(DMSO-d
6?400MHz)δ9.62(1H,s),7.90(1H,s),7.81(2H,d,J=8Hz),7.20(2H,d,J=8Hz),5.64(2H,s),2.33(3H,s)。
Step D:5 (S)-butyl-4-[1-(4-cyano group benzyl)-2-methyl-5
-imidazolyl methyl]-1-(2, the 3-3,5-dimethylphenyl)-piperazine-2-ketone dihydrochloride
With sodium triacetoxy borohydride (0.265g, 1.25mmol) join 1-(4-cyano group benzyl)-2-imidazoles-5-formaldehyde (0.190g, 0.843mmol), 5 (S)-butyl-1-sodium triacetoxy borohydride piperazine-2-keto hydrochloride (0.250g, 0.843mmol), N-methylmorpholine (0.093mml, 0.843mmol) in the solution in ethylene dichloride (10ml), according to example 39, the described method of step e is carried out.Title compound is purified with preparation HPLC, carries out gradient elution with the 70-45% solvent orange 2 A.Isolate free alkali, and convert it into dihydrochloride.Obtain the title compound of white solid form.FAB?ms:470(m+1)。Analyze: calculated value C
29H
35N
5O2HCl1.45H
2O:
C, 61.25; H, 7.07; N, 12.32 measured values: C, 61.56; H, 6.99; N, 11.32.
Example 49
4-[1-(2-(4-cyano-phenyl)-2-propyl group)-5-imidazoles methyl]-1
-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-ketone two hydrochloric acid
Salt
Steps A: 4-(t-butyldimethylsilyloxy ylmethyl)-1-trityl miaow
Azoles
(2.83g, (5.80g, 17.05mmol) (3.48g is in the suspension among DMF 51.1mmol) (200ml) containing imidazoles 18.76mmol) to join 4-methylol-1-trityl imidazole with tert-butyldimethylsilyl chloride.After 15 minutes, obtain colourless transparent solution, it is at room temperature stirred.After reacting completely, remove DMF under vacuum, residue distributes between ethyl acetate and water.With organic phase water successively and saturated brine washing, use dried over mgso.Obtain transparent gelationus title compound.
Step B:5-t-butyldimethylsilyloxy ylmethyl-1-(4-cyano group benzyl)
Imidazoles
(4.66g, 10.26mmol) (2.01g, acetonitrile 10.26mmol) (50ml) solution refluxed 4 hours with 1-brooethyl-4-cyano group benzene with 4-(t-butyldimethylsilyloxy ylmethyl)-1-trityl imidazole.With the reaction mixture cooling, under vacuum, remove acetonitrile, residue is dissolved in the methyl alcohol (30ml), this solution was refluxed 2 hours, cooling evaporates methyl alcohol then.Residue distributes between ethyl acetate and saturated sodium bicarbonate.Crude product carries out silica gel column chromatography purifies, with 3% methyl alcohol/chloroform wash-out.Obtain the title compound of white solid form.
Step C:5-t-butyldimethylsilyloxy ylmethyl-1-[2-(4-cyano group
Phenyl)-and the 2-propyl group] imidazoles
(1.005g, THF 3.07mmol) (25ml) solution is cooled to-78 ℃ under nitrogen atmosphere with 5-t-butyldimethylsilyloxy ylmethyl-1-(4-cyano group benzyl) imidazoles.Add hexamethyl two silicon Lithium Azides (4.61ml, 1M THF solution), under agitation, in 30 minutes, be warmed to-60 ℃ then-78 ℃ of reactions 1 hour.Reaction mixture is cooled to-78 ℃.(0.287ml 4.61mmol), continues to stir 2 hours at-78 ℃ again, is warmed to 0 ℃ then in 2 hours to add methyl-iodide.After 30 minutes, reaction mixture is cooled to-78 ℃, adds hexamethyl two silicon Lithium Azides (4.61ml, 1M THF solution).After 1 hour, (0.287ml 4.61mmol), allows reaction mixture be warmed to ambient temperature overnight to add methyl-iodide.The water termination reaction is used ethyl acetate extraction, and organic phase is washed with saturated brine.Crude product carries out silica gel column chromatography purified, with 6: 4 ethyl acetate/dichloromethane wash-out.Obtain golden oily title compound.
1H?NMR(CDCl
3,400MHz)δ7.78(1H,s),7.61(2H,d,J=8Hz),7.15(2H,d,J=8Hz),7.02(1H,s),4.00(2H,s),1.99(6H,s),0.79(9H,s),-0.74(6H,s)。
Step D:1-[2-(4-cyano-phenyl)-2-propyl group)]-5-methylol miaow
Azoles
To fluoridize four-N-fourth ammonium (2.99ml, 1M THF solution) and join uncle's 5-fourth oxygen dimethylsilane oxygen ylmethyl-1-[2-(4-cyano-phenyl)-2-propyl group] (0.750g is in THF 2.72mmol) (10ml) solution for imidazoles.At room temperature, in reaction mixture impouring ethyl acetate, extract with saturated sodium bicarbonate solution through after 2 hours.Organic phase extracts with saturated brine, uses dried over mgso.Crude product carries out silica gel column chromatography purifies, and with 3% methanol/ethyl acetate wash-out, obtains the title compound of semi-solid.
1H?NMR(CDCl
3,400MHz)δ7.77(1H,s),7.62(2H,d,J=8Hz),7.19(2H,d,J=8Hz),7.02(1H,s),4.01(2H,s),2.57(1H,br?s),2.01(6H,s)。
Step e: 1-[2-(4-cyano-phenyl)-2-propyl group] imidazoles-5-formaldehyde
With 1-[2-(4-cyano-phenyl)-2-propyl group)]-(0.450g, 1.87mmol) (1.62g's 5-hydroxy methylimidazole together 18.7mmol) refluxed 5 hours for De diox (20ml) solution and Manganse Dioxide.With the reaction mixture cooling, by diatomite filtration, also concentrated.Crude product is purified with silica gel column chromatography, isolates the title compound of semi-solid.
1H?NMR(CDCl
3,400MHz)δ9.37(1H,s),8.11(1H,s),7.92(1H,s),7.58(2H,d,J=8Hz),7.15(2H,d,J=8Hz),2.01(6H,s)。
Step F: 4-[1-(2-(4-cyano-phenyl)-2-propyl group)-5-miaow
The azoles methyl]-1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2
-ketone dihydrochloride
This title compound is according to example 39; the described program preparation of step e; different has been to use 1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-keto hydrochloride (0.297g; 0.84mmol), 1-[2-(4-cyano-phenyl)-2-propyl group] imidazoles-5-formaldehyde (0.200g; 0.84mmol), N-methylmorpholine (0.092ml; 0.84mmol) and sodium triacetoxy borohydride (0.267g, 1.26mmol).Crude product is purified with preparation HPLC, with 80-58% solvent orange 2 A gradient elution.Pure fraction is merged, and change into hydrochloride, obtain title compound.FAB?ms:540(M+1)。Analyze: calculated value C
27H
30ClN
5O
3S2HCl3H
2O:
C, 48.62; H, 5.74; N, 10.50 measured values: C, 48.62; H, 5.73; N, 9.89.
Example 50
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-1
-(2-aminomethyl phenyl) piperazine-2-ketone dihydrochloride
Steps A: N-(2-aminomethyl phenyl)-2 (S)-(t-butoxycarbonyl amino)-oneself
Amine
This title compound is according to example 39, the described program preparation of step C, different has been to use Ortho Toluidine (0.32ml, 3.00mmol), 2 (S)-(t-butoxycarbonyl amino) hexanal (0.538,2.50mmol), sodium triacetoxy borohydride (0.795g, 3.75mmol), (10ml) carries out at ethylene dichloride.Thick product is purified with column chromatography, obtains title compound.
Step B:4-tertbutyloxycarbonyl-5 (S)-normal-butyl-1-(2-aminomethyl phenyl)
Piperazine-2-ketone
This title compound is basically according to example 39, the described program preparation of step D, different has been to use N-(2-aminomethyl phenyl)-2 (S)-(t-butoxycarbonyl amino) hexylamine (0.506g, 1.65mmol), chloroacetyl chloride (0.158ml, 1.98mmol), in ethyl acetate-saturated sodium bicarbonate of 0 ℃, carry out.The crude product that obtains thus is dissolved among the DMF (15ml), is cooled to 0 ℃ under nitrogen atmosphere, (1.61g 4.95mmol) handles with cesium carbonate.Under agitation, at room temperature reacted then 2 hours 0 ℃ of reaction 2 hours.Use the saturated ammonium chloride termination reaction, use ethyl acetate extraction.Obtain title compound after the evaporation of extract drying.
Step C:5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl
Methyl]-1-(2-aminomethyl phenyl) piperazine-2-ketone dihydrochloride
(0.534g is 1.50mmol) with trifluoroacetic acid (4ml) deprotection in methylene dichloride (10ml) for the product of step B.This title compound is according to example 39, the described program preparation of step e, different has been to use 5 (S)-normal-butyl-1-(2-aminomethyl phenyl) piperazine-2-ketone two (trifluoroacetic acid) salt, 1-(4-cyano group benzyl imidazole)-5-formaldehyde (0.317g, 1.50mmol) and sodium triacetoxy borohydride (0.477g, 2.25mmol), in ethylene dichloride (15ml), carry out.Crude product is injected preparation HPLC post, purify with acetonitrile/0.1%TFA and 0.1% TFA aqueous solution mixing gradient elution.Each pure fraction is merged, change into hydrochloride, obtain the title compound of white solid form.FAB?ms:(m+1)442。Analyze: calculated value C
27H
31N
5O2.5HCl2.05H
2O:
C, 56.95; H, 6.66; N, 12.30 measured values: C, 56.93; H, 5.75; N, 11.55.
Example 51
4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5 (S)-(2-fluorine second
Base)-1-(3-chloro-phenyl-) piperazine-2-ketone dihydrochloride
Steps A: 4-tertbutyloxycarbonyl-1-(3-chloro-phenyl-)-5 (S)-(2-fluorine
Ethyl)-piperazine-2-ketone
4-tertbutyloxycarbonyl-1-(3-chloro-phenyl-)-5 (S)-(2-mesyloxy ethyl)-piperazine-2-ketone (0.433g, 1.00mmol) and fluoridize uncle's fourth ammonium (3.0ml, 1MTHF solution) at room temperature in acetonitrile (5ml) the stirring 72 hours.Use the saturated sodium bicarbonate termination reaction, use ethyl acetate extraction.With organic extract drying, concentrated, and,, obtain a kind of viscous crude shape title compound with 20% ethyl acetate/hexane wash-out with the column chromatography purification.
Step B:4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5 (S)-(2
-fluoro ethyl)-1-(3-chloro-phenyl-) piperazine-2-ketone dihydrochloride
(0.191g is 0.54mmol) with trifluoroacetic acid (4ml) deprotection in methylene dichloride (10ml) for 4-tertbutyloxycarbonyl-1-(3-chloro-phenyl-)-5 (S)-(2-fluoro ethyl)-piperazine-2-ketone.This title compound is pressed example 39, the described program preparation of step e, different is to use 1-(3-chloro-phenyl-)-5 (S)-(2-fluoro ethyl) piperazine-2-ketone two (trifluoroacetic acid) salt, 1-(4-cyano group benzyl imidazole)-5-formaldehyde (0.114g, 0.54mmol) and sodium triacetoxy borohydride (0.172g, 2.25mmol), in ethylene dichloride (5ml), carry out.Crude product is injected preparation HPLC post, purify with acetonitrile/0.1% TFA and 0.1% TFA aqueous solution mixing gradient elution.Each pure fraction is merged, change into hydrochloride, obtain the title compound of white solid form.FAB?ms:(m+1)452。Analyze: calculated value C
24H
23ClFN
5O2HCl1.7H
2O:
C, 51.90; H, 5.15; N, 12.61 measured values: C, 52.22; H, 5.10; N, 12.22.
Example 52
4-[3-(4-cyano group benzyl) pyridin-4-yl]-1-(3-chloro-phenyl-)-
5 (S)-(2-methylsulfonyl ethyl)-piperazine-2-ketone
Steps A: 3-(4-cyano group benzyl) pyridine-4-carboxylate methyl ester
With about 3 minutes time with the 4-cyano-benzyl bromide (625mg, anhydrous THF (4ml) solution 3.27mmol) joins 0 ℃ the active Zn (dust under argon atmospher at leisure; In THF 250mg) (2ml) suspension.
Remove ice bath, at room temperature with soup compound restir 30 minutes.(540mg 2.5mmol), then adds dichloro two (triphenyl phosphine) nickel (II) (50mg) to add 3-bromopyridine-4-carboxylate methyl ester then.The reddish-brown mixture that is generated stirred 3 hours at about 40-45 ℃.With the mixture cooling, be allowed to condition between EtOAc (100ml) and 5% aqueous citric acid solution (50ml) and distribute.Organic layer H
2(Na is used in 2 * 50ml) washings to O
2SO
4Dry.Residue is purified with silica gel column chromatography after the solvent evaporation, with 35% EtOAc/ hexane wash-out, provides the transparent jelly of 420mg.FAB?ms(M+1)253。
Step B:3-(4-cyano group benzyl)-4-(methylol) pyridine
This title compound is that the ester (415mg) by steps A at room temperature makes with sodium borohydride (300mg) reduction in methyl alcohol (5ml).Stir after 4 hours, with solution evaporation, product is purified with silica gel column chromatography, with 2% methyl alcohol/chloroform wash-out, provides title compound.FAB?ms(M+1)225。
Step C:3-(4-cyano group benzyl)-4-pyridine aldehydes
This title compound is that (240mg 1.07mmol) makes with activated manganese dioxide (1.0g) oxidation in backflow De diox by the alcohol of step B.Obtain title compound, fusing point 80-83 ℃ after filtration and the solvent evaporation.
Step D:4-[3-(4-cyano group benzyl) pyridin-4-yl]-1-(3-chlorine
Phenyl)-5 (S)-(2-methylsulfonyl ethyl)-piperazine-2-ketone
This compound is gone up substantially according to example 39; the described same method preparation of step e; different is; step C product (referring to above) with equivalent replaces imidazole formaldehyde; 1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl)-piperazine-2-ketone with equivalent replaces piperazine ketone, makes title compound thus.FAB?ms?523。Analyze: calculated value C
27H
27ClN
4O
3S0.15CHCl
3:
C, 60.28; H, 5.06; N, 10.36 measured values: C, 60.37; H, 5.03; N, 10.64.
Example 53
4-[5-(4-cyano group benzyl) 1-imidazolyl methyl]-1-(3-chloro-phenyl-)
Piperazine-2-ketone
Steps A: 1-trityl-4-(4-cyano group benzyl)-imidazoles
(3.57g, (0.315ml 3.60mmol), under agitation reacts at 20 ℃ in argon atmospher to add ethylene dibromide in THF 54.98mmol) (50ml) suspension toward active zinc powder.This suspension is cooled to 0 ℃, dropwise adds α-bromo-p-methylphenyl nitrile (9.33g, THF 47.6mmol) (100ml) solution with 10 fens clock times.Then under agitation 20 ℃ the reaction 6 hours, disposable adding chlorination two (triphenyl phosphine) nickel (II) (2.4g, 3.64mmol) and 5-iodine trityl imidazole (15.95g, 36.6mmol).The gained mixture stirred 16 hours at 20 ℃, added saturated NH then
4Cl solution (100ml) makes reaction terminating, and mixture was stirred 2 hours.Add saturated NaHCO
3Solution makes pH=8, gained solution with EtOAc extraction (2 * 250ml), use MgSO
4Drying, vacuum evaporating solvent.Residue carries out chromatogram purification (SiO
2, 0-20% EtOAc/CH
2Cl
2) obtain the title compound of white solid form.
1H NMR δ CDCl
3(7.54 (2H, d, J=7.9Hz), 7.38 (1H, s), 7.36-7.29 (11H, m), 7.15-7.09 (6H, m), 6.58 (1H, s) and 3.93 (2H, s) ppm.
Step B:1-methyl acetyl-5-(4-cyano group benzyl)-imidazoles
Toward 1-trityl-4-(4-cyano group benzyl)-imidazoles (3.01g, 6.91mmol) and add methyl bromoacetate in acetonitrile (50ml) solution (0.687ml, 7.26mmol), mixture heated 16 hours at 55 ℃, then vacuum evaporating solvent.Solids is developed with EtOAc, filters and collects, and is dissolved in the methyl alcohol (60ml).This suspension heated 20 minutes under refluxing, and cooled off, is evaporated to dried then.Residue is developed with EtOAc, filters the title compound that obtains the white solid form.
1H NMR δ CDCl
3(7.61 (2H, d, J=7.9Hz), 7.53 (1H, s), 7.27 (2H, d, J=7.9Hz), 6.89 (1H, s), 4.47 (2H, s), 3.98 (2H, s) and 3.66 (3H, s) ppm.
Step C:1-hydroxyethyl-5-(4-cyano group benzyl)-imidazoles
(80.7mg 2.1mmol) handles 1-methyl acetyl-5-(4-cyano group benzyl)-imidazoles (0.113g, 0 ℃ of methyl alcohol (2ml) solution 0.472mmol) with sodium borohydride.After 1 hour, add saturated NH
4Cl solution (2ml) makes reaction terminating.Add saturated NaHCO
3, (MgSO is used in 3 * 25ml) extractions to mixture with ethyl acetate
4Drying and vacuum-evaporation.With chromatography (SiO
2, 10% MeOH/CH
2Cl
2) isolate the title compound of white solid form.
1H NMR δ CDCl
3(7.61 (2H, d, J=7.9Hz), 7.55 (1H, s), 7.27 (2H, d, J=7.9Hz), 6.83 (1H, s), 4.05 (2H.s), 3.87 (2H, t, J=5.1Hz) and 3.74 (2H, t, J=5.1Hz) ppm.
Step D:2-(5-(4-cyano group benzyl)-imidazolyl) ethyl methane sulfonate ester
With Hunigs alkali (0.489ml, 2.81mmol) and methylsulfonyl chloride (0.219ml 2.81mmol) handles 1-hydroxyethyl-5-(4-cyano group benzyl)-imidazoles (0.532g, 0 ℃ of methylene dichloride (70ml) solution 2.34mmol).After 2 hours, add saturated NaHCO
3Solution (50ml) makes reaction terminating, and mixture is used MgSO with methylene dichloride (50ml) extraction
4Drying, vacuum evaporating solvent.The title compound that obtains need not further to purify just can use.
1H NMR δ CDCl
3(7.62 (2H, d, J=7.9Hz), 7.54 (1H, s), 7.29 (2H, d, J=7.9Hz), 6.87 (1H, s), 4.25 (2H, t), 4.10-4.00 (4H, m), 3.74 (2H, t, J=5.1Hz) and 2.90 (3H, s) ppm.
Step e: 4-[5-(4-cyano group benzyl)-1-imidazolyl methyl]-1-(3
-chloro-phenyl-) piperazine-2-ketone
With 2-(5-(4-cyano group benzyl)-imidazolyl) ethyl methane sulfonate ester (24mg, 0.079mmol) DMF (0.2ml) solution join 3-(chloro-phenyl-) piperazine-2-ketone (17.7mg, 0.084mmol), sodium iodide (50mg, 0.336mmol) and Hunigs alkali (0.0146ml, 0.084mmol) in.Mixture stirred 12 hours at 55 ℃, and solvent is fallen in vacuum-evaporation then.Residue is purified with the preparation thin-layer chromatography, with 10% saturated ammonia/acetonitrile wash-out, obtains title compound.
1H NMR δ CDCl
3(7.61 (2H, d, J=8.4Hz), 7.56 (1H, s), 7.35-7.20 (7H, m), 7.16 (1H, d, J=8Hz), 6.85 (1H, s), 4.03 (2H, s), 3.83 (2H, t, J=6.5Hz), 3.61 (2H, t, J=5.4Hz), 3.27 (2H, s), 2.68 (2H, t is J=5.4Hz) with 2.57 (2H, t, J=6.5Hz) ppm.
Example 54
The vitro inhibition of ras farnesyl tranfering enzyme
The farnesyl-protein transferase test.Partially purified ox FPT enzyme and Ras peptide (Ras-CVLS, Ras-CVIM and Ras-CAIL) are respectively according to (Schaber
Et Al.,
J. Biol. Chem.265:14701-14704 (1990), Pompliano,
Et Al.,
Biochemistry31:3800 (1992) and Gibbs
Et Al.,
PNASU.S.A.86:6630-6634 (1989)) described method prepares.Ox FPT enzyme test 60 minutes in 31 ℃ of 100 μ l volumes that containing following ingredients: 100mM N-(2-hydroxyethyl) piperazine-N-(2 ethane sulfonic aicd) (HEPES), pH 7.4,5mM MgCl
2, 5mM dithiothreitol (DTT) (DTT), 100mM [
3H]-farnesyl diphosphate ([
3H]-FPP; 740 CBq/mmol, NEN), 650 nM Ras-CVLS and 10 μ g/ml FPT enzymes.Reaction causes with the FPT enzyme, stops with 1ml 1.0M HCl ethanolic soln.Utilize a Tom Tec Mach II cell harvestor that throw out is collected on the filter leaching material, use 100% washing with alcohol, drying is with a LKB β-plate count device counting.Test is linear for two kinds of Substrates, FPT enzyme and time; Utilized between the reaction period less than 10% [
3H]-FPP.The compound dissolution of purifying and dilutes 20 times and tests in 100% dimethyl sulfoxide (DMSO) (DMSO).The amount of incorporating under the radioactivity amount of incorporating under test compound exists or not with test compound relatively is used for weighing percent inhibition.
Human body FPT enzyme is according to people such as Omer, the described method preparation of Biochemistry 32:5167-5176 (1993).The test of human body FPT enzymic activity is with the above, and different is to add 0.1% (weight/volume) polyoxyethylene glycol, 20,000,10 μ MZnCl in reaction mixture
2With 100nM Ras-CVIM.Reaction was carried out 30 minutes, stopped with 100 μ l 30% (volume/volume) trichoroacetic acid(TCA) (TCA) ethanolic solns, and handled like that the ox enzyme is described by above.
More than listed The compounds of this invention described in each example and in following each table, all test and test its inhibition activity, and find its IC human body FPT enzyme with the above
50Be≤50 μ M.
Example 55
Ras farnesylation test in the live body
The clone of using in this test is Rat1 or the cell-derived a kind of v-ras clone of NIH3T3 from having expressed viral Ha-ras p21.Test is basically according to DeClue, and people such as J.E. carry out in method described in the Cancer Research 51:712-717 (1991).The cell that reaches 50~75% symphysis rates on the 10cm culture dish is handled (ultimate density of solvent methanol or dimethyl sulfoxide (DMSO) is 0.1%) with test compound.At 37 ℃ after 4 hours, adding 10% conventional DMEM, 2% foetal calf serum and 400mCi[
35S] 3ml of methionine(Met) (1000Ci/mmol) do not have among the methionine(Met) DMEM these cells carried out mark.After spending 20 hours again, cytolysis at the molten born of the same parents' buffer reagent of 1ml (1% NP40/20mM HEPES, pH 7.5/5mMMgCl
2/ 1mM DTT/10mg/ml aprolinen/2mg/ml leupeptin (leupeptin)/2mg/ml antipain/0.5mM PMSF) in, molten cytosol is with 100, and 000xg made it clarification in centrifugal 45 minutes.The some parts of molten cytosols that contain the precipitable counting of equivalent acid are transferred to 1ml with IP buffer reagent (molten born of the same parents' buffer reagent of no DTT), carry out immunoprecipitation (Furth, people such as M.E., J.Virol.43:294-304 (1982)) with ras obligate monoclonal antibody Y13-259.After 2 hours antibody of 4 ℃ are cultivated, add 25% suspension that 200ml scribbles the albumin A-agarose of exempting from the mouse IgG of the Chinese People's Anti-Japanese Military and Political College, kept 45 minutes.Immunoprecipitate IP buffer reagent (20nM HEPES, pH 7.5/1mM EDTA/1% Triton X-100 0.5% deoxycholate salt/0.1%/SDS/0.1MNaCl) wash 4 times, in SDS-PAGE sample buffer reagent, boil, be added on 13% acrylamide gel.When the dyestuff forward position reaches the bottom, make this gel sets, thermal treatment under light, drying and autoradiograph.Relatively the intensity of the corresponding band of the ras albumen of farnesylation and non-farnesylation determines that farnesyl shifts proteic inhibition percentage.
Example 56
Growth inhibition test in the live body
For the biology consequence of determining that the FPT enzyme suppresses, tested the influence of The compounds of this invention to the no anchorage dependent form growth of the Rat1 cell that changes with v-ras, v-raf or v-mos oncogene.In this analyzes, also can comprise the cell that changes by v-Raf and v-Mos, Ras be brought out the specificity that cell changes with the assessment The compounds of this invention.
The Rat1 cell that changes with v-ras, v-raf or v-mos is with every plate (diameter 35mm) 1 * 10
4The density of cell is inoculated in 0.3% top agarose of the above culture medium A of bottom-layer agar sugar (0.6%) (having added the Dulbecco modification Eagle's medium of 10% foetal calf serum).The two-layer The compounds of this invention (1000 times with used ultimate density in the test are dissolved in the methyl alcohol) that all contains 0.1% methyl alcohol or proper concn.These cells are fed twice with the 0.5ml culture medium A of the The compounds of this invention that contains 0.1% methyl alcohol or this concentration weekly.Culture is inoculated back 16 days and is taken Photomicrograph, compares.
Example 57
Table 1~18 show, of the present invention other compound preparation according to program described in the example 1~53.These compounds are intended to become illustrative, and are not intended to become restrictive.In table 2, the stereochemistry that contains amino carbon atom is (R or S) as noted, perhaps if do not know, just these two kinds of isolating steric isomers is appointed as " A " or " B ".
Table 1
Chemical formula R FAB ms (m+1)
Table 2
The upright structure X Y (M+1) of FAB amine mass spectrum analyzes (calculated value, measured value) A n-Bu 2-O (CH
2)
13CH
3642.5 C
42H
63N
3O
22.55HCl
C,68.46;H,8.97;N,5.70.
C,68.40;H,8.70;N,5.61.B n-Bu 2-O(CH
2)
13CH
3 642.6 C
42H
63N
3O
2·2.65HCl
C,68.63;H,8.99;N,5.72.
C,68.66;H,8.90;N,5.70.A n-Bu 2-O(CH
2)
11CH
3 614.4 C
40H
59N
3O
2·2.8HCl
C,67.09;H,8.70;N,5.87.
C,67.03;H,8.66;N,5.76.B n-Bu 2-O(CH
2)
11CH
3 614.4 C
40H
59N
3O
2·2.85HCl·0.05H
2O
C,66.84;H,8.69;N,5.85.
C,67.20;H,8.70;N,5.45.
The upright structure X Y (M+1) of FAB amine mass spectrum analyzes (calculated value, measured value) A n-Bu 2-O (CH
2)
9CH
3586.5 C
38H
55N
3O
23HCl0.25hexane
C,66.18;H,8.65;N,5.86.
C,66.14;H,8.44;N,5.50.B n-Bu 2-O(CH
2)
9CH
3?586.5 C
38H
55N
3O
2·3HCl·0.15hexane
C,65.97;H,8.55;N,5.93.
C,66.04;H,8.41;N,5.57.A n-Bu 2-O(CH
2)
7CH
3?558 C
36H
51N
3O
2·2.15HCl·0.65H
2
C,66.73;H,8.47;N,6.49.
C,66.74;H,8.46;N,6.52.B n-Bu 2-O(CH
2)
7CH
3?558 C
36H
51N
3O
2·2.15HCl·0.65H
2O
C,66.82;H,8.42;N,6.49.
C,66.85;H,8.43;N,6.52.A n-Bu 2-O(CH
2)
3Ph 564 C
37H
45N
3O
2·2HCl·1.05H
2O
C,67.78;H,7.55;N,6.41.
C,67.78;H,7.52;N,6.26.B n-Bu 2-O(CH
2)
3Ph 564 C
37H
45N
3O
2·2HC·1.05H
2O
C,67.78;H,7.55;N,6.41.
C,67.78;H,7.44;N,6.33.A n-Bu 3-OCH
2Ph 536 C
35H
41N
3O
2·3.55HCl
C,63.19;H,6.75;N,6.32.
C,63.12;H,6.61;N,6.47.B n-Bu 3-OCH
2Ph 536 C
35H
41N
3O
2·3.55HCl·0.4H
2O
C,62.52;H,6.80;N,6.25.
C,62.14;H,6.69;N,6.65.
The upright structure X Y (M+1) of FAB amine mass spectrum analyzes (calculated value, measured value) A n-Bu 3-O (CH
2)
13CH
3642 C
42H
63N
3O
22.4HCl
C,69.15;H,9.04;N,5.76.
C,69.08;H,9.08;N,5.73.B n-Bu 3-O(CH
2)
13CH
3?642.5 C
42H
63N
3O
2·2.35HCl·0.25H
2O
C,69.15;H,9.04;N,5.76.
C,69.08;H,9.08;N,5.73.R n-Bu 4-O(CH
2)
13CH
3?642 C
42H
63N
3O
2·2.2HCl·1H
2O
C,68.14;H,9.15;N,5.68.
C,68.13;H,9.03;N,5.68.S n-Bu 4-O(CH
2)
13CH
3?642 C
42H
63N
3O
2·2.8HCl
C,67.79;H,8.91;N,5.65.
C,67.77;H,9.80;N,5.64.S n-Bu 4-OCH
2Ph 536 C
35H
41N
3O
2·2.15HCl·1H
2O
C,66.49;H,7.20;N,6.65.
C,66.48;H,7.15;N,6.62.R/S H 2-O(CH
2)
13CH
3?586 C
38H
55N
3O
2·1.5HCl·0.3H
2O
C,66.88;H,8.58;N,6.16.
C,66.82;H,8.64;N,6.15.
Table 3
FAB
Mass spectrum Y (M+1) analyzes (calculated value, measured value) 3-SO
2Me 506 C
27H
31N
5O
3S3.0HCl0.10H
2O
C,52.61;H,5.59;N,11.36.
C,52.63;H,5.41;N,10.72.3-OCF
3 512.23 C
27H
28N
5O
2F
3·2.30HCl·0.50H
2O
C,53.66;H,5.22;N,11.59.
C,53.73;H,5.23;N,10.86.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CH
2OCH
2Ph CF
3574 C
32H
30N
5O
2F
31.40HCl0.30H
2O
C,61.02;H,5.12;N,11.12.
C,61.01;H,5.10;N,10.78.CH
2SO
2Et CF
3 560 C
27H
28N
5O
3F
3S
·3.20HCl·0.10H
2O
C,47.86;H,4.67;N,10.34.
C,47.89;H,4.49;N,9.92.CH
2SO
2Ph CF
3 608 C
31H
28N
5O
3F
3S·2.10HCl
C,54.42;H,4.43;N,10.24.
C,54.43;H,4.42;N,9.98.CH
2SO
2Me Cl 512 C
25H
26N
5O
3ClS
·2.0HCl·0.25CHCl
3·0.25H
2O
C,48.97;H,4.68;N,11.31.
C,48.95;H,4.64;N,11.51.
Table 4 (continuing)
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CH
2SO
2Et Cl 526 C
26H
28N
5O
3C1S2HCl0.25CHCl
3
C,5O.14;H,4.85;N,11.14.
C,50.20;H,4.91;N,10.93.CONHMe CF
3 511 C
26H
25N
6O
2F
3·1.90HCl·1.70H
2O
C,51.20;H,5.01;N,13.78.
C,51.17;H,4.99;N,13.36.CONHEt CF
3 525 C
27H
27N
6O
2F
3·1.60HCl·0.10H
2O
C,55.54;H,4.97;N,14.39.
C,55.57;H,4.87;N,15.28.CH
2SO
2Ph Cl 574 C
30H
28N
5O
3ClS·2HCl·0.30H
2O
C,55.23;H,4.73;N,10.73.
C,55.25;H,4.57;N,10.61.
Table 4 (continuing)
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CONHMe Cl 477 C
25H
25N
6O
2Cl2HCl
·0.105CHCl
3·0.85H
2O
C,52.24;H,5.03;N,14.56.
C,52.21;H,5.07;N,14.98.CONHEt Cl 491 C
26H
27N
6O
2Cl·2HCl·0.25CHCl
3
C,53.10;H,4.97;N,14.15
C,53.32;H,5.21;N,13.77.CONHc-Pr Cl 503 C
27H
27N
6O
2Cl·2HCl·0.40CHCl
3
C,52.77;H,4.75;N,13.47.
C,53.01;H,4.99;N,13.32.CONHc-Pr CF
3 537 C
28H
27N
6O
2F
3
·2.45HCl·0.55dioxane
C,53.81;H,5.06;N,12.47.
C,53.76;H,5.09;N,12.44.
Table 4 (continuing)
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) NHCOMe Cl 477 C
25H
25N
6O
2Cl
·2HCl·0.60CHCl
3·2.0H
2O
C,46.76;H,4.84;N,12.78.
C,46.79;H,4.46;N,12.37.CONMe
2 CF
3 525 C
27H
27N
6O
2F
3·2.0HCl·0.10H
2O
C,54.12;H,4.91;N,14.02.
C,54.10;H,4.96;N,13.79.SO
2Et Cl 512 C
25H
26N
5O
3ClS·2.0HCl·0.10H
2O
C,51.18;H,4.84;N,11.94.
C,51.24;H,5.19;N,11.10.CH
2SMe Cl 480 C
25H
26N
5OClS
·0.15CHCl
3·0.05H
2O
C,52.83;H,4.98;N,12.25.
C,52.82;H,5.36;N,11.85.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) (±) C ≡ CMe Cl 458 C
26H
24N
5OCl2.0HCl1.00H
2O
C,56.89;H,5.14;N,12.76.
C,56.99;H,5.20;N,12.42.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CH
2CH
2H 386 C
23H
23N
5O1.40HCl0.40H
2O
C,62.29;H,5.73;N,15.79.
C,26.26;H,5.71;N,15.43.CH
2CO H 400 C
23H
21N
5O
2·2.6HCl·1.70H
2O
C,52.71;H,5.19;N,13.36.
C,52.82;H,5.21;N,13.04.CH
2 H 372 C
22H
21N
5O·2.0HCl·2.60H
2O
C,53.80;H,5.79;N,14.26.
C,52.86;H,5.98;N,13.92CH
2 3-Cl 406 C
22H
20N
5OCl·2.50HCl·0.90H
2O
C,51.48;H,4.77;N,13.65.
C,51.55;H,4.75;N,13.34
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) NHSO
2H C
21H
20N
6O
3S1.0HCl2.60H
2O
C,48.53;H,5.08;N,16.17
C,48.60;H,5.19;N,15.80.CH
2CH
2CO 3-Cl 448 C
24H
22N
5O
2Cl·1.0HCl·1.10H
2O
C,57.17;H,5.04;N,13.89.
C,57.22;H,4.94;N,13.47.CH
2 2,3-Cl
2 440 C
22H
19N
5OCl
2·2.0HCl·0.60H
2O
C,50.42;H,4.27;N,13.36.
C,50.51;H,4.56;N,12.18.CH
2 2-Br 450 C
22H
20N
5OBr·2.0HCl·0.30H
2O
C,49.98;H,4.31;N,13.25.
C,49.94;H,4.47;N,12.53.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CH
23-CF
3440 C
23H
20N
5OF
31.70HCl0.40H
2O
C,54.40;H,4.47;N,13.79.
C,54.45;H,4.49;N,13.82.CH
2 4-Cl C
22H
20N
5OCl·1.50HCl·0.80H
2O
C,55.71;H,4.91;N,14.77.
C,55.81;H,4.94;N,14.11.CH
2CO 3-Cl C
23H
20N
5O
2Cl·1.40HCl·1.10H
2O
C,54.73;H,4.71;N,13.87.
C,54.80;H,4.73;N,13.46.CH
2 3-F C
22H
20N
5OF·2HCl
·0.35CHCl
3·0.95H
2O
C,51.50;H,4.69;N,13.44.
C,51.56;H,4.73;N,13.30.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) CH
23-Br C
22H
20N
5OBr1.40HCl1.30H
2O
C,50.35;H,4.61;N,13.34.
C,50.36;H,4.63;N,12.84.
Table 6
FAB
Mass spectrum X Y Z (M+1) analyzes (calculated value, measured value) 4-CN CH
25-CH
2CH
2CO 554 C
27H
28N
5O
4ClS1.30HCl1.20H
2O
C,52.05;H,5.13;N,11.24.
C,52.09;H,5.15;N,10.95.3-CN CH
2 5-CH
2 512 C
25H
26N
5O
3ClS·
2.0HCl·0.10CHCl
3·0.6OH
2O
C,49.61;H,4.86;N,11.52.
C,49.63;H,5.01;N,11.14.2-CN CH
2 5-CH
2 512 C
25H
26N
5O
3ClS·2HCl·0.35H
2O
C,50.79;H,4.89;N.11.84.
C,50.82;H,5.29;N,11.90.4-CN CH
2 4-CH
2CH
2CO?554 C
27H
28N
5O
4ClS
·2.0HCl·0.50CHCl
3·0.60H
2O
C,47.36;H,4.58;N,10.04.
C,47.35;H,4.60;N,9.66.
Table 6 (continuing)
FAB
Mass spectrum X Y Z (M+1) analyzes (calculated value, measured value) 4-CN (CH
2)
24-CH
2CH
2CO C
28H
30N
5O
4ClS
·1.0HCl·0.40CHCl
3·0.95H
2O
C,50.96;H,5.01;N,10.46.
C,50.91;H,5.02;N,10.13.
FAB
Mass spectrum X Y (M+1) analyzes (calculated value, measured value) 4-Me CH
2CH
2SO
2Me 526 C
26H
28N
5O
3ClS
·2HCl·0.35CHCl
3·0.85H
2O
C,48.24;H,4.92;N,10.67.
C,48.25;H,4.93;N,10.36.4-Me H 420 C
23H
22N
5OCl·2.0HCl·0.90H
2O
C,54.27;H,5.11;N,13.76.
C,54.21;H,5.37;N,12.97.2-Me H 420 C
23H
22N
5OCl·3.20HCl·0.10H
2O
C,51.31;H,4.76;N,13.01.
C,51.30;H,4.74;N,12.87.
Chemical formula Y FAB ms analytical calculation value
(m+1) measured value 3-CF
3496 C
27H
28F
3N
5O2HCl1.55H
2C
C,54.36;H,5.59;N,11.74
C,54.40;H,5.29;N,11.263-CH
3 442 C
27H
31N
5O·2HCl
C,63.01;H,6.47;N,13.61
C,63.45;H,6.71;N,13.532,3-(CH
2)
4 482 C
30H
35N
5O·5.2HCl·0.1H
2C
C,53.66;H,6.06;N,10.43
C,53.62;H,5.30;N,9.353-OCH
3 458 C
27H
31N
5O
2·2HCl
C,61.13;H,6.27;N,13.20
C,62.43;H,6.53;N,13.24
Chemical formula Y FAB ms analytical calculation value
(m+1) measured value 3-Cl 463 C
26H
28ClN
5O2HCl0.75H
2C
C,56.94;H,5.79;N,12.77
C,56.92;H,5.59;N,12.302-CH
3,3-Cl 477 C
27H
30ClN
5O
2·2HCl·3.1H
2O
C,53.62;H,6.37;N,11.58
C,53.44;H,5.37;N,10.76H 428 C
26H
29N
5O·3.9HCl·2H
2O
C,51.63;H,6.51;N,11.58
C,51.59;H,5.10;N,10.35
Chemical formula Y FAB ms analytical calculation value
(m+1) measured value 3-F 446 C
26H
28FN
5O2HCl2.55H
2C
C,55.87;H,6.22;N,12.53
C,55.83;H,5.84;N,11.71
Table 9
Chemical formula
FAB msR (m+1) calculated value
Analyze
Measured value CH
2CH
2OCH
2CF
3566 C
27H
25F
6N
5O
22HCl0.67H
2O
C,49.85;H,4.39;N,10.77
C,56.38;H,5.07;N,11.74
C,56.21;H,5.27;N,11.46CH
2CH
2N
3 509 C
25H
23F
3N
8O
2·2HCl·2.35H
2O
C,48.14;H,4.80;N,17.96
C,48.79;H,4.38;N,16.99CH
2CH
2NHCOCH
3 525 C
27H
27F
3N
6O
2·2HCl·0.7H
2O
C,53.16;H,5.02;N,13.78
C,53.30;H,5.07;N,13.39CH
2CH
2NHCOC
2H
5 539 C
28H
29F
3N
6O
2·2HCl·3.66H
2O
C,52.43;H,5.39;N,13.10
C,52.44;H,5.20;N,12.48
Table 9 (continuing)
Chemical formula R FAB ms
The analytical calculation value
(m+1)
Measured value CH
2CH
2SO
2CH (CH
3)
2574 C
28H
30F
3N
5O
3S2HCl1.35H
2O
C,50.13;H,5.21;N,10.44
C,50.10;H,4.88;N,10.08CH
2CH
2SCH(CH
3)
2 542 C
28H
30F
3N
5OS·2HCl·0.75H
2O
C,53.55;H,5.38;N,11.51
C,53.57;H,5.33;N,11.04CH
2CH
2S(O)CH(CH
3)
2 558 C
28H
30F
3N
5O
2S·2HCl·0.7H
2O
C,52.29;H,5.23;N,10.89
C,52.27;H,5.08;N,10.35
Chemical formula R FAB ms
Analyze measured value
C,48.69;H,5.26;N,9.46
C,48.70;H,4.42;N,9.12
470 C
29H
35N
5O·2HCl·0.3CH
2Cl
2
0.6C
6H
14
C,63.76;H,7.48;N,11.30
C,64.41;H,7.21;N,11.13
C,66.35;H,7.28;N,11.25
445 C
28H
36N
4O·2HCl·1.3H
2O
C,62.17;H,7.56;N,10.36
C,58.30;H,7.27;N,11.72
C,58.30;H,6.28;N,10.90
548,550 C
29H
34BrN
5O·2HCl·0.1H
2O
C,55.89;H,5.85;N,11.24
C,55.91;H,5.96;N,10.73
Chemical formula
FAB?ms
The analytical calculation value
·2HCl·2.85H
2O
C,49.16;H,5.51;N,8.82
·2HCl·1.65H
2O
C,50.20;H,5.27;N,11.71
C,50.19;H,4.90;N,11.44
Cl 527 C
26H
28ClN
5O
3S
·2HCl·0.55H
2O
C,51.29;H,5.15;N,11.50
·3HCl·0.6HCl
C,48.02;H,5.61;N,10.77
C,48.30;H,5.91;N,9.78
Chemical formula
FAB ms calculated value
R (m+1) analyzes measured value
545 C
26H
30ClN
5O
4S
·2HCl·0.75H
2O
C,49.53;H,5.36;N,11.11
·2HCl
C,53.90;H,5.01;N,11.22
·2HCl·0.7H
2O
C,42.41;H,4.90;N,11.64
C,42.98;H,5.49;N,11.06
544 C
26H
30ClN
5O
4S
·2HCl·0.75H
2O
C,49.51;H,5.36;N,11.11
C,49.74;H,5.66;N,10.11
FABms
The analytical calculation value
C,58.67;H,4.92;N,10.03
C,58.71;H,4.94;N,9.95
523 C
28H
28ClN
3O
3S·0.1CHCl
·0.2CH
3OH
C,62.89;H,5.39;N,7.78
C,62.87;H,5.37;N,7.84
Table 13
Chemical formula
R FAB?ms
The analytical calculation value
(m+1) measured value
563 C
30H
31ClN
4O
3S
·2HCl·1.8H
2O
C,53.90;H,5.52;N,8.38
·2HCl·1.35H
2O
C,50.88;H,5.49;N,10.99
2HCl·0.3H
2O
C,50.86;H,4.88;N,11.86
C,51.06;H,5.33;N,10.87
415 C
28H
27ClN
4O
3S
·3HCl·4H
2O
C,36.25;H,6.42;N,9.39
·2HCl·0.85H
2O
C,44.93;H,5.08;N,10.48
C,44.96;H,5.08;N,9.96
Table 14
Chemical formula
FAB ms calculated value R
1R
2(m+1) analyze
·2HCl·0.5H
2O
C,52.25;H,5.08;N,12.83
C,52.31;H,5.14;N,12.23
CH
2CH
2F 452 C
24H
23ClFN
5O
·2HCl·1.70H
2O
C,51.90;H,5.15;N,12.61
H 448 ·0.30CHCl
3·0.85H
2O
C,54.50;H,4.71;N,13.08
C,54.51;H,4.69;N,12.87
Chemical formula R Y FABms analytical calculation value
·2HCl·0.15H
2O
C,62.31;H,5.89;N,13.97
·2HCl·1.0H
2O
C,54.08;H,5.13;N,13.71
C,54.57;H,5.77;N,12.92
3-Cl 420 C
22H
18ClN
5O
2
·2HCl·0.5H
2O
C,56.78;H,4.33;N,15.05
C,56.79;H,4.69;N,13.47
Chemical formula
FAB ms R (m+1) analytical calculation value
Measured value
506 C
32H
35N
5O3.2CF
3CO
2H
·2.65H
2O
C,54.14;H,5.75;N,9.15
C,51.03;H,6.35;N,10.26
C,51.02;H,5.66;N,9.67
506 C
32H
35N
5O·2HCl·1.7H
2C
C,63.09;H,6.68;N,10.26
C,51.02;H,5.66;N,9.67
Chemical formula
FAB?msR
(m+1) analytical calculation value
·0.4CH
3OH
C,67.71;H,6.26;N,14.62
C,67.71;H,6.26;N,14.53
358 C
23H
23N
3O·0.55CHCl
3
C,66.85;H,5.61;N,9.93
C,66.87;H,5.70;N,10.03
Table 18
FAB?mass
Mass spectrum
0.25CHCl
3·0.70H
2O
C,62.45;H,6.39;N,12.45.
C,62.45;H,6.46;N,12.37.
406 C
22H
20N
5OCl·2.60HCl
C,53.97;H,4.78;N,14.30
C,50.32;H,5.26;N,11.28
C,50.31;H,5.31;N,10.72.
Table 18 (continuing)The FAB mass spectrum
(M+1) Analyze (calculated value, measured value) 420 C
23H
22N
5OCl2.0HCl2.10H
2O
C,52.06;H,5.36;N,13.20
C,51.99;H,5.36;N,12.57.
Claims (42)
1. formula A compound or its optically active isomer or its pharmaceutically acceptable salt that can suppress farnesyl-protein transferase:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom randomly by be selected from O, S (O) m ,-NC (O)-and-N (COR
10)-group replace;
R
4And R
5Be independently selected from H and CH
3And R
2, R
3, R
4And R
5In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O) 2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Y is an aryl unsubstituted or that replace, or heterocycle unsubstituted or that replace, and wherein the heterocycle of aryl of Qu Daiing or replacement is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7、
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5.
2. formula B compound or its optically active isomer or its pharmaceutically acceptable salt that can suppress farnesyl-protein transferase:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2Or O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN、
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5,
But its condition be when G be H
2, and W is when being imidazolyl, substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not H, and
Its condition be when X be-C (=O)-, or-S (=O) during m-, t is 1, and substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not hydrogen.
3. formula C compound or its optically active isomer or its pharmaceutically acceptable salt that can suppress farnesyl-protein transferase:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10, (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 1;
T is 0 or 1; With
U is 4 or 5.
4. according to formula A compound or its optically active isomer or its pharmaceutically acceptable salt of claim 1:
In the formula:
R
1aBe independently selected from: hydrogen or C
1-C
6Alkyl;
R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, cycloalkyl, R
10O-,-N (R
10)
2Or C
2-C
6Alkenyl,
C) the unsubstituted or C that replaces
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocycle, cycloalkyl, alkenyl, R unsubstituted or that replace
10O-and-N (R
10)
2
R
3, R
4And R
5Be independently selected from H and CH
3
R
2Be H;
Or C
1-C
5Alkyl can be unbranched or side chain is arranged, and can be unsubstituted or replaced by following one or more groups:
1) aryl,
2) heterocycle,
3)OR
6,
And R
2, R
3, R
4And R
5In any 2 can randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H; C
1-C
4Alkyl, C
3-C
6Cycloalkyl, aryl, heterocycle can be unsubstituted, or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
6aBe selected from: C
1-C
4Alkyl or C
3-C
6Cycloalkyl, can be unsubstituted or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
8Be independently selected from:
A) hydrogen,
B) C
1-C
6Alkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) by C
1-C
6Perfluoroalkyl, R
10O-, R
10C (O) NR
10-, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) unsubstituted or by C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl or aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: a key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-, O ,-N (R
10)-, or S (O) m;
V is selected from:
A) hydrogen,
B) be selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo pyridine base, indyl, quinolyl, isoquinolyl and thienyl,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl,
But its condition is if A
1Be S (O) m, then V is not a hydrogen, and if A
1Be a key, n is 0, A
2Be S (O) m, then V neither hydrogen;
W is selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo-piperidine base, indyl, quinolyl, or isoquinolyl;
X is-CH
2Or-C (=O)-;
Y is monocycle or bicyclic aryl, and perhaps monocycle or bicyclic heterocycle can be unsubstituted or replaced by following one or more groups:
A) C
1-C
4Alkyl,
B) C
1-C
4Alkoxyl group,
C) halogen, or
d)NR
6R
7;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
R is 0-5, but r is 0 when V is hydrogen;
S is 0 or 1; And
T is 0 or 1.
5. according to formula B compound or its pharmaceutically acceptable salt of claim 2:
In the formula:
R
1aBe independently selected from: hydrogen or C
1-C
6Alkyl;
R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, cycloalkyl, R
10O-,-N (R
10)
2Or C
2-C
6Alkenyl,
C) the unsubstituted or C that replaces
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocycle, cycloalkyl, alkenyl, R unsubstituted or that replace
10O-and-N (R
10)
2
R
3And R
4Be independently selected from H and CH
3R
2Be H;
Or C
1-C
5Alkyl can be unbranched or side chain is arranged, and can be unsubstituted or replaced by following one or more groups:
1) aryl,
2) heterocycle,
3)OR
6,
And R
2, R
3, R
4And R
5In any 2 can randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H; C
1-C
4Alkyl, C
3-C
6Cycloalkyl, aryl, heterocycle can be unsubstituted, or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
6aBe selected from: C
1-C
4Alkyl or C
3-C
6Cycloalkyl, can be unsubstituted or replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) halogen, or
C) aryl or heterocycle;
R
8Be independently selected from:
A) hydrogen,
B) C
1-C
6Alkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) by C
1-C
6Perfluoroalkyl, R
10O-, R
10C (O) NR
10-, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
9Be selected from:
A) hydrogen,
B) C
2-C
6Alkenyl, C
2-C
6Alkynyl, C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, NO
2, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10-and
C) unsubstituted or by C
1-C
6Perfluoroalkyl, F, Cl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-,-N (R
10)
2, or R
11OC (O) NR
10The C of-replacement
1-C
6Alkyl;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl or aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: a key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-, O ,-N (R
10)-, or S (O) m;
V is selected from:
A) hydrogen,
B) be selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo pyridine base, indyl, quinolyl, isoquinolyl and thienyl,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl,
But its condition is if A
1Be S (O) m, then V is not a hydrogen, and if A
1Be a key, n is 0, A
2Be S (O) m, then V neither hydrogen;
G is H
2Or O;
W is selected from following heterocyclic radical: pyrrolidyl, imidazolyl, pyridyl, thiazolyl, pyriconyl, 2-oxo-piperidine base, indyl, quinolyl, or isoquinolyl;
X is-CH
2Or-C (=O)-;
Z is monocycle or bicyclic aryl, monocycle or bicyclic heteroaryl, monocycle or bicyclic aryl methyl, monocycle or bicyclic heteroaryl methyl, monocycle or bicyclic aryl sulphonyl, monocycle or bicyclic heteroaryl sulphonyl can be unsubstituted or replaced by following one or more groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5,
But its condition be when G be H
2, and W is when being imidazolyl, substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not H, and
Its condition be when X be-C (=O)-, or-S (=O) during m-, t is 1, and substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is not hydrogen.
6. can suppress compound or its pharmaceutically acceptable salt of farnesyl-protein transferase, these compounds are:
2 (S)-butyl-1-(2,3-diamino third-1-yl)-4-(1-naphthoyl)-piperazine
1-(3-amino-2-(2-naphthyl methyl amino) third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-{5-[1-(2-naphthyl methyl)]-4, the 5-glyoxalidine } methyl-4-(1-naphthoyl)-piperazine
1-[5-(1-benzyl imidazole) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-{5-[1-(4-nitrobenzyl) imidazolyl] methyl }-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(3-kharophen methylthio group-2 (R)-amino third-1-yl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[2-(1-imidazolyl) ethyl] sulphonyl-4-(1-naphthoyl)-piperazine
2 (R)-butyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-4-(1-naphthoyl)-1-(3-pyridylmethyl) piperazine
1-2 (S)-butyl-(2 (R)-(4-nitrobenzyl) amino-3-hydroxypropyl)-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-hydroxyl heptadecyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-benzyl-1-imidazolyl-4-methyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-(3-benzylthio-) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-[3-(4-nitrobenzyl sulfenyl) propyl group]))-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(4-imidazolyl) ethyl]-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(4-imidazolyl) methyl]-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-and 1H-imidazoles-5-yl) ethanoyl]-4-(1-naphthoyl)-piperazine
2 (S)-butyl-1-[(1-naphthalene-2-ylmethyl)-and 1H-imidazoles-5-yl) ethyl]-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-3-hydroxypropyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2 (R)-amino-4-hydroxy butyl)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2-amino-3-(2-benzyloxy phenyl) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-(2-amino-3-(2-hydroxy phenyl) propyl group)-2 (S)-butyl-4-(1-naphthoyl)-piperazine
1-[3-(4-imidazolyl) propyl group]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(1-naphthyl methyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-naphthyl methyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-methoxy-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(3-methyl-2-butene base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-luorobenzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(4-benzyl chloride base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
1-[1-(4-bromobenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
1-[1-(4-bromobenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethyl benzyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-1-[1-(4-methyl-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-1-[1-(3-methyl-benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
1-[1-(4-phenylbenzyl) imidazoles-5-ylmethyl]-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(2-phenylethyl) imidazoles-5-ylmethyl]-piperazine
2 (S)-normal-butyl-4-(1-naphthoyl)-1-[1-(4-trifluoromethoxy) imidazoles-5-ylmethyl]-piperazine
1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
5 (S)-normal-butyl-1-(2, the 3-3,5-dimethylphenyl)-4-(4-imidazolyl methyl)-piperazine-2-ketone
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2, the 3-3,5-dimethylphenyl) piperazine-2-ketone
4-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-1-(2,3-3,5-dimethylphenyl-5 (S)-(2-methoxy ethyl) piperazine-2-ketone
(S)-the 1-[3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(methylsulfonyl) ethyl]-2-piperazine ketone
(S)-the 1-[3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) ethyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[2-(ethylsulfonyl) methyl]-2-piperazine ketone
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5-[N-ethyl-2-kharophen]-2-piperazine ketone
(±)-5-(2-butyne base)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-2-piperazine ketone
1-(3-chloro-phenyl-)-4--[1-(4-cyano group benzyl)-5-imidazolyl methyl]-2-piperazine ketone
5 (S)-butyl-4-[1-(4-cyano group benzyl-2-methyl)-5-imidazolyl methyl]-1-(2, the 3-3,5-dimethylphenyl)-piperazine-2-ketone
4-[1-(2-(4-cyano-phenyl)-2-propyl group)-5-imidazolyl methyl]-1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-ketone
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-1-(2-aminomethyl phenyl) piperazine-2-ketone
4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-5 (S)-(2-fluoro ethyl)-1-(3-chloro-phenyl-) piperazine-2-ketone
4-[3-(4-cyano group benzyl) pyridin-4-yl]-1-(3-chloro-phenyl-)-5 (S)-(2-methylsulfonyl ethyl) piperazine-2-ketone
4-[5-(4-cyano group benzyl)-1-imidazolyl ethyl]-1-(3-chloro-phenyl-) piperazine-2-ketone.
7. can suppress compound or its pharmaceutically acceptable salt or its optically active isomer of farnesyl-protein transferase, these compounds are: table 1
Table 2
Upright structure X YR n-Bu 2-O (CH
2)
13CH
3S n-Bu 2-O (CH
2)
13CH
3R n-Bu 2-O (CH
2)
11CH
3S n-Bu 2-O (CH
2)
11CH
3R n-Bu 2-O (CH
2)
9CH
3S n-Bu 2-O (CH
2)
9CH
3R n-Bu 2-O (CH
2)
7CH
3S n-Bu 2-O (CH
2)
7CH
3R n-Bu 2-O (CH
2)
3PhS n-Bu 2-O (CH
2)
3PhR n-Bu 3-OCH
2Ph
Table 2 (continuing) Upright structure X YS n-Bu 3-OCH
2PhR n-Bu 3-O (CH
2)
13CH
3S n-Bu 3-O (CH
2)
13CH
3R n-Bu 4-O (CH
2)
13CH
3S n-Bu 4-O (CH
2)
13CH
3S n-Bu 4-OCH
2PhR/S H 2-O (CH
2)
13CH
3 Table 3 Y3-SO
2Me3-OCF
3 Table 4 X YCH
2OCH
2Ph CF
3CH
2SO
2Et CF
3CH
2SO
2Ph CF
3CH
2SO
2Me ClCH
2SO
2Et ClCONHMe CF
3CONHEt CF
3CH
2SO
2Ph ClCONHMe ClCONHEt ClCONHc-Pr ClCONHc-Pr CF
3 Table 4 (continuing) X YNHCOMe ClCONMe
2CF
3SO
2Et ClCH
2SMe Cl (±) C ≡ CMe Cl
Table 5 X YCH
2CH
2HCh
2CO HCH
2HCH
23-ClNHSO
2HCH
2CH
2CO 3-ClCH
22,3-Cl
2CH
22-BrCH
23-CF
3CH
24-ClCH
2CO 3-ClCH
23-FCH
23-Br
Table 6 X Y Z4-CN CH
25-CH
2CH
2CO3-CN CH
25-CH
22-CN CH
25-CH
24-CN CH
24-CH
2CH
2CO4-CN (CH
2)
24-CH
2CH
2CO
Table 7 X Y4-Me CH
2CH
2SO
2Me4-Me H2-Me H
Table 8
Y
3-CF
3
3-CH
3
2,3-(CH
2)
4
3-OCH
3
3-Cl
2-CH
3.3-Cl
H
8. according to compound or its pharmaceutically acceptable salt of claim 6, this compound is:
1-{5-[1-(4-nitrobenzyl)] imidazolyl methyl }-2 (S)-butyl-4-(1-naphthoyl)-piperazine
9. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
1-[5-(1-benzyl imidazole) methyl]-2 (S)-butyl-4-(1-naphthoyl)-piperazine
12. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
2 (S)-normal-butyl-1-[1-(4-cyano group benzyl) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
14. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
2 (S)-normal-butyl-1-[1-(4-benzyl chloride base) imidazoles-5-ylmethyl]-4-(1-naphthoyl)-piperazine
15. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
1-{[1-(4-cyano group benzyl)-1H-imidazoles-5-yl] ethanoyl }-2 (S)-normal-butyl-4-(1-naphthoyl)-piperazine
17. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
5 (S)-normal-butyl-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-1-(2-aminomethyl phenyl) piperazine-2-ketone
19. according to compound or its pharmaceutically acceptable salt of claim 6, or its optically active isomer, this compound is:
(S)-1-(3-chloro-phenyl-)-4-[1-(4-cyano group benzyl)-5-imidazolyl methyl]-the 5-[(2-ethylsulfonyl) ethyl]-2-piperazine ketone
22. contain the pharmaceutical composition of the pharmaceutical carrier and the compound of the claim 1 that is dispersed in treatment significant quantity wherein.
23. contain the pharmaceutical composition of the pharmaceutical carrier and the compound of the claim 2 that is dispersed in treatment significant quantity wherein.
24. contain the pharmaceutical composition of the pharmaceutical carrier and the compound of the claim 3 that is dispersed in treatment significant quantity wherein.
25. contain the pharmaceutical composition of the pharmaceutical carrier and the compound of the claim 6 that is dispersed in treatment significant quantity wherein.
26. a method that suppresses farnesyl-protein transferase, this method comprise the composition to the claim 22 of the administration treatment significant quantity of this treatment of needs.
27. a method that suppresses farnesyl-protein transferase, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
28. a method that suppresses farnesyl-protein transferase, this method comprise the composition to the claim 24 of the administration treatment significant quantity of this treatment of needs.
29. a method that suppresses farnesyl-protein transferase, this method comprise the composition to the claim 25 of the administration treatment significant quantity of this treatment of needs.
30. a method that suppresses farnesyl-protein transferase, this method comprise containing pharmaceutical carrier and being dispersed in the formula B compound of treatment significant quantity wherein or the pharmaceutical composition of its pharmaceutically acceptable salt the administration treatment significant quantity of this treatment of needs:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is an imidazolyl;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 1; With
U is 4 or 5;
Its condition is substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is H.
31. a method that suppresses farnesyl-protein transferase, this method comprise containing pharmaceutical carrier and being dispersed in the formula B compound of treatment significant quantity wherein or the pharmaceutical composition of its pharmaceutically acceptable salt the administration treatment significant quantity of this treatment of needs:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom randomly by be selected from O, S (O) m ,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) HR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2Or O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5;
Its condition is if t is 1, then substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is H.
32. a treatment method for cancer, this method comprise the composition to the claim 22 of the administration treatment significant quantity of this treatment of needs.
33. a treatment method for cancer, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
34. a treatment method for cancer, this method comprise the composition to the claim 24 of the administration treatment significant quantity of this treatment of needs.
35. a treatment method for cancer, this method comprise the composition to the claim 25 of the administration treatment significant quantity of this treatment of needs.
36. a method for the treatment of the optimum proliferative imbalance of nerve fiber protein, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
37. the method for the blindness that a treatment is relevant with retinal vesselization, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
38. a method for the treatment of hepatitis-δ and relevant virus infection, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
39. a method for the treatment of prevention of restenosis, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
40. a method for the treatment of polycystic disease, this method comprise the composition to the claim 23 of the administration treatment significant quantity of this treatment of needs.
41. treatment or prevention are selected from the method for the optimum proliferative imbalance of cancer, nerve fiber protein, some blindness, hepatitis-δ and relevant virus infection, restenosis and the polycystic disease relevant with retinal vesselization, this method comprises containing pharmaceutical carrier and being dispersed in the formula B compound of treatment significant quantity wherein or the pharmaceutical composition of its pharmaceutically acceptable salt the administration treatment significant quantity of this treatment of needs and prevention:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
6,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
2) C
3-C
6Cycloalkyl,
3)OR
6,
4)SR
6a,S(O)R
6a,SO
2R
6a,
5)-NR
6R
7
15) N
3, or
16) F; Or
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
d)HO,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is an imidazolyl;
X is-CH
2-,-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 1; With
U is 4 or 5;
Its condition is substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is H.
42. treatment or prevention are selected from the method for the optimum proliferative imbalance of cancer, nerve fiber protein, some blindness, hepatitis-δ and relevant virus infection, restenosis and the polycystic disease relevant with retinal vesselization, this method comprises containing pharmaceutical carrier and being dispersed in the formula B compound of treatment significant quantity wherein or the pharmaceutical composition of its pharmaceutically acceptable salt the administration treatment significant quantity of this treatment of needs and prevention:
In the formula:
R
1aAnd R
1bBe independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, CN (R
10)
2N-C (O)-, (R
10)
2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-,
C) C that does not replace or replace
1-C
6Alkyl, wherein the C of replacement
1-C
6Substituting group on the alkyl is selected from aryl, heterocyclic radical, C unsubstituted or that replace
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2N-C (O)-, CN, (R
10)
2N-C (NR
10)-, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, and R
11OC (O) NR
10-;
R
2And R
3Be independently selected from: H, the C that does not replace or replace
1-C
8Alkyl, the C that does not replace or replace
2-C
8Alkenyl, the C that does not replace or replace
2-C
8Alkynyl, the aryl that does not replace or replace, the heterocycle that does not replace or replace,
Or
Wherein, substituting group is to be replaced by one or more groups in the following groups:
1) aryl or the heterocycle that does not replace or replaced by following groups:
A) C
1-C
4Alkyl,
b)(CH
2)
pOR
b,
c)(CH
2)
pNR
6R
7,
D) halogen,
e)CN,
R
2And R
3Be connected in and lump together formation-(CH on the same carbon atom
2) u-, one of them carbon atom is randomly by being selected from O, S (O)
m,-NC (O)-and-N (COR
10)-group replace;
R
4Be selected from H and CH
3And R
2, R
3And R
4In any 2 randomly be connected on the same carbon atom;
R
6, R
7And R
7aBe independently selected from: H, C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, aroyl, 4-hetaroylpyrazol, arylsulfonyl, heteroaryl sulphonyl, these groups can be unsubstituted or be replaced by following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
G) N (R
10)
2Or
R
6And R
7Can be connected in the ring;
R
7And R
7aCan be connected in the ring;
R
6aBe selected from: C
1-C
4Alkyl, C
3-C
6Cycloalkyl, heterocycle, aryl, these groups can be unsubstituted or replace with following groups:
A) C
1-C
4Alkoxyl group,
B) aryl or heterocycle,
C) halogen,
F)-SO
2R
11, or
g)N(R
10)
2;
R
8Be independently selected from:
A) hydrogen,
B) aryl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: aryl, cyano-phenyl, heterocycle, C
3-C
10Cycloalkyl, C
2-C
6Alkenyl, C
2-C
6Alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NH-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
10OC (O) NH-;
R
9Be selected from:
A) hydrogen,
B) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, NO
2, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-and
C) C unsubstituted or that replaced by following groups
1-C
6Alkyl: perfluoroalkyl, F, Cl, Br, R
10O-, R
11S (O) m-, R
10C (O) NR
10-, (R
10)
2NC (O)-, R
10 2N-C (NR
10)-, CN, R
10C (O)-, R
10OC (O)-, N
3,-N (R
10)
2, or R
11OC (O) NR
10-;
R
10Be independently selected from hydrogen, C
1-C
6Alkyl, benzyl and aryl;
R
11Be independently selected from C
1-C
6Alkyl and aryl;
A
1And A
2Be independently selected from: key ,-CH=CH-,-C ≡ C-,-C (O)-,-C (O) NR
10-,-NR
10C (O)-, O ,-N (R
10)-,-S (O)
2N (R
10)-,-N (R
10) S (O)
2-or S (O) m;
G is H
2Or O;
V is selected from:
A) hydrogen,
B) heterocycle,
C) aryl,
D) C
1-C
20Alkyl, wherein have 0-4 carbon atom be selected from O, S and N heteroatoms displacement and
E) C
2-C
20Alkenyl.
Its condition is: if A
1Be S (O) m, then V is not a hydrogen; If A
1Be a key, n is 0, and A
2Be S (O) m, then V is not a hydrogen;
W is a heterocycle;
X is-C (=O)-or-S (=O) m-;
Z is an aryl unsubstituted or that replace, heteroaryl, arylmethyl, heteroaryl methyl, arylsulfonyl, heteroaryl sulphonyl, and wherein the group of Qu Daiing is replaced by one or more following groups:
1) C unsubstituted or that replaced by following groups
1-C
4Alkyl:
A) C
1-C
4Alkoxyl group,
b)NR
6R
7,
C) C
3-C
6Cycloalkyl,
D) aryl or heterocycle,
e)HO,
F)-S (O) mR
6a, or
g)-C(O)NR
6R
7,
2) aryl or heterocycle,
3) halogen,
4)OR
6,
5)NR
6R
7
6)CN,
7)NO
2,
8)CF
3,
9)-S(O)mR
6a,
10)-C (O) NR
6R
7, or
11) C
3-C
6Cycloalkyl;
M is 0,1 or 2;
N is 0,1,2,3 or 4;
P is 0,1,2,3 or 4;
Q is 1 or 2;
R is 0-5, and its condition is that r is 0 when V is hydrogen;
S is 0 or 1;
T is 0 or 1; With
U is 4 or 5;
Its condition is if t is 1, then substituting group (R
8) r-V-A
1(CR
1a 2) nA
2(CR
1a 2) n-is H.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41282995A | 1995-03-29 | 1995-03-29 | |
US08/412,829 | 1995-03-29 | ||
US47069095A | 1995-06-06 | 1995-06-06 | |
US08/470,690 | 1995-06-06 | ||
US08/600,728 | 1996-03-01 | ||
US08/600,728 US5856326A (en) | 1995-03-29 | 1996-03-01 | Inhibitors of farnesyl-protein transferase |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1195340A true CN1195340A (en) | 1998-10-07 |
Family
ID=27410959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96194206A Pending CN1195340A (en) | 1995-03-29 | 1996-03-25 | Inhibitors of farnesyl-protein transferase |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0820445A1 (en) |
JP (1) | JP3043815B2 (en) |
CN (1) | CN1195340A (en) |
AR (1) | AR002726A1 (en) |
AU (1) | AU710672B2 (en) |
BG (1) | BG101973A (en) |
BR (1) | BR9607953A (en) |
CA (1) | CA2216707A1 (en) |
CZ (1) | CZ306297A3 (en) |
EE (1) | EE9700314A (en) |
HR (1) | HRP960143A2 (en) |
HU (1) | HUP9801883A3 (en) |
IL (1) | IL117580A0 (en) |
IS (1) | IS4568A (en) |
MX (1) | MX9707459A (en) |
NO (1) | NO974457L (en) |
NZ (1) | NZ305254A (en) |
PL (1) | PL322549A1 (en) |
SK (1) | SK129297A3 (en) |
TR (1) | TR199701056T1 (en) |
WO (1) | WO1996030343A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110294713A (en) * | 2018-03-22 | 2019-10-01 | 西华大学 | A kind of preparation method of imidazoles methylamine like derivative |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
GB9516709D0 (en) * | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
JP2000504336A (en) | 1996-02-02 | 2000-04-11 | ゼネカ・リミテッド | Heterocyclic compounds useful as pharmaceutical preparations |
AU716153B2 (en) * | 1996-04-03 | 2000-02-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6063930A (en) * | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5919785A (en) * | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5780488A (en) * | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5852010A (en) * | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) * | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5780492A (en) * | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5885995A (en) * | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036877A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5939557A (en) * | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5859012A (en) * | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU707139B2 (en) * | 1996-04-03 | 1999-07-01 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2249601A1 (en) * | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
EP0900081A4 (en) * | 1996-04-03 | 2002-01-09 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US5922883A (en) * | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5874452A (en) * | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
EP0959883A4 (en) * | 1996-04-03 | 2001-05-09 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US6001835A (en) * | 1996-04-03 | 1999-12-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250232A1 (en) * | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
US6080870A (en) * | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5925651A (en) * | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
KR20000029984A (en) * | 1996-08-14 | 2000-05-25 | 사라 엔 람베쓰 | Substituted pyrimidine derivatives and their pharmaceutical use |
UA56197C2 (en) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Heterocyclic derivatives |
CA2276081A1 (en) * | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
US6440972B1 (en) | 1997-02-13 | 2002-08-27 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
DE69815509T2 (en) | 1997-02-13 | 2004-05-13 | Astrazeneca Ab | HETEROCYCLIC COMPOUNDS THAT APPLY AS OXIDO-SQUALEN-CYCLASE INHIBITORS |
US5972942A (en) * | 1997-03-27 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
EP1019529A4 (en) * | 1997-08-27 | 2002-09-11 | Merck & Co Inc | A method of treating cancer |
US6103487A (en) * | 1997-08-27 | 2000-08-15 | Merck & Co., Inc. | Method of treating cancer |
US6387903B1 (en) | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO1999041242A1 (en) * | 1998-02-13 | 1999-08-19 | Rhone-Poulenc Rorer S.A. | Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them |
FR2774985A1 (en) * | 1998-02-13 | 1999-08-20 | Rhone Poulenc Rorer Sa | New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer |
AU5086499A (en) * | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
EP1165082A4 (en) * | 1999-03-03 | 2002-06-12 | Merck & Co Inc | Inhibitors of prenyl-protein transferase |
EP1158982A4 (en) * | 1999-03-03 | 2002-06-12 | Merck & Co Inc | Inhibitors of prenyl-protein transferase |
EP1165013A4 (en) * | 1999-03-03 | 2002-08-07 | Merck & Co Inc | Inhibitors of prenyl-protein transferase |
AU3390000A (en) * | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6211182B1 (en) * | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
US6458935B1 (en) | 1999-06-23 | 2002-10-01 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
FR2819510B1 (en) * | 2001-01-18 | 2003-10-31 | Servier Lab | NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2819509B1 (en) * | 2001-01-18 | 2004-04-16 | Servier Lab | NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2819512B1 (en) * | 2001-01-18 | 2003-02-21 | Servier Lab | NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
ATE550019T1 (en) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER |
RS51470B (en) | 2005-09-16 | 2011-04-30 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
UA98449C2 (en) | 2005-12-13 | 2012-05-25 | Инсайт Корпорейшин | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
JP2010513482A (en) * | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | Imidazoles as aldosterone synthase inhibitors |
PL2109608T3 (en) | 2007-01-10 | 2011-08-31 | Msd Italia Srl | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
WO2008106692A1 (en) | 2007-03-01 | 2008-09-04 | Novartis Vaccines And Diagnostics, Inc. | Pim kinase inhibitors and methods of their use |
KR20100017866A (en) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r inhibitors, compositions, and methods of use |
RS53245B2 (en) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
ES2615389T3 (en) | 2007-10-05 | 2017-06-06 | Acucela, Inc. | Alkoxyphenylpropylamines for the treatment of age-related macular degeneration |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
AU2010234526B2 (en) | 2009-04-06 | 2016-07-21 | Agios Pharmaceuticals, Inc. | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use |
LT2432472T (en) | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
BRPI1012159B1 (en) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
TWI598337B (en) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
US10471027B2 (en) | 2009-07-02 | 2019-11-12 | Acucela, Inc. | Pharmacology of visual cycle modulators |
AR078012A1 (en) | 2009-09-01 | 2011-10-05 | Incyte Corp | HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS |
BR112012008849A2 (en) | 2009-10-14 | 2015-09-22 | Schering Corp | compound, pharmaceutical composition, and use of a compound |
EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
CN103080093A (en) | 2010-03-16 | 2013-05-01 | 达纳-法伯癌症研究所公司 | Indazole compounds and their uses |
CN103002875B (en) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Topical formulations of JAK inhibitors |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CN103068980B (en) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | Using short interfering nucleic acid(siNA)The connection albumen led of mediated rnai(Cadherin related protein matter), β 1(CTNNB1)The suppression of gene expression |
SI2606134T1 (en) | 2010-08-17 | 2019-08-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
PE20140146A1 (en) | 2010-11-19 | 2014-02-06 | Incyte Corp | PYRROLOPYRIDINE DERIVATIVES AND PYRROLOPYRIMIDINE SUBSTITUTED WITH CYCLOBUTYL AS JAK INHIBITORS |
ES2536415T3 (en) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pyrrolopyridines and heterocyclic substituted pyrrolopyrimidines as JAK inhibitors |
CA2821975A1 (en) | 2010-12-17 | 2012-06-21 | Shunqi Yan | N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
ES2569712T3 (en) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | PKM2 bicyclic activators |
TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
IN2013MN02170A (en) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
EP2704720B1 (en) | 2011-05-03 | 2019-08-07 | Agios Pharmaceuticals, Inc. | Pyruvate kinase r activators for use in therapy |
KR101873543B1 (en) | 2011-05-03 | 2018-07-02 | 아지오스 파마슈티컬스 아이엔씨. | Pyruvate kinase activators for use in therapy |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
AR086983A1 (en) | 2011-06-20 | 2014-02-05 | Incyte Corp | DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
JP6106685B2 (en) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitors of C-JUN-N-terminal kinase (JNK) |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
JP6399660B2 (en) * | 2012-04-10 | 2018-10-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Cancer treatment compositions and methods |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JP6280554B2 (en) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
MY191357A (en) | 2012-11-15 | 2022-06-19 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
PL2925888T3 (en) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
UA120162C2 (en) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Processes and intermediates for making a jak inhibitor |
AU2014249003A1 (en) | 2013-03-13 | 2015-10-15 | Forma Therapeutics, Inc. | Novel compounds and compositions for inhibition of FASN |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN105593215B (en) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 2,4- the or 4,6- diaminopyrimidine compounds as IDH2 mutant inhibitor for treating cancer |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
PT3030227T (en) | 2013-08-07 | 2020-06-25 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP3057955B1 (en) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
KR20220070066A (en) | 2014-03-14 | 2022-05-27 | 아지오스 파마슈티컬스 아이엔씨. | Pharmaceutical compositions of therapeutically active compounds |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
PL3209655T3 (en) | 2014-10-24 | 2020-12-28 | Landos Biopharma, Inc. | Lanthionine synthetase c-like 2-based therapeutics |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
JP6861166B2 (en) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitor of cyclin-dependent kinase |
MD3307271T2 (en) | 2015-06-11 | 2024-01-31 | Agios Pharmaceuticals Inc | Methods of using pyruvate kinase activators |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
HRP20211790T1 (en) | 2015-10-15 | 2022-03-04 | Les Laboratoires Servier | Combination therapy for treating malignancies |
PL3362065T3 (en) | 2015-10-15 | 2024-09-16 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
CN110650976B (en) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | Anti-SIRP alpha antibodies |
AU2018289303B2 (en) | 2017-06-20 | 2023-12-21 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
KR20200129099A (en) | 2018-01-30 | 2020-11-17 | 인사이트 코포레이션 | Method for producing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-one) |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
CN112423759A (en) | 2018-03-30 | 2021-02-26 | 因赛特公司 | Treatment of hidradenitis suppurativa with JAK inhibitors |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
CA3135502C (en) | 2019-12-20 | 2024-01-09 | Josep Bassaganya-Riera | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1056055B (en) * | 1974-03-01 | 1982-01-30 | Malesci Sas Inst Farmaco Bilog | Substd 1-alkyl 4-phenylpiperazines - with anti-hypertensive, vasodilating, alpha-inhibiting, anti-histamine and anti-bradykinin activity |
US4371737A (en) * | 1981-05-04 | 1983-02-01 | Merrell Dow Pharmaceuticals Inc. | 5-Aminomethyl-2,3-dihydro-2-oxo-1H-imidazole-4-carboxylic acid derivatives |
US5159083A (en) * | 1990-12-28 | 1992-10-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands |
WO1995000497A1 (en) * | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5478934A (en) * | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
-
1996
- 1996-03-20 IL IL11758096A patent/IL117580A0/en unknown
- 1996-03-25 EE EE9700314A patent/EE9700314A/en unknown
- 1996-03-25 CZ CZ973062A patent/CZ306297A3/en unknown
- 1996-03-25 MX MX9707459A patent/MX9707459A/en unknown
- 1996-03-25 PL PL96322549A patent/PL322549A1/en unknown
- 1996-03-25 WO PCT/US1996/004019 patent/WO1996030343A1/en not_active Application Discontinuation
- 1996-03-25 CN CN96194206A patent/CN1195340A/en active Pending
- 1996-03-25 CA CA002216707A patent/CA2216707A1/en not_active Abandoned
- 1996-03-25 NZ NZ305254A patent/NZ305254A/en unknown
- 1996-03-25 EP EP96909851A patent/EP0820445A1/en not_active Withdrawn
- 1996-03-25 SK SK1292-97A patent/SK129297A3/en unknown
- 1996-03-25 JP JP8529559A patent/JP3043815B2/en not_active Expired - Fee Related
- 1996-03-25 BR BR9607953A patent/BR9607953A/en not_active IP Right Cessation
- 1996-03-25 AU AU53223/96A patent/AU710672B2/en not_active Ceased
- 1996-03-25 HU HU9801883A patent/HUP9801883A3/en unknown
- 1996-03-25 TR TR97/01056T patent/TR199701056T1/en unknown
- 1996-03-27 HR HR08/600,728A patent/HRP960143A2/en not_active Application Discontinuation
- 1996-03-27 AR ARP960101942A patent/AR002726A1/en unknown
-
1997
- 1997-09-24 IS IS4568A patent/IS4568A/en unknown
- 1997-09-26 NO NO974457A patent/NO974457L/en unknown
- 1997-10-15 BG BG101973A patent/BG101973A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110294713A (en) * | 2018-03-22 | 2019-10-01 | 西华大学 | A kind of preparation method of imidazoles methylamine like derivative |
CN110294713B (en) * | 2018-03-22 | 2022-08-02 | 西华大学 | Preparation method of imidazole methylamine derivative |
Also Published As
Publication number | Publication date |
---|---|
NO974457L (en) | 1997-11-28 |
AU5322396A (en) | 1996-10-16 |
WO1996030343A1 (en) | 1996-10-03 |
JPH10511098A (en) | 1998-10-27 |
PL322549A1 (en) | 1998-02-02 |
MX9707459A (en) | 1997-12-31 |
BR9607953A (en) | 1998-07-14 |
AR002726A1 (en) | 1998-04-29 |
NZ305254A (en) | 1999-03-29 |
HUP9801883A2 (en) | 1999-06-28 |
HUP9801883A3 (en) | 2000-09-28 |
NO974457D0 (en) | 1997-09-26 |
EE9700314A (en) | 1998-06-15 |
JP3043815B2 (en) | 2000-05-22 |
EP0820445A1 (en) | 1998-01-28 |
TR199701056T1 (en) | 1998-02-21 |
CZ306297A3 (en) | 1998-03-18 |
AU710672B2 (en) | 1999-09-23 |
HRP960143A2 (en) | 1998-04-30 |
IS4568A (en) | 1997-09-24 |
BG101973A (en) | 1998-05-29 |
SK129297A3 (en) | 1998-05-06 |
CA2216707A1 (en) | 1996-10-03 |
IL117580A0 (en) | 1996-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1195340A (en) | Inhibitors of farnesyl-protein transferase | |
CN1213040C (en) | Serine protease inhibitors | |
CN1062865C (en) | Process for production of amidinobenzofuran and amidionbenzothiophen derivatives and salt thereof | |
CN1207288C (en) | Retroviral protease inhibiting compounds | |
CN1044117C (en) | Inhibitors of HIV protease useful for the treatment of aids | |
CN1167422C (en) | Quinazoline derivatives as angiogenesis inhibitors | |
CN1291988C (en) | Triazaspiro [5,5] undecane derivatrives and drugs containing the same as active ingredient | |
CN1230431C (en) | Arylmethy lamine derivatives for use as tryptase inhibitors | |
CN1119340C (en) | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | |
CN1078889C (en) | Non-peptide tachykinin receptor antagonists | |
CN1039321C (en) | New beta-amino-alpha-hydroxycarboxylic acids and their use | |
CN1173867A (en) | Indolyl neuropeptide Y receptor antagonists | |
CN1085546A (en) | Aminediol protease inhibitors | |
CN101031559A (en) | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
CN1832925A (en) | New p2x7 receptor avtagonists and their use | |
CN1106003A (en) | Inhibitors of microsomal triglyceride transfer protein and method | |
CN1107149A (en) | Piperazine derivatives | |
CN1255401C (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
CN1434805A (en) | Selective neurokinin antagonists | |
CN1285588C (en) | Farnesyl protein transferase inhibitors | |
CN1708493A (en) | Selected CGRP antagonists, method for production and use thereof as medicament | |
CN1391564A (en) | Chemical compounds | |
CN1914182A (en) | Quinazoline derivatives | |
CN1229373C (en) | Piperidinee derivatives as neurokinin/antagonists | |
CN1768041A (en) | Acylated spiropiperidine derivatives as the melanocortin-4 receptor agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |